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yThe efficacy of cardiac resynchronization therapy (CRT) through 
biventricular pacing (BVP) has been demonstrated by numerous 
studies in patients suffering from congestive heart failure. In 
order to achieve a guideline for optimal treatment with BVP 
devices, an automated non-invasive strategy based on an elect-
rophysiological computer model of the heart is presented. The 
presented research investigates an off-line optimization algo-
rithm based on different electrode positioning and timing delays. 
A computer model of the heart was used to simulate the left 
bundle branch block (LBBB), myocardial infarction (MI) and 
reduction of intraventricular conduction velocity. The optimiza-
tion method evaluates the error between the healthy case and 
the pathology with/without pacing case in terms of activation 
times and QRS duration.The clinical measurements of body 
surface potential map (BSPM) are used to parameterize the 
computer model of the heart to represent the individual patho-
logy by solving the inverse problem, which leads to a more rea-
listic heart model for simulations. Afterwards, the simulated 
ECGs for optimal pacing are compared to the measured ECGs 
after implantation. The similarity in the QRS duration between 
measured and simulated ECG signals indicates the success of 
the method.
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1Introduction
1.1 Motivation
Cardiovascular diseases are a major cause of mortality in western countries. American
Heart Association statistics indicate 5 million individuals in the United States with chronic
heart failure [10]. An early diagnosis will reduce the risk factors and enhance the prognosis
and life quality of patients.
In patients with heart failure, cardiac resynchronization therapy (CRT) in forms of biven-
tricular pacing (BVP) has emerged as a treatment option for patients with New York Heart
Association classification III-IV heart failure. CRT leads to an improvement in hemody-
namics and less hospitalization [121, 169]. Nevertheless, about 20 - 30 % of the patients
in randomized clinical trials do not respond to biventricular pacing (BVP) therapy. This
may be due to a variety of reasons such as patient selection, inappropriate lead position-
ing or suboptimal pacemaker device programming, especially concerning timing delays
[55, 169, 268]. Congestive heart failure leads to a ventricular contraction dyssynchrony
which is usually observed in patients with dilated cardiomyopathy and left bundle branch
block [10].
The goal of this thesis is to optimize biventricular pacing (BVP) as cardiac resynchroniza-
tion therapy, using computer based heart models of electrophysiology individualized to the
patient in terms of anatomy and pathophysiology. The purpose of BVP optimization is
to provide a significant improvement of patient’s hemodynamic parameters by increasing
cardiac output in patients suffering from left bundle branch block (LBBB) and cardiac
contraction dyssynchrony. The three dimensional geometry extracted from the patient
imaging data set can be used to create a biophysical detailed computer model of ventricles
that incorporates both structural and electrophysiological heterogeneities. Such a model is
of great importance because it allows the investigation of underlying electrical excitation
conduction in the ventricles at physiological and pathological states.
2 Chapter 1. Introduction
The present work suggests a pre-operative BVP optimization strategy based on computer
simulations, enabling a straightforward parameter optimization for an individual patient.
A large amount of work was performed to setup several individual patient models. It can
be summarized as follows.
1. Data acquisition: Several MR data sets were acquired from University Hospital Hei-
delberg and University Hospital Mannheim. The individual models were generated by
segmentation of high-resolution imaging techniques (MRI, CT) in order to obtain the
patient’s anatomy. The model of the left ventricle was subdivided into 17 segments
according to the American Heart Association (AHA) suggestion, which simplified the
determination of myocardial infarction positions in accordance with the corresponding
coronary artery.
2. Heart model creation: A 3D ventricular model was extracted from a series of segmented
short axis 2D MR data sets for each patient. The segmentation was done by using inter-
active deformable contours based on a triangle mesh forming the borders of different
parts of the organ. The cardiac conduction system including the bundle of His, left
and right bundle branch and Purkinje fibers was implemented into the ventricles. The
electrophysiological properties of the heterogeneous ventricle and the pathophysologi-
cal properties according to the patients symptoms (ischemic cardiomyopathy and left
bundle branch block) were implemented into ventricular myocytes.
3. Optimization: Two optimization algorithms were executed for different BVP setups in
order to find the optimal electrode positions and timing delays (A-V and V-V delay) for
a pathological model, which leads to a depolarization sequence similar to the healthy
model. In the first approach, the activation times (isochrones) were optimized while in
the second approach, the QRS durations were optimized.
4. Classification: The optimal results achieved by both optimization methods were com-
pared and classified.
5. Torso model creation: A 3D volume conductor model was extracted from a series of
segmented frontal axis 2D MR data for each patient.
6. Forward solution: The body surface potential of several patient models based on the
optimal BVP setup were simulated. 12 standard ECG channels were extracted in order
to estimate the efficacy of the optimization methods for optimal parameters.
7. Clinical measurements: Multichannel ECG measurements were carried out on the pa-
tients before and after implantation at University Hospital Mannheim in order to gain
the individual patient depolarization sequence by solution of the inverse problem. The
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pathophysiological models representing the patient’s pathology in addition with the
parameters obtained from the inverse problem are implemented into the anatomical
models. Hence, accurate simulation of excitation propagation is enabled. Several sig-
nal processing algorithms were applied on the ECG signals such as denoising, baseline
wander correction, averaging in time, peak and QRS detection.
8. Inverse solution: The epicardial potential of several patient heart models based on the
measured pre-implantation body surface potential maps (BSPM) was calculated. This
parameter optimization gave a personalized model of the pathology, in which the 64
simulated ECG channels were similar to the measured one.
9. Verification: The simulated ECGs for optimal pacing setup was compared to the mea-
sured ECG after implantation. Similarity in QRS duration between measured and
simulated channel indicated the success of the method.
The clinical measurements of BSPM will be used to parameterize the computer model of
the heart to represent the individual pathology of the patient by solving the inverse prob-
lem, which leads to a more realistic and individualized heart model for simulations. The
influence of changed pacemaker timings on the BSPM of the patient after implantation
is investigated, which will provide valuable information for verification of the BVP opti-
mization method. In addition, given patient specific data by measurements of the body
surface potential map and detailed information on contraction delays by Tissue Doppler
Imaging (TDI) later can be used to verify the simulation results by forward calculation.
1.2 Outline of the Thesis
Current thesis is divided to three parts. The first five chapters describe the present state of
the art, two chapters explain the data acquisition and methodology, two chapters present
the results of this work and the last two chapters provide the discussion and conclusion.
Chapter 2 provides an overview of the heart’s anatomy, electrophysiology and pathology
with emphasis on the development of the ECG signal, measuring methods and standard
leads system. Current state of the art of therapy is described in chapter 3, which includes
recent methods presented in more than one hundred publications. Chapter 4 presents the
methods used to create a computer model with respect to anatomy, electrophysiology
and pathologies. Then, cellular and excitation propagation models are introduced which
are used to precalculate the transmembrane voltage of a myocyte using a number of ionic
currents based on a mathematical description. Chapter 5 describes the forward and inverse
problem of electrocardiography. Chapter 6 includes the steps of creating the 3 dimensional
model of the ventricles for 13 patients data sets. Furthermore, it is explained how the
electrophysiology and pathophysiology were modeled in order to investigate the different
parameter setups of therapy. Therapy simulation and optimization methods of the cardiac
4 Chapter 1. Introduction
resynchronization therapy applied in this work are outlined in chapter 7. In addition, a
numerical algorithm reducing the time of optimization and several statistical algorithms
in order to verify and classify the results are presented. Finally the results of this thesis
are presented in chapter 8 and 9 of part III. The discussion and conclusion along with an
outlook on future work are explained in chapters 10 and 11, respectively.
Part I
Medical Background and Current State of the Art

2Medical Foundations
In order to obtain a reliable model of the heart, it is necessary to understand the heart’s
anatomy and physiology. The anatomy includes the structure of the heart and the cells. The
physiology contains the electrophysiological function of the cells and their aggregations.
Since the anatomy and physiology are tightly joined together, this chapter considers both
anatomy and physiology in the macroscopic and microscopic levels.
2.1 Cardiac Anatomy
The heart, together with the blood vessels compose the cardiovascular system. The main
task of the heart is to pump the blood into the vessels in order to supply the body with
oxygen and nutrients. This essential task is fulfilled by a periodic contraction and relaxation
of the heart. The mechanism of the heart can be investigated through the macroscopic or
microscopic point of view in which the anatomy and physiology are correlated.
2.1.1 Cardiac Macroscopic Structure
The heart is a hollow organ with the size of a human fist, which is situated near the center
of the chest cavity between the right and left lung. The main axis of the heart is oriented
from back-top-right to front-bottom-left with the base at the upper and the apex at the
lower end. The heart is supported inside a membranous structure, the pericardial sac. The
outer layer of the pericardium surrounds the roots of heart’s major blood vessels and is
attached by ligaments to the spinal column, diaphragm and other parts of the body. The
inner layer of the pericardium is attached to the heart muscle. A coating of fluid separates
the two membrane layers, letting the heart move as it beats [14, 23, 108, 241, 266].
There are four major chambers in the heart as well as various accessory tissues (see figure
2.1). The heart is divided into left and right halfes by the septal wall, so there are no
internal connections between the opposing chambers through which blood may flow. The
larger, lower, thicker walled chambers are the left ventricle and the right ventricle, while the
smaller upper chambers are the left atrium and the right atrium. The atria are relatively
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thin walled chambers, which collect the blood before feeding it into the ventricles upon
contraction.
Figure 2.1. The anatomy of the heart and the blood flow. The right and the left atrium are located
at the upper half of the heart. The left and the right ventricle are at the lower half of the heart. The
venous blood flows through the vena cava superior and vena cava inferior into the right atrium. During
the contraction of the atria, the blood is pressed from the atria through the tricuspid and bicuspid valve
into the ventricles. During the contraction of the ventricles, the blood from the right ventricle is pumped
through the pulmonary circulation into the left atrium; the blood from the left ventricle is ejected into the
body circulation through the aorta [115].
In contrast, the ventricles are larger chambers that forcefully contract. Therefore, the heart
is separated into two functionally and anatomically similar structures: the right and the
left halfes. The right half collects the deoxygenated blood from the body and pumps it to
the lungs. The left half receives the oxygenated blood from the lungs to deliver it to the
body. Since the circulation path into the body is much longer than the circulation path of
the lung, the left half has to generate a higher pressure and is therefore larger [216, 233].
2.1.1.1 Atria and Ventricles
The atria form the upper part of the heart. The right and left atrium are separated by the
interatriale septum. Both atria have an appendage, which is capable to store the blood.
This leads to a capacity enlargement of the atria. The structure of the atria is developed
in a way that the left and right atrium regions get stimulated closely together [222, 241].
The right atrium consists of two parts:
1. A posterior, smooth walled part in which the superior and inferior vena cava enter
2. A very thin walled part, which constitutes the embryonic right atrium
The left atrium consists mainly of a smooth walled sac, the transverse axis of which is
somewhat larger than the vertical and sagittal axes. The wall of the left atrium is distinctly
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thicker than that of the right atrium. A ridge of muscle called crista terminalis (CT) with
a thickness of 5− 8 mm is located at the inner side of the right atrium (see figure 2.2).
The triangular shaped superior portion of the right atrium called right auricle is filled
with pectinate muscles. The left auricle is a continuation of the left upper anterior part of
the left atrium with a variable shape. The two ventricles form the lower part of the heart.
The right and left ventricles are also separated by a septum. The right ventricular cavity
can be divided into a posteroinferior inflow portion including the tricuspid valve and an
anterosuperior outflow portion from which the pulmonary trunk originates. A number of
papillary muscles attach the tricuspid valve to the right ventricular wall. The pulmonary
trunk arises superiorly from the right ventricle and passes backwards and slightly upward
[191, 241].
Figure 2.2. View of the right atrium: Interatrial septum, pectinate muscles and tricuspid valve are demon-
strated [191].
The left ventricle, which is egg shaped has a thicker wall compared to the right ventricular
wall. The mitral and aortic valves are close to each other (see figure 2.3). Papillary muscles
are connected on one side to the subendocardial myocardium and on the other side to the
mitral valve [171, 191, 241].
The atrio-ventricular valves are composed of similar components: leaflets (3 leaflets for
tricuspid valve, 2 leaflets for the bicuspid valve), a fibrous ring that encircles the valve
called annulus and fibrous ligaments (chordae tendineae) which connect the leaflets to the
papillary muscles which in turn flex during the contraction of the ventricles to stabilize
the atrio-ventricular valves. The semilunar valves have simpler structures than the atrio-
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Figure 2.3. View of the left ventricle. Papillary muscles and mitral valve are demonstrated [191].
ventricular valves. The pulmonic and aortic valves are identical although the aortic valve
consists of a thicker fibrous structure than the pulmonic valve [191].
The valves are responsible for ensuring the unidirectional blood flow and prevent the back
flow of blood. The atrio-ventricular valves are closed during the ventricular systole while
the semilunar valves are open to ensure the blood flow in the arteries (see figure 2.4).
Figure 2.4. Heart in systole. The atrio-ventricular valves are closed [191].
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In the ventricular diastole phase, the atrio-ventricular valves are open to ensure the blood
flows from atria to ventricles (see figure 2.5).
Figure 2.5. Heart in diastole. The semilunar valves are closed [191].
2.1.1.2 Blood Vessels
The blood circulates through the arteries in order to provide oxygen and nutrients to the
body. After passing through the body, the blood loaded with carbon dioxide and waste
substances flows through the vena cava superior and vena cava inferior to the right atrium.
When the ventricles relax, blood from the right atrium passes through the tricuspid valve
into the right ventricle. When the ventricles contract, blood from the right ventricle is
pumped through the pulmonic valve into the lungs in order to reload with oxygen and
remove carbon dioxide. The oxygenated blood then returns to the left atrium and passes
through the mitral valve into the left ventricle. Blood is pumped by the left ventricle across
the aortic valve into the aorta and the arteries of the body. In general, arteries are blood
vessels that carry blood away from the heart. For instance, the pulmonary arteries carry
blood from the heart to the lungs. In the circulatory system, a vein is a blood vessel that
carries blood towards the heart. All veins except the pulmonary veins transport deoxy-
genated blood (see figure 2.6).
The heart’s oxygen supply is provided by the coronary vessels, especially by two coronary
arteries: the left coronary artery and the right coronary artery (see figure 2.7). The left
coronary artery, which supplies blood to the left ventricle and left atrium, originates from
the aorta above the left cusp of the aortic valve. The left coronary artery (LCA) then
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Figure 2.6. Schematic drawing of the connection of the heart’s major vessels. On the left side, the vena
cava superior and the vena cava inferior are connected to the right atrium. From the right ventricle, the
pulmonary artery leads to the pulmonary circulation. On the right side of the schematic, the pulmonary
vein returns from the lungs. The aorta carries the blood from the left ventricle into the body circulation
[116].
bifurcates into the left anterior descending artery (LAD) and the left circumflex artery
(LCX). The LAD branches off the left coronary artery and supplies blood to the front of
the left side of the heart.
(a) (b)
Figure 2.7. Heart and coronary arteries [172]: (a) Anterior view. (b) Posterior view.
The LCX, which branches off the left coronary artery and encircles the heart muscle
supplies blood to the lateral side and back of the heart. The right coronary artery (RCA)
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which divides into the right posterior descending and acute marginal arteries, supplies
blood to the right ventricle, right atrium, and sinoatrial node (cluster of cells in the right
atrial wall that regulate the heart’s rhythmic rate).
2.1.2 Cardiac Microscopic Structure
The heart consists of millions of cells called myocardial cells. The structure of the myocar-
dial cells is dependent on the electrophysiological function of the specific cell. The vast
majority of these cells belong to the working myocardium, which contracts upon excita-
tion. In the working myocardium, the excitation is passed from cell to cell through direct
intercellular connections, called gap junctions. A part of the myocardial cells is specialized
in electrical excitation initiation and conduction. These cells form the excitation conduc-
tion system, which consists of the sinus node, the atrio-ventricular node, the Purkinje
fibers and the His bundles. The excitation conduction system is described in section 2.2.5.
2.1.2.1 Myocytes
A myocyte is a cell of the myocardium and hence the basic unit of the heart’s muscle. A sin-
gle working myocyte is approximately 50− 120 µm long and has a diameter of 5− 25 µm
[23].
The myocytes are joined together into long fibers by the intercalated discs. The myocytes
belonging to the working myocardium are roughly cylindrical shaped cells, which provide
the myocardial contraction by generating mechanical tension. The tension is generated by
intracellular contractile structures, which produce the necessary force by using adenosine
triphosphat (ATP) and calcium ions [192].
The contractile structures of a myocyte consist of longitudinal arranged formations, called
myofibrilles. The myofibrilles take up the whole length of a myocyte and are divided into
sarcomeres by so-called Z-discs (see figure 2.8). The sarcomeres are the fundamental struc-
tural and functional elements of the myofibrilles [192].
The sarcomeres contain filament-shaped structures called the myofilaments. There are two
types of myofilaments: thick and thin myofilaments. Within a sarcomere, thick and thin
myofilaments overlap, depending on the current state of contraction (see figure 2.9).
The thin myofilamants are formed by actin, while the thick myofilaments consist of myosin.
Inside the overlapping zone, the mechanical force is produced using ATP and calcium ions
[192]. In order to ensure the supply of the myocytes with oxygen and nutrients, every
myocyte is connected to one or more capillary vessels (see figure 2.10).
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Figure 2.8. A schematic overview of myocardium. The figure shows the myocytes connected into long
fibers by the intercalated discs. Every myocyte contains the usual cell organelles like nucleus and mito-
chondria. The myofibrils are located in the interior of the myocytes. The myofibrils consist of thick and
thin myofilaments, which form the contractile structure [188].
The myocyte is sourrounded by a cell membrane in order to separate the interior of the
cell (intracellular space) and the surrounding medium (extracellular space). Referring to
myocytes, the cell membrane is called sarcolemma and has specific electrophysiological
Figure 2.9. A schematic representing the structure of the sarcomeres, myofibrilles and myofilaments. A
sarcomere is limited by the Z-discs. Within a sarcomere, there are thin and thick myofilaments, which over-
lap. The upper figure shows a myofibril in a relaxed state. The overlap of the thin and thick myofilaments
is small. The lower figure shows the myofibril in the contracted state. The overlap of the myofilaments
results in a contraction of the sarcomere [12].
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properties. The sarcolemma is a semi-permeable membrane formed by a pospholipid bi-
layer of around 3− 5 µm thickness. The phospholipids molecules have two hydrophobic
tails attached to a hydrophilic head. In the phospholipid bilayer membrane, the hydropho-
bic tails are joined to each other inside the membrane. Hence, the hydrophilic heads of the
phospholipid molecules are located on the interior and exterior surface of the membrane
[87].
Figure 2.10. A microscopic photography of myocytes surrounded by capillary vessels. Each cell is supplied
by capillaries [13].
There are a number of transmembrane proteins essential for the cell’s function, such as
ionic channels, ionic pump proteins, exchangers and receptors. The ionic channels are
usually specific to certain ion types, such as potassium, sodium and calcium.
2.1.2.2 Gap Junctions
Gap junctions are proteins connecting the intracellular spaces of two neighboring myocytes.
The gap junctions are usually located at the intercalated discs of the myocytes. They pro-
vide a low-ohmic electrical coupling and additionally a mechanical connection between the
intracellular spaces of the connected cells. Since the gap junctions have a barrel-shaped
structure with a diameter of typically 1.5− 2 nm, which is much larger than the typical
diameter of an ion, free diffusion of ions through the junction is possible without any
ion selectivity. In addition, metabolites and cell communication transmitters can be ex-
changed through the channel [271, 279]. Additionally, the pH value of the extracellular
medium affects the gap junction’s resistivity [197]. Gap junctions consist of two so-called
connexons, each provided by one cell. In myocardium, a gap junction typically has a length
of 2− 12 nm and bridges a gap of 2− 3 nm (see figure 2.11) [74, 75, 137, 185, 241, 290].
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Additionally, longitudinal and transversal gap junctions can be differed. A longitudinal
gap junction is orientated in parallel with the myocyte, while a transversal gap junction
is orientated perpendicular to the myocyte.
Figure 2.11. Schematic drawing of gap junctions providing electrical and mechanical coupling between
the intercellular spaces of cardiac cells. The gap junctions consist of two connexons, each originating from
one cell [138].
2.2 Cardiac Cellular Electrophysiology
The periodic mechanical contraction of the heart is the result of a complex interaction of
several different types of cardiomyocytes. The electrophysiological properties of special-
ized myocytes initiate the electrical excitation, conduct the excitation along certain paths
in the heart and produce mechanical tension via the electro-mechanical coupling in the
myocytes of the working myocardium.
In the following sections, the first description refers to the cell membrane with its embed-
ded ion pores. Then, the electrophysiological behavior of the gap junctions is discussed.
Afterwards, the generation of transmembrane voltages and action potentials is explained.
An overview over the excitation conduction system and the ECG can be found at section
2.2.6.
2.2.1 Cell Membrane, Ion Channels and Ion Exchangers
As discussed in section 2.1.2.1, the sarcolemma of the cardiac myocytes contains ion chan-
nels, ion pumps and exchangers, enabling an exchange of ions between the extracellular
space and the myocyte’s intracellular space. The ions most relevant in cardiac electro-
physiological transport phenomenon are Na+, K+ and Ca2+ [216]. Ion channels provide
2.2. Cardiac Cellular Electrophysiology 17
a passive gate through the sarcolemma for ions. The driving forces for ion channels are
chemical concentration gradients and electrical gradients across the cell membrane. The
concentration gradient and the electrical gradient sum up to the electrochemical gradient.
Ion channels are selective for a distinct type of ion. Ion selectivity of the channels is
achieved by chemical reactions. In aqueous solutions, ions are surrounded by water dipoles
electrostatically attached to the ion. In order to enable passage of the ion through the
channel, the ion must be dehydrated by the binding energy between the channel and the
ion. The different hydration energies of different ions in cooperation with the fixed binding
energy of the channel enable ion selectivity in such a way that only the ion matching to
the channel is dehydrated and passes through the channel. Important ion channels are the
Na+, the K+ and the Ca2+ channels. A schematic of an ion channel can be found in figure
2.12 [241]. Ion channels can be gated, which means they can be activated and deactivated.
Transmembrane voltage and several (neuro-)transmitter receptors are possible means for
providing the gating trigger of the channels [32, 236, 246, 276].
Ionic pumps transport ions against the electrochemical gradient by using energy in terms
of ATP. Ionic pumps produce an electrochemical gradient of specific ions, which is used as
the driving force for passive ion channels. Important ion pumps are the (Na-K ) pump and
the Ca2+ pump, both located in the sarcolemma [241]. Ionic exchangers are capable of
exchanging ions in an aqueous solution by using either chemical or electrical gradients. Ion
exchangers are considered as a means of “secondary active” transport since they transport
an ion actively and simultaneously transport an ion passively. An important example is
the (Na/Ca) exchanger located in the sarcolemma [241].
Figure 2.12. A schematic showing the components of a cell membrane. The cell membrane consists of the
phospholipide bilayer, in which ion channels and ion pumps are embedded. Red and blue circles characterize
Na+ and K+ ions, respectively. The Na-K pump and the one exemplary K+ channel as transmembrane
proteins are marked in yellow. The binding sites of the K+ channel are displayed with a minus sign. The
thin arrows across the membrane depict the direction of concentration and voltage gradients. The thick
arrow shows the direction of the ion flow through the membrane proteins [87, 241].
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2.2.2 Electrophysiological Behavior of Gap Junctions
As discussed in section 2.1.2.2, the myocytes of the working myocardium are connected
by gap junctions. The gap junctions conduct the excitation from one cell to another. The
resistivity of the gap junctions is dependent on the concentration of several ions, like the
H+, Ca2+, Na+,Mg2+.
Since the pH value of the extracellular medium affects the gap junction’s resistivity [197],
the resistivity of gap junctions can be altered by drugs affecting the ion concentrations,
or by ischemia, which changes the pH value of the extracellular medium.
2.2.3 Resting Potential and Action Potential
Due to the activity of ion pumps and selective ion channels, the concentrations of ions
differ between the extracellular and intracellular space (see table 2.1). This electrochem-
ical gradient of ions causes a potential difference across the cell membrane called the
transmembrane voltage. The transmembrane voltage is defined as:
Vm = φi − φe (2.1)
where φi is the intracellular potential and φe the extracellular potential.
Ion Concentration (mM)
[Na+]i 10
[Na+]e 140
[K+]i 145
[K+]e 5.4
[Ca2+]i 0.00012
[Ca2+]e 1.8
Table 2.1. Intracellular and extracellular concentrations of several ions [216].
As discussed in section 2.2.1, driving forces for an ion exchange can be the chemical gra-
dient or the electrical gradient. Since ions have a charge (valence z ), every variation in the
chemical gradient leads to a change of the electrical gradient in a way, that it opposes the
chemical gradient.
For every specific type of ion, there exists an equilibrium voltage, where the chemical
and electrical forces are in equilibrium. The equilibrium voltage for a specific ion of a
resting cell can be described by the Nernst equation. The Nernst potential Ex for an ion
x calculates as:
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Ex =
RT
zxF
ln
[x]e
[x]i
(2.2)
In this equation, R is the universal gas constant, T the absolute temperature, zx the
valance of the ion x, F the Faraday’s constant, [x]e and [x]i are the extracellular and intra-
cellular concentration of the ion x, respectively [216]. The equation 2.2 is valid if only one
ion can pass the membrane. The Nernst equation can be expanded to many types of ions,
called the Goldman-Hodgkin-Katz equation. In this equation, each ion concentration [x ] is
associated with the corresponding permeability of the membrane Px. The transmembrane
potential can be calculated as [103, 125]:
E =
RT
F
ln
PK+ [K+]e + PNa+ [Na+]e + PCl− [Cl−]i
PK+ [K+]i + PNa+ [Na+]i + PCl− [Cl−]e
(2.3)
The permeability PK , PNa and PCl of K+, Na+ and Cl− ions, respectively, is given by:
Px =
Dx βx
∆x
(2.4)
with the diffusion coefficent Dx of the ion x, the water-membrane partition coefficient βx
and the thickness ∆x of the membrane. The equation 2.3 is valid if multiple ions can pass
the membrane.
The resting voltage for cardiac myocytes ranges between −30 mV and −100 mV , depend-
ing on the cell type [88].
Excitable cells, such as nervous cells and cardiac tissue cells, can be depolarized by an
external stimulus. The cell reacts with a so-called action potential, which is caused by a
sequence of ion fluxes through the cell membrane. During the action potential, the trans-
membrane voltage rises quickly up to a positive voltage followed by a slow recovery of the
equilibrium state. A typical action potential for a working myocardium myocyte is shown
in figure 2.13.
The action potential can be divided into 5 typical phases. Phase 0 is the rapid depolariza-
tion of the cell. It is caused by a rapid influx of Na+ ions into the cell. In phase 1, the cell
performs a rapid partial repolarization. The Na+ channels are closed and a slow outflow
of K+ ions causes the repolarization. The flat plateau of the action potential at phase 2 is
caused by an inflow of Ca2+ ions. The K+ outflow continues and when the Ca2+ inflow
stops in phase 3, the cell is repolarized to its resting transmembrane potential (phase 4)
[216].
In order to trigger an action potential, the stimulus must be lager than a certain level,
which is called the threshold potential. For sub-threshold stimuli only a passive response
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Figure 2.13. Typical action potential of a myocyte with the 5 typical phases. Phase 4 is the resting
potential in the beginning and in the end. Phase 0 is the rapid upstroke caused by an Na+ influx. The fast
repolarization in phase 1 is caused by a K+ outflux. The plateau of phase 2 is caused by a Ca2+ influx.
The repolarization to equilibrium voltage in phase 3 is caused by a K+ outflux [7].
occurs to reestablish the equilibrium voltage. For a stimulus larger than the threshold
potential, an active response is generated and an action potential will occur [216].
2.2.4 Intracellular Units
In myocytes, the sarcoplasmatic recticulum (SR) plays an important role in intracellu-
lar regulation of the calcium ions concentration. During contraction, the sarcoplasmatic
recticulum releases Ca2+ ions in order to enable coupling between actin and myosin. In
relaxation phase, the SR collects the Ca2+ ion in order to decrease the intracellular Ca2+
concentration and enable relaxation.
2.2.5 Cardiac Excitation Conduction System
The cardiac excitation conduction system consists of pacemakers and conducting tissues.
Pacemaker cells are capable of periodical spontaneous depolarization. The main pacemaker
of the heart is the sinus-atrial (SA) node located in the right atrium. The rate of pace-
making can be controlled by nervous signals. After depolarization of the pacemaker cells
in the sinus-atrial node, the excitation propagates through both atria until it reaches the
antrio-ventricular node (AV node). In a healthy heart, the AV node is the only conducting
connection between the atria and the ventricles.
The AV node delays the propagation of the excitation from the atria to the ventricles and
acts as a frequency limiter. If the rate of pacemaking of the sinus-atrial node gets too high
(approx. 180 bpm), the AV node limits the excitation frequency of the ventricles in order
to ensure the pumping function of the heart. After passing the AV node, the excitation
is propagated by the ventricular conduction system, consisting of the bundle of His and
the Purkinje fibers. The excitation is conducted down the septum and from there it is
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branched to the left and right ventricle. The conduction system consists of specialized
cells ensuring rapid conduction [216]. The sequence of conduction is listed in table 2.2 and
visualized in figure 2.14.
Normal sequence of Conduction velocity Time for impulse to
excitation (ms−1) traverse structure (s)
SA node < 0.01 ᵀ
↓ 0.03
Atrial myocardium 1.0-1.2 ⊥
↓
AV node 0.02-0.05 0.09
↓
Bundle of His 1.2-2.0 ᵀ
↓ 0.04
Bundle branches ᵀ ⊥
↓ 1.5-4.0
Purkinje network ⊥ 0.03
↓
Ventricular myocardium 0.3-0.5 0.3
Table 2.2. Sequence of cardiac excitation with corresponding conduction velocities and intrinsic pacemak-
ing frequencies [216].
2.2.6 Electrocardiogram (ECG)
The electrical activity generated in the heart can be recorded on the body surface providing
a non-invasive measurement of cardiac electrical function [147]. The ECG signal commonly
shows which part of the heart is currently depolarizing and repolarizing. Thus, the ECG
signal reflects the combined effect of depolarization and repolarization for all the individual
cells in the heart. A typical ECG tracing of a normal heart beat consists of a P wave, a
QRS complex and a T wave. The P wave represents the depolarization of the atria from
the sinus-atrial node to the AV node, which is a signature of the current atrial contraction.
The QRS complex represents the depolarization of the ventricles, which corresponds to
the current ventricular contraction. Ventricular depolarization typically occurs rapidly
with duration of 0.06 to 0.1 s. The repolarization of the ventricles generates the T wave
in the ECG [111]. A typical ECG, as it would be recorded by a modern ECG recording
system, is shown in figure 2.14. More detailed information about ECG and standard lead
system will be described as follows.
2.2.7 The Role of Heart Cells in ECG:
The heart consists of three types of cells [267]:
Pacemaker cells, which are small cells approximately 5 to 10 µm size as the cells that
normally initiate depolarization of the heart. These cells are frequently able to depolarize
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Figure 2.14. Schematic of the cardiac excitation as it propagates from the SA-node through the atria to
the AV-node and from there down the septum into the ventricles [67]. Schematic of ECG. The P wave is
caused by the depolarization of the atria. Repolarization of the atria and depolarization of the ventricles
generates the QRS complex. The repolarization of the ventricles is represented by the T wave [91].
spontaneously at a particular rate. The rate of depolarization is determined by the intrin-
sic electrical characteristics of the cell and modified by an external neurohormonal input.
Each spontaneous depolarization works as the source of the depolarization wave, which
initiates one complete cycle of cardiac contraction and relaxation.
An action potential (AP) could be registered by recording one electrical cycle of depolar-
ization and repolarization from a single cell. With each spontaneous depolarization a new
AP is generated which in turn stimulates neighboring cells to depolarize and generate their
own AP. The AP of a cardiac pacemaker cell differs from the generic AP, since it does
not have a true resting potential. Its electrical charge drops to a minimal negative poten-
tial, which maintains only for a short time. Afterward it rises gradually until it reaches
the threshold for the sudden depolarization that is an action potential. These events are
illustrated in figure 2.15.
The SA node is triggered at a rate of 60 to 100 times per minute. The rate can vary
depending on to the activity of the autonomic nervous system (see figure 2.16.a).
Every cell in the heart has the ability to behave like a pacemaker cell. The autonomous
ability is normally suppressed except once the dominant cells of the sinus node fail or an
2.2. Cardiac Cellular Electrophysiology 23
Figure 2.15. The electrical depolarization-repolarization cycle of a cardiac pacemaker cell. Point A is the
minimal negative potential. The gentle rising slope between points A and B represents a slow, gradual
depolarization. At point B, the threshold is crossed and the cell dramatically depolarizes which means an
AP is produced. The downslope between point C and D represents repolarization [267].
external stimulation takes place.
Electrical conduction cells, which are long, thin cells, carry the current rapidly to
the distant regions of the heart. The electrical conducting cells of the ventricles join to
form distinct electrical pathways (see figure 2.16.b). The conducting pathways in the atria
have more anatomic variability, prominent among these are fibers at the top of intra atrial
septum in region called Bachman bundle which allow the rapid activation of the left atrium
from the right atrium.
(a) (b)
Figure 2.16. Pacemaker and conduction system [267]: (a) The SA node triggers 60 to 100 times per
minute producing a regular series of AP, which initiates a depolarization wave to spread through the heart.
(b) Conducting system of the atria and ventricles.
Myocardial cells, which are about 50 to 100 µm size and form the major part of heart
tissue. They are responsible for contracting and relaxing, since these cells contain contrac-
tile proteins (actin and myosin). Once a depolarization wave reaches a myocyte, calcium is
released within the cell causing it to contract (excitation contraction coupling). Myocardial
cells can transmit an electrical current similar to electrical conducting cells but they do
it less efficiently. Thus, a wave of depolarization upon reaching the myocardial cells will
spread slowly across the entire myocardium (see figure 2.17).
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Figure 2.17. Depolarization causes calcium to be released within a myocyte. This influx of calcium allows
actin and myosin to interact [267]: (a) A resting myocardial cell. (b) A depolarized, contracted myocardial
cell.
2.2.8 Depolarization and Repolarization Phases of ECG
The electrical activity of the heart can be recorded on the body surface providing non-
invasive measurements of the cardiac electrical function. The perturbations in normal
electrical patterns are useful to diagnose many different cardiac disorders.
Atrial depolarization: The sinus node triggers spontaneously, producing a depolariza-
tion wave spreading outwards into the atrial myocardium. The depolarization results in
atrial contraction. During atrial depolarization and contraction, electrodes placed on the
surface of the body record a small burst of electrical activity lasting a fraction of a second.
This is the P wave, which is a recording of the spread of depolarization through the atrial
myocardium from beginning to end.
Since the SA is located in the right atrium, the right atrium begins to depolarize before the
left atrium and stops earlier as well. Therefore, the first part of the P wave predominantly
represents right atrial depolarization and the second part left atrial depolarization (see
figure 2.18).
In healthy hearts, there is an electrical gate at the junction of the atria and the ventricles.
The wave of depolarization spreads into the atria. Then electrical conduction must be
directed along inter-ventricular septum through atrio-ventricular node (AV), which slows
down the conduction. This physiological delay in conduction is essential to allow the atria
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(a) (b)
Figure 2.18. Deploarization of atria [267]: (a) After triggering SA node, the wave of depolarization
propagates through both atria, causing them to contract. (b) P wave.
to finish contracting before the ventricles begin to contract.
Ventricular depolarization: The ventricular conducting system consists of bundle of
His, bundle branches and Purkinje fibers.
The bundle of His emerges from the AV node and immediately divides into the right and
left bundle branches. The right bundle branch carries the current down the right side of
the inter-ventricular septum all the way to the apex of the right ventricle. The left bundle
branch divides into three major fascicles:
1. Septal fascicle, which depolarizes the inter-ventricular septum in a left to right direc-
tion.
2. Anterior fascicle, which runs along the anterior surface of the left ventricle.
3. Posterior fascicle, which sweeps over the posterior surface of the left ventricle.
The right bundle branch and the fascicles terminate in countless tiny Purkinje fibers. These
fibers deliver the electrical current into the ventricular myocardium (see figure 2.19).
The ventricular contraction is evident as a QRS complex on the ECG, due to ventricular
depolarization. The amplitude of the QRS complex is much bigger than P wave since ven-
tricles contain more muscle mass than atria. The QRS complex is complicated and variable
in shape reflecting the greater complexity of the ventricular depolarization pathway. The
earliest part of the QRS complex represents the septal depolarization. Although the right
and left ventricles depolarize approximately simultaneously, the signal visible on the ECG
is caused by the left ventricular activation since the left ventricle has three times more
muscle mass than the right ventricle. There is an atrial repolarization wave as well, but it
is hidden by the prominent QRS complex.
The QRS complex consists of several distinct waves, which can be identified as follows
[267]:
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(a) (b)
Figure 2.19. Excitation conduction system [267]: (a) Ventricular conduction system. (b) Ventricular
pacemaker and bundles.
1. Q wave as the first downward deflection
2. R wave as the first upward deflection
3. R′ wave as second upward deflection
4. S wave as a downward deflection followed by an upward deflection. Therefore if the first
wave of the complex is R wave, the ensuring downward deflection is S wave otherwise
Q wave while there is only one downward deflection in the whole complex.
5. QS wave if there is only one downward deflection in the whole complex without any
upward deflection.
The above QRS configurations are demonstrated in figure 2.20.
Figure 2.20. Different configurations of the QRS complex [267].
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The interval starting at the beginning of atrial depolarization and ending at the beginning
of ventricular depolarization is called PQ interval with a duration of 120 to 200 ms.
Ventricular repolarization: The third wave on ECG, named repolarization T wave,
belongs to the refractory period of ventricular myocardium. Normally, the sign of the T
peak amplitude is equal to R peak. The complete ventricular activity is represented by the
time interval starting at the Q peak to the end of the T wave (QT interval). QT interval
duration depends on the heart rate. Therefore it is useful to correct the QT interval fre-
quency e.g. by the Bazett equation [27, 105]:
QTc =
QT√
RR
(2.5)
where QT is the interval measured inms and RR is the interval from R peak from one cycle
to the R Peak of the next cycle. Ventricular repolarization and T wave are demonstrated
in figure 2.21.
(a) (b)
Figure 2.21. Repolarization of ventricles [267]: (a) Ventricular repolarization. (b) T wave.
The ST segment records the time from the end of ventricular depolarization to the start
of ventricular repolarization.
2.2.9 ECG Leads System
The conventional electric connections used for recording the electrocardiogram are the
limb leads, augmented limb leads and precordial leads. This 12 leads ECG system has the
widest clinical application [193]. Each lead is determined by the placement and orienta-
tion of various electrodes on the body. Each lead observes the heart at a unique angle,
enhancing its sensitivity to a particular region of the heart at the expense of the others.
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The more views, the more information provided [267].
To prepare the setup for the 12 lead ECG, two electrodes are placed on the arms and two
on the legs. These provide the six limb leads, which include the three standard leads and
three augmented leads. The rest six electrodes are placed across the chest forming the six
precordial leads. The 12-lead standard ECG comprises 3 bipolar Einthoven I, II, III, 3
uniploar (Goldberger aVL, aVR, aVF) and 6 chest (Wilson V1 - V6) leads.
The six limb leads: The limb leads view the heart in a vertical plane (frontal plane). To
produce the six leads of the frontal plane, each of the electrodes is designated as positive
or negative automatically by the internal circuit of ECG device. Each lead has its own
specific view of the heart’s angle of orientation. The angle of each lead can be determined
by drawing a line from the negative to the positive electrode. The resulted angle is then
expressed in degrees by superimposing it on 360◦ circle of the frontal plane [267].
The three standard bipolar limb leads are defined as follows:
1. A positive signal in lead I is created by making the left arm positive and the right arm
negative. The orientation angle is 0◦.
2. A positive signal in lead II is created by making the legs positive and the right arm
negative. The orientation angle is 60◦.
3. A positive signal in lead III is created by making the legs positive and the left arm
negative. The orientation angle is 120◦.
These three standard bipolar limb leads are developed by Einthoven et al. [167] and mea-
sured as follows:
I = φLA − φRA, (2.6)
II = φLL − φRA, (2.7)
III = φLL − φLA, (2.8)
II = I + III, (2.9)
where φLA, φRA and φLL denote the electrical potential recorded on the left arm (LA),
right arm (RA) and left leg (LL).
The three augmented limb leads are created differently. A single lead is chosen to be
positive and all the others are made negative. The three augmented leads are defined as
follows:
1. A positive signal in lead aVL is created by making the left arm positive and the other
limbs negative. The orientation angle is −30◦.
2.2. Cardiac Cellular Electrophysiology 29
2. A positive signal in lead aVR is created by making the right arm positive and the other
limbs negative. The orientation angle is −150◦.
3. A positive signal in lead aVF is created by making the legs positive and the other limbs
negative. The orientation angle is 90◦.
These three augmented limb leads are developed by Goldberger et al. [167] and measured
as follows:
aV R = φRA − φLA + φLL2 , (2.10)
aV L = φLA − φRA + φLL2 , (2.11)
aV F = φLL − φRA + φLA2 , (2.12)
where φLA, φRA and φLL denote the electrical potential recorded on the left arm (LA),
right arm (RA) and left leg (LL).
All six leads orientation angles are demonstrated in figure 2.22. Leads II, III and aVF are
referred to inferior leads on the other hand leads I and aVL are referred to the left lateral
leads.
Figure 2.22. Orientation angles of limb leads [267].
The six precordial leads: The six precordial leads are arranged across the chest in a
horizontal plane as illustrated in figure 2.23. To create the six precordial leads, each chest
electrode is made positive in turn and the whole body is considered as common ground.
The six positive electrodes are positioned as follows:
1. Lead V1 is placed in the fourth intercostal space to the right of the sternum.
2. Lead V2 is placed in the fourth intercostal space to the left of the sternum.
3. Lead V3 is placed between V2 and V4.
4. Lead V4 is placed in the fifth intercostal space in the midclavicular line.
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5. Lead V5 is placed between V4 and V6.
6. Lead V6 is placed in the fifth intercostal space in the midclavicular line.
All six lead orientation angles are demonstrated in figure 2.23. Leads V1 to V4 are referred
to anterior leads on the other hand leads V5 and V6 are referred to left lateral leads.
Figure 2.23. Orientation angles of precordial leads [267].
Wilson [267] introduced a common point where the limb leads are connected together
through resistors each with 5 kΩ. The potential of this point known as Wilson Central
Terminal (WCT) is almost constant over time with respect to the zero potential as infinity.
φWCT is calculated as:
φWCT =
φRA + φLA + φLL
3
(2.13)
Multichannel ECG lead system: In order to measure a body surface potential map
(BSPM), a multichannel ECG with more than 12 leads is necessary. Using more leads
results in higher spatial resolution, which provides a widespread three dimensional view
of cardiac electrical activity. This can be useful in order to solve the inverse problem for
setting the patient heart model parameters in which a high correlation between measured
and simulated BSPM could be achieved.
A multichannel recording system for biopotential measurements as EEG signals and fur-
thermore ECG signals could be applied to measure the BSPM. The multichannel ECG
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recording system used in this work was the ActiveTwo system of Biosemi [34] with 64
electrodes (see figure 2.24) [164, 165].
1. Six limb leads: three bipolar limb leads of Einthoven and the three augmented unipo-
lar leads of Goldberger could be determined through electrodes A13, C13, C24 and
equation 2.6 to 2.9.
2. Six precordial leads: six unipolar precordial leads of Wilson could be determined
through electrodes A7, B5, B18, C6, C18 and A2.
As shown in figure 2.24, the extracting 12 standard ECG system is possible as follows:
Figure 2.24. The IBT 64-channel ECG lead positions on the human torso with the corresponding electrode
labels.
A BSPM can be measured to assess the electrical information of the heart such as infraction
location and excitation propagation velocity in the conduction system through the math-
ematical computations by solving the inverse problem. In addition, BSPM can be helpful
to investigate the excitation spread over the thorax related to the forward problem.
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2.3 Cardiac Pathology
Since electrical activity triggers mechanical activity, abnormal electrical patterns normally
lead to an abnormal contractile activity of the heart. The main differences from physiology
are classified as follows [245]:
1. Abnormalities in rate
2. Abnormalities in rhythm
3. Congestive heart failure
However, there is no absolute distinction between above classes while some pathologies
belong to more than one groups.
2.3.1 Abnormalities in Rate
A rapid heart rate of more than 100 beats per minute in rest is called tachycardia whereas
slow heart rate of fewer than 60 beats per minute is called bradycardia. Different types of
tachycardia are as follows [11]:
1. Supraventricular tachycardia (SVT): A fast heart rate often over 150 beats
minute, which starts in the heart’s atria or in the upper part of the electrical con-
duction system. Symptoms include palpitations, chest pains, upset stomach, decreased
appetite, lightheadedness or weakness. Patients often need to have a radiofrequency
ablation to cure the problem.
2. Atrial tachycardia: A fast heart rate which starts in the heart’s atria and is con-
ducted to the ventricles. Atrial tachycardia, sometimes called atrial flutter is a particu-
lar type of SVT observed in young adults, which can be classified as rhythm abnormal-
ities too. Besides a fast heart rate, other symptoms are fatigue, dizziness, lighthead-
edness and fainting. It usually requires treatment with medications, radiofrequency
ablation or surgery.
3. Ventricular tachycardia: A fast heart rate which starts in the heart’s ventricles.
It usually results from serious heart disease and often requires prompt or emergency
treatment. Symptoms can be mild but are generally severe. They include dizziness,
lightheadedness and fainting. Treatment options include medication, radiofrequency
ablation, implanting a device that shocks the heart into a normal rhythm or surgery.
2.3.2 Abnormalities in Rhythms (Cardiac Arrhythmia)
Any deviation from the normal rhythm and sequence of excitation of the heart is an ar-
rhythmia. It may result from SA node activity alternation or intervention with conduction.
Instances of abnormal rhythm are heart block, atrial flutter, atrial fibrillation, ventricular
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fibrillation, extrasystoles or premature ventricular contractions originating from an ectopic
focus, which can be detected with ECG. Atrial flutter and atrial fibrillation have a close
clinical interrelationship [281]. The most common abnormalities are as follows [245].
1. Atrial flutter: A rapid but regular sequence of atrial depolarization at rates between
200 and 380 beats per minute, which is usually associated with a fast heart rate or
tachycardia and belongs to the category of supra-ventricular tachycardia. Since the
refractory period of conducting tissues is longer than atrial muscle, the AV node is
unable to respond to every impulse that converges on it from the atria. Possibly one
from every two or three atrial impulses successfully passes through the AV node to
the ventricles (2:1 or 3:1 rhythm). Atrial flutter occurs when electrical impulses take
an abnormal path through the atria, typically circulating around the tricuspid valve
in the right atrium. Atrial flutter is arising from a macro reentrant circuit in the right
atrium or around scar tissue [222, 238]. It often occurs in individuals with cardiovas-
cular disease (eg: hypertension, coronary artery disease, and cardiomyopathy).
2. Atrial fibrillation (AF): A rapid, irregular, uncoordinated depolarization of atria.
Accordingly, the normal electrical impulses generated by the SA node are plagued by
disorganized electrical impulses originating in the atria and pulmonary veins. This phe-
nomenon leads to an irregular impulse conduction to the ventricles, which results in
an irregular heartbeat. Atrial fibrillation may be continuous (persistent or permanent
AF) or alternating between periods of a normal heart rhythm (paroxysmal AF). The
natural tendency of AF is to become a chronic condition. Chronic AF leads to a small
increase in the risk of death [31, 70, 190, 245, 280]. Atrial fibrillation may be treated
with medications, which either slow the heart rate or revert the heart rhythm back to
normal. Synchronized electrical cardioversion may also be used to convert AF to a nor-
mal heart rhythm. Surgical and catheter-based therapies may also be used to prevent
recurrence of AF in certain individuals. In general, atrial flutter should be treated the
same as atrial fibrillation. Atrial flutter is considerably more sensitive to electrical car-
dioversion than atrial fibrillation, and usually requires a lower energy shock. Because
of the reentrant nature of atrial flutter, it is often possible to ablate the circuit that
causes atrial flutter.
3. Ventricular fibrillation (VF): Very serious rhythmic abnormality in ventricular my-
ocardium reveals uncoordinated, chaotic contractions. Multiple impulses travel errati-
cally in all directions within the ventricles. It generally occurs within diseased hearts.
In most cases, VF is a manifestation of underlying ischemic heart disease. Ventricular
fibrillation is also observed in those patients with cardiomyopathy, myocarditis, and
other heart pathologies. If circulation is not restored in less than a few minutes through
external cardiac compression or electrical defibrillation, irretrievable brain damage oc-
curs and death is expected [245]. In patients at high risk of ventricular fibrillation,
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the use of an implantable cardioverter defibrillator has been shown to be beneficial. A
premature contraction of the heart independent of the normal heart rhythm may cause
an extrasystole.
4. Heart block: A type of arrhythmia appears from the defection in the cardiac con-
ducting system. The atria still beat regularly but the ventricles occasionally fail to
be stimulated. Therefore, the ventricles do not contract following atrial contraction.
Impulses between atria and ventricles can be blocked to varying degrees [245]. In heart
block, the atrial rate is normal but the ventricular rate is less than normal. Complete
heart block is characterized by complete distinction between atrial and ventricular acti-
vation whereas the impulses from atria could not be conducted to the ventricles. When
a bundle branch or fascicle becomes injured, it may affect the conduction of electri-
cal impulses. This results in altered pathways for ventricular depolarization. Since the
electrical impulses can no longer use the preferred pathway across the bundle branch, it
may move instead through muscle fibers in a way that both slows the electrical move-
ment and changes the direction of the impulses. As a result, there is a loss of ventricular
synchrony, ventricular depolarization is prolonged and there may be a corresponding
drop in cardiac output. When heart failure is present, a pacemaker may be used to
resynchronize the ventricles. The blockage can occur in any stage of conduction system:
• Atrio-ventricular block (AVB), is a type of heart block involving the disconnection
between the atrial and ventricluar conduction of the heart. If the conduction sys-
tem is blocked after the atrio-ventricular node, the excitation can not propagate to
the bundle of His, the AVB is resulted which leads to hardly any excitation of the
ventricles [222].
• Left bundle branch block (LBBB), is a type of heart block involving the disconnec-
tion between the bundle of His and left bundle branch. If the conduction system
is blocked after bundle of His in which, the excitation can not propagate to the
left ventricle, the LBBB is resulted. LBBB leads to a delayed excitation of the left
ventricle not via the physiological conduction [222].
• Right bundle branch block (RBBB), is a type of heart block involving the disconnec-
tion between the bundle of His and right bundle branch. If the conduction system
is blocked after bundle of His where, the excitation can not propagate to the right
ventricle, the RBBB is resulted. RBBB leads to a delayed excitation of the right
ventricle not through the physiological conduction system [222]. Both LBBB and
RBBB lead to asynchronous ventricular contraction.
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2.3.3 Congestive Heart Failure
The traditional view that heart failure is a constellation of signs and symptoms caused by
inadequate performance of the heart focuses on only one aspect of the pathophysiology
involved in the syndrome [133].
1. Cardiac myopathy: is a deterioration of the function of the myocardium. It is the
damage of the heart muscle by ischemia, as a most common cause. Ischemic cardiomy-
opathy is a weakness in the muscle of the heart due to inadequate oxygen delivery to the
myocardium with coronary artery blockage as a common cause. This condition is acute
myocardial infarction commonly called heart attack. The area of the heart affected by
a myocardial infarction will initially become necrotic, and then will be replaced by
scar tissue (fibrosis). This tissue is no longer muscle and can not contribute to the
heart’s function as a pump [68]. Not only working myocardium suffers from ischemic
cardiomyopathy but also the conduction pathways can be disturbed, since the conduc-
tion system remains at decreased oxygen supply [222]. Figure 2.25 demonstrates the
different infarction positions caused by different blocked locations of coronary artery.
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 2.25. Several infarction positions [191]. (a) Anterolateral. (b) Anteroseptal. (c) Apical. (d) Antero-
basal. (e) Posteroinferior. (f) Posteroseptal. (g) Posterolateral. (h) Posterobasal.
2. Left ventricular remodeling: is the process by which mechanical, neurohormonal
and genetic factors alter ventricular size, shape, and function. Remodeling occurs in
several clinical conditions, including myocardial infarction, cardiomyopathy, hyperten-
sion, and valvular heart disease [92, 133, 259]. For example, after a myocardial in-
farction, the acute loss of myocardial cells results in abnormal loading conditions that
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involve not only the central and border zone of the infarction, but also remote my-
ocardium. These abnormal loading conditions induce dilatation and change the shape
of the ventricle, rendering it more spherical, as well as causing hypertrophy. Remodeling
continues for months after the initial insult, and the eventual change in the shape of the
ventricle becomes deleterious to the overall function of the heart as a pump (see figure
2.26) [133, 205]. In cardiomyopathy, the process of progressive ventricular dilatation
or hypertrophy occurs without the initial apparent myocardial injury observed after
myocardial infarction (see figure 2.27) [133]. Several trials involving patients who were
studied after a myocardial infarction or who had dilated cardiomyopathy found a bene-
fit from ACE (Angiotensin Converting Enzyme) inhibitors, beta-adrenergic antagonists
or cardiac resynchronization [49, 109, 112, 133, 237]. Such beneficial effects were asso-
ciated with so-called reverse remodeling, in which the therapy promoted a return to a
more normal ventricular size and shape [49, 109, 112, 133, 237]. The reverse-remodeling
process is a mechanism through which a variety of treatments palliate the heart failure
syndrome.
Figure 2.26. Ventricular remodeling after acute infarction [133].
3. Mitral regurgitation: An outcome of remodeling is the development of mitral re-
gurgitation. As the left ventricle dilates and the heart assumes a more globular shape,
the geometric relation between the papillary muscles and the mitral leaflets changes,
causing restricted opening of the leaflets and distortion of the mitral apparatus. Dilata-
tion of the annulus occurs as a result of increasing left ventricular or atrial size or as
a result of regional abnormalities caused by myocardial infarction [71, 114, 133, 199].
The presence of mitral regurgitation results in an increasing volume overload on the
overburdened left ventricle that further contributes to remodeling, the progression of
disease, and to symptoms. Correction of mitral regurgitation has been an appropriate
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Figure 2.27. Ventricular remodeling in diastolic and systolic heart failure [133].
focus of therapy.
4. Hypertensive heart disease: caused by high blood pressure. Hypertensive heart
disease is a late complication of hypertension (high blood pressure) in which the heart
is affected. High blood pressure increases the heart’s workload and over time, this can
cause the heart muscle to thicken. As the heart pumps against elevated pressure in
the blood vessels, the left ventricle becomes enlarged (hypertrophy) and the amount
of blood pumped by the heart each minute (cardiac output) decreases. Without treat-
ment, symptoms of congestive heart may develop [127].
5. Diastolic heart failure: Some patients with heart failure have preserved systolic
function or a normal left ventricular ejection fraction. Although such hearts contract
normally, relaxation (diastole) is abnormal. Cardiac output, especially during exercise,
is limited by the abnormal filling characteristics of the ventricles. For a given ventricular
volume, ventricular pressures are elevated, leading to pulmonary congestion, dyspnea
and edema identical to those seen in patients with a dilated, poorly contracting heart
[21, 52, 133, 275, 302]. The diagnosis of diastolic heart failure is usually made by
a clinician who recognizes the typical signs and symptoms of heart failure systolic
function (i.e., a normal ejection fraction) on echocardiography. Echocardiography may
be useful in the detection of diastolic filling abnormalities.
2.4 Cardiac Function Parameters
Abnormal ECG waves are important in recognizing and assessing cardiac myopathies,
left bundle branch block, right bundle branch block, extrasystole and some other abnor-
malities. In order to investigate the function of the heart to determine whether there is
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an abnormality or not, following parameters could be measured in clinical studies [60, 245]:
End diastolic volume (EDV): The volume of the blood in the ventricle at the end of
diastole, which averages about 135 ml.
End systolic volume (ESV): The amount of blood left in the ventricle at the end of
systole when ejection is complete. It averages about 65 ml.
Stroke volume (SV): The difference between the blood volume in the ventricle before
contraction and the volume after contraction.
SV = EDV − ESV (2.14)
Ejection fraction (EF): The percentage fraction of blood ejected by the ventricle (often
left ventricle) during the contraction phase of the cardiac cycle.
EF =
SV
EDV
× 100% (2.15)
Cardiac output (CO): The volume of blood pumped by each ventricle per minute. This
is achieved by multiplication of stroke volume and heart rate (HR). Since the average
resting heart rate is 70 beats per minute and the average resting stroke volume is 70 ml
per beat, an average cardiac output of 4900 ml/min is expected for a normal heart.
CO = SV ×HR (2.16)
Cardiac index (CI): A cardiodynamic measure based on the cardiac output, which is
the amount of blood the left ventricle ejects into the systemic circulation in one minute,
measured in liters per minute (l/min). Cardiac output can be indexed to a patient’s body
size by dividing by the body surface area (called the BSA) to yield the cardiac index. The
normal range of cardiac index is 2.6− 4.2 l/min per square meter.
CI = SV × HR
BSA
(2.17)
Maximal oxygen consumption (VO2max): VO2max is reached when oxygen consumption
remains at a steady state despite an increase in workload during clinical exercices. VO2max
is properly defined by the Fick Equation:
VO2max = CO × (CaO2 − CvO2) (2.18)
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where CO is the cardiac output of the heart, CaO2 is the arterial oxygen content, and
CvO2 is the venous oxygen content.
Ratio of early to late ventricular filling (E/A): Echocardiographic phases of ven-
tricular filling are defined as early E-wave and atrial A-wave. The area under the E-wave
reflects the rapid filling phase in LV diastolic filling. The area under A-wave reflects the
contribution of atrial contraction to LV diastolic filling. The E/A ratio is reduced in dias-
tolic dysfunction. Figure 2.28 demonstrates the ECG and transmitral flow velocity curve.
Transmitral flow
velocity curve
ECG
mitral E wave mitral A wave
DT mitral A duration
Figure 2.28. ECG and transmitral flow velocity curve. DT ist the deceleration time which is a measure
of how rapidly early diastolic filling stops [89].

3Cardiac Resynchronization Therapy
In patients with heart failure, the first choice of therapy is medication. Nevertheless, resis-
tance to drugs mainly over a long time requires other treatment options. Cardiac resyn-
chronization therapy (CRT) in forms of biventricular pacing (BVP) has emerged as an
alternative treatment for patients classified by the New York Heart Association (NYHA)
classification as type III-IV heart failure, which is the result of normal ventricular func-
tion loss. CRT leads to an improvement in hemodynamics by coordinating the ventricular
contraction and results in less hospitalization [2, 50, 64, 66, 121, 169, 230, 292].
Dyssynchronous left ventricular contraction reduces myocardial efficiency, which leads to
abnormal diastolic interactions between the ventricles, increasing the mitral regurgitation
and the risk of sudden cardiac death. Therefore, the patients with congestive heart failure,
who have sufficiently low left ventricular ejection fraction (LVEF) and usually prolonged
QRS duration in ECG, are candidates for CRT [143].
It is important to identify the exact patients who may respond to the therapy in order to
optimize the lead positioning and device programming to maximize the benefit of CRT.
The diagnosis of heart failure patients can be confirmed by a number of tests including
electrocardiogram (ECG), echocardiography, magnetic resonance imaging, radionuclide
ventriculography, angiography as well as blood tests [95, 189].
At present, the best established evidence of heart failure is the presence of the echocar-
diographic left ventricular dyssynchrony [25, 53, 203]. However, several different methods
have been proposed for assessment and interpretation of dyssynchrony. Further, these pa-
rameters can be technically difficult to assess in some patients.
Moreover, studies have demonstrated that dyssynchrony can be determined via longitudi-
nal delay of tissue Doppler imaging [25, 251], color coded dyssynchrony imaging [297] and
myocardial speckle tracking [258].
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3.1 History of CRT
Cardiac resynchronization therapy was introduced in the early 1990s and developed signif-
icantly over time [3]. At the beginning of the 90s, Hochleitner et al. [123] proposed for the
first time artificial cardiac pacing (dual chamber pacemaker with a short atrio-ventricular
interval) as a treatment for refractory heart failure. Early clinical trials of the CRT were
carried out in the USA and Europe from 1995 to 1998 using a thoracoscopic procedure for
lead positioning on the lateral wall of the left ventricle [17, 62]. In 1998 Daubert et al. [72]
reported a technique of transvenous implantation by passing a lead through a cardiac vein
via the coronary sinus to enable left ventricular pacing on the epicardial surface. However,
despite further developments, this implantation technique remains challenging and time
consuming [97].
Nevertheless, about 20 - 30 % of patients in randomized clinical trials do not respond to
CRT [154]. This may be due to a variety of reasons, such as improper patient selection,
inappropriate lead positioning or suboptimal pacemaker device programming concerning
the timing delays [121, 169, 268].
According to the reasons above, it is important to identify accurately those patients who
may respond to the therapy in order to further optimize lead pacing and device program-
ming to maximize the benefit of CRT.
3.2 Etiology of Heart Failure: Indication for CRT
Heart function can be investigated either hemodynamically by left ventricular ejection
fraction (LVEF) or electrically by analyzing the shape and duration of QRS complex of
an ECG waveform, or mechanically by measuring the contraction delay in Doppler echog-
raphy.
Patients with an extensive QRS complex frequently have dyssynchronous ventricular con-
traction while the broad QRS indicates the sequence of electrical activation of the ventricles
as well as the time taken for depolarization [189].
Most patients who receive CRT will have an improvement in their symptomatic status. Tri-
als have demonstrated an overall mean increase in maximal oxygen consumption (VO2max)
during the exercises of patients who are on CRT. In addition, echocardiographic data
demonstrate a reduction in left ventricular dimensions and severity of mitral regurgitation
[97, 295].
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Nevertheless, dramatic treatment results were observed in patients who have no objective
clinical benefit after implantation of CRT [1, 223]. For instance Buch et al. [53] hypothe-
sized that in the presence of apical left ventricular (LV) dysfunction, BVP might be less
effective.
Moreover Bleeker et al. [37] recently showed that even in the presence of dyssynchrony,
patients with posterolateral scar (see figure 2.25) were unlikely to respond to CRT, prob-
ably because of ineffective LV pacing. Therefore in the stage of CRT assessment for an
individual patient, it is important to identify the exact responders and non-responders.
Analysis of the ventricular activation by vectorcardiography, signal averaged ECG or non-
contact endocardial mapping might play a role in patient selection [152]. The accepted
patient selection criteria of CRT are described as follows [16, 40, 97, 144, 228]:
1. NYHA functional class III - IV
2. Left ventricular ejection fraction < 35 %
3. Left ventricular end diastolic diameter > 55 mm
4. QRS duration > 120 ms [16, 206, 287] or 135 ms [97, 230]
5. QRS duration < 130 ms with LV intra-ventricular dyssynchrony
6. Left or right bundle branch block and other intra-ventricular delays
Left ventricular ejection fraction (LVEF) can be estimated by echocardiography in which
the volume of the left ventricle is measured during the cardiac cycle, contrast ventriculog-
raphy or radionuclide scanning. Intra-ventricular dyssynchrony in criterion 5 is defined as
the difference of at least 60 ms between the timing of the peak systolic velocities of the
septum versus the lateral wall by tissue Doppler imaging (TDI) [26, 293].
The impact of age and gender on CRT outcome has been investigated by Zardkoohi et al.
[299]. There were no significant differences between men and women regarding age except
those suffering from ischemic cardiomyopathy. This finding was also supported by study
of Bleeker et al. [38].
Buch et al. [53] showed that the presence of preimplantation apical wall motion abnor-
mality in patients with ischemic cardiomyopathy and cardiac dyssynchrony determined by
either prolonged QRS duration or echocardiographic dyssynchrony, was associated with a
lower rate of CRT response. This may be attributable to increased wall stress due to late
activated myocardial segments but the underlying mechanisms require further investiga-
tion. Outcomes in major randomized CRT trials including MIRACLE, MIRACLE-ICD,
COMPANION, CARE-HF show an improvement in NYHA functional class, ejection frac-
tion and quality of life [150].
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In most studies, echocardiographic parameters including LVEF, left ventricular end dias-
tolic diameter (LVEDd) and regional wall motion were recorded before CRT implantation
(baseline) and after implantation weeks or months later (follow up).
Table 3.1 demonstrates several studies in which the parameters determining the responders
or non-responders to CRT are investigated.
Study Criteria Responders Non-responders
Baseline Follow up Baseline Follow up
Penicka et al. [203]
LVEF (%) 24 ± 5 37 ± 8 27 ± 6 27 ± 8
LVEDd (mm) 73 ± 7 67 ± 8 73 ± 7 73 ± 7
LVESd (mm) 61 ± 6 52 ± 7 62 ± 8 60 ± 9
LVEDV (ml) 289 ± 72 251 ± 79 297 ± 82 298 ± 87
LVESV (ml) 224 ± 63 159 ± 58 219 ± 75 223 ± 80
E/A of mitral inflow 1.57 ± 0.97 1.28 ± 0.73 2.16 ± 1.24 1.44 ± 0.74
Buch et al. [53]
LVEF (%) 22.9 ± 6.7 29.8 ± 9.9 23.1 ± 8.3 26 ± 11.1
LVEDd (mm) 63 ± 9 64 ± 8 63 ± 9 63 ±10
MR quantification 1.6 ± 0.8 1.1 ± 0.4 1.5 ± 0.7 1.6 ± 0.7
QRS duration (ms) 159 ± 43 150 ± 18 159 ± 36 167 ± 24
Toggweiler et al. [268]
LVEF (%) 27.5 ± 12.8 29.8 ± 34.5 - -
LVEDV (ml) 187 ± 84 183 ± 74 - -
LVESV (ml) 144 ± 82 126 ± 65 - -
VTILVOT(cm) 10.8 ± 3.7 13 ± 4 - -
Becker et al. [28]
LVEF (%) 31 ± 5 43 ± 7 - -
LVEDV (ml) 312 ± 97 289 ± 81 - -
LVESV (ml) 214 ± 68 172 ± 60 - -
VO2max(ml/kg/min) 10.8 ± 3.7 13 ± 4 - -
Van de Veire et al. [73]
LVEF (%) 23 ± 7 24 ± 8 32 ± 9 25 ± 9
LVEDV (ml) 266 ± 93 219 ± 74 224 ± 93 215 ± 88
LVESV (ml) 207 ± 85 170 ± 74 156 ± 77 167 ± 85
LVEF: left ventricular ejection fraction, LVEDd: left ventricular end diastolic diameter, LVESd: left
ventricular end systolic diameter, LVEDV: left ventricular end diastolic volume, LVESV: left ventricular
end systolic volume, MR: mitral regurgitation, VTILVOT: velocity time integral in left ventricular outflow
tract, VO2max : peak oxygen consumption
Table 3.1. Some studies determining the CRT responders and non-responders due to the parameters
change representing the efficacy.
3.3 Biventricular Pacing
The pacemaker is an electronic, battery-powered device that is surgically implanted sub-
cutaneously. The purpose of a biventricular pacemaker is to improve the ventricular syn-
chronization and cardiac output. The BVP device comprises 3 electrode leads, which are
positioned in the heart to help the ventricles contraction in a more balanced way. The leads
are implanted through a vein in the right atrium and right ventricle as well as the coronary
sinus vein to pace the left ventricle. Modern pacemakers are externally programmable in
which the cardiologist might be able to select the finest pacing mode. Patients with a risk
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of cardiac arrest due to ventricular tachycardia or ventricular fibrillation may receive an
implantable cardioverter defibrillator (ICD) device to detect and rip such arrhythmia. CRT
device can be performed with or without ICD. Two main types of CRT devices available
in Europe are CRT-P (without ICD, low energy) and CRT-D (with ICD, high energy)[61].
The CRT devices are available from a variety of companies, for example St. Jude Medical,
Medtronic ELA Medical, Biotronik, Sorin and Guidant. Modern pacemakers have multiple
functions. The InSync R© cardiac resynchonization system (Medtronic) has globally been
available since 2001 while the Guidant cardiac resynchronization therapy defibrillator sys-
tem was approved by the US Food and Drug Administration (FDA) in 2002 (see figure
3.1) [173, 272].
Biventricular pacing either simultaneously or sequentially improves the left ventricular
systolic performance and reduces the ventricular dyssynchrony in patients with heart fail-
ure and bundle branch block.
(a) (b)
Figure 3.1. BVP devices from Medtronic [128].
3.3.1 Implantation Techniques
The BVP device can be implanted using endocardial or epicardial approach with the aid
of a fluoroscopy machine to perform correct electrode conduction. A small incision after a
local anesthetic or general anesthesia is made on the chest where the leads and device are
inserted. The leads are guided transvenously through a vein into the heart. The leads are
directed to the right atrium, right ventricle and left ventricle (see figure 3.2). Therefore,
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implantation of the lead, which previously required thoracotomy, has been very simplified
with the adoption of the endocavitary access, being performed with local anesthesia. The
lead tips are attached to the heart muscle, while the other ends of the leads are attached to
the pulse generator, which is placed under the chest skin. Since the left ventricle belongs
to the cardiovascular high-pressure system, the left ventricular (LV) implantation is more
difficult. The LV lead is usually positioned at the lateral, anterolateral or posterolateral
wall of left ventricle and this is performed transvenously using a coronary sinus branch.
Implantation of an epicardial pacemaker lead in the left ventricle which previously required
thoracotomy has been simplified with the adoption of the endocavity access [98]. There
are several studies, which investigate the influence of various pacing sites on the LV in
cardiac output [100, 228, 273, 274].
(a) (b)
Figure 3.2. Biventricular pacing device: (a) Passing the electrodes through the venous system [210]. (b)
Location of the device under the chest skin [120].
Several studies illustrated techniques for BVP implantation in clinical trials and the ef-
fects of BVP on the patient heart [150, 264]. The techniques involve obtaining of venous
access using either the cephalic vein cut-down or subclavian puncture. The coronary sinus
is then cannulated using an electrophysiological catheter and a long guiding sheath. Once
the coronary sinus is cannulated, the sheath is advanced into the coronary sinus. After
removing the electrophysiological catheter, a balloon tipped catheter is inserted via the
sheath into the coronary sinus. The balloon is inflated temporarily to occlude flow in the
coronary sinus. Then an amount of non-ionized contrast medium is injected to visualize
the venous system and the branches of the coronary sinus (see figure 3.3). Images are
captured generally at 30 degrees right anterior oblique, 60 degrees left anterior oblique
and anteroposterior. The catheter is then removed and the left ventricular lead advanced
into the coronary sinus. Soft tines at the tip of the lead enable successful passive fixation
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in the coronary sinus [264]. The optimal site for left ventricular pacing is in the lateral or
posterolateral cardiac vein, while pacing from the mid lateral wall or posterior wall results
in a raise in pulse pressure and left ventricular dP/dt [295].
However, if there is not enough time to carry out the pacing procedure, a stable position is
not achievable. Therefore in these cases, the lead is positioned in the anterior great cardiac
vein. Once the left ventricular lead is secured, the right ventricular apex lead and right
atrial lead are then implanted in the usual manner for a dual chamber pacemaker. Where
possible, the RV and LV lead should however be anatomically as far apart as possible (see
figure 3.4). The three leads are then connected to the pulse generator device and the whole
system placed in the subcutaneous pocket just above the pectoralis major muscle on the
chest (Guidant or the Medtronic Insync CRT devices are used commonly).
(a) (b)
Figure 3.3. Illustration of coronary sinus branches using angiography [264]: (a) Right anterior oblique 30
degree view. (b) Left anterior oblique 60 degree view.
Buch et al. [53] utilized a similar implantation approach. The LV lead implantation was
performed via coronary sinus in order to achieve permanent epicardial stimulation from
a lateral or posterolateral vein. If these veins were not accessible, the LV lead was im-
planted in a diagonal vein near the lateral LV wall. The RV lead was placed in the RV
apex. The lead position was determined during implantation by fluoroscopy in the left
anterior oblique and right anterior oblique projections. Final lead position was assessed by
postoperative chest radiograph in the anteroposterior and lateral views.
Implantation of a BVP device is expensive, time consuming and involves risks, so it is im-
portant to accurately identify patients who are responders and to optimize lead positioning
and device programming in order to maximize the patient’s benefit.
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(a) (b)
Figure 3.4. Illustration of leads position using radiographs [264]: (a) Right anterior oblique 30-degree
view. (b) Left anterior oblique 60-degree view.
3.3.2 Electrode Positions
Butter et al. [57] showed that the LV pacing site was a crucial factor in determining the
effects of CRT, with lateral sites constantly producing better hemodynamic response than
anterior sites. Most studies suggest a posterolateral position for the LV lead. This can be
explained by the fact that these sites are consistently the latest to be activated during
contraction. Contrarily, anterior wall sites are usually activated earlier [6, 19].
Pacing on the free wall includes the implantation of the lead in lateral, anterolateral and
posterolateral veins. It is difficult to deliver a lead to the most suitable site of the ventricle
and this may be one reason for the proportion of the non-responders. In these cases the
surgical epicardial lead implantation should be applied instead of transvenous pacing.
Several studies investigated the influence of the various electrode positions on the cardiac
output improvement. For instance, Sogaard et al. [252] examined the high inter-ventricular
septum or the right ventricular outflow tract (RVOT) for pacing the RV electrode and the
LV free wall for the LV pacing. Liberman et al. [157] has also suggested the RVOT as a
more physiological site for cardiac pacing. Once the boundaries of the RVOT have been
defined, it is necessary to define the actual pacing positions within this area. For sim-
plicity, the RVOT was divided into four quadrants. The RVOT is divided horizontally
by a line midway between the pulmonary valve and the lower border, forming an upper
and lower half. These two halves can be divided vertically by a line that connects the
pulmonary valve to the RVOT lower border and in this way dividing the RVOT into the
right ventricular septal and free wall. The created quadrants define high and low septal
RVOT and high and low free-wall RVOT positions. The ECG confirmation of pacing in the
right ventricular septum is manifested by a negative QRS morphology in lead I, whereas
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pacing in the right ventricular free wall manifests as a positive QRS morphology in lead I.
Furthermore, ventricular pacing in a high position will result in an upright QRS in aVF,
whereas with a lower position it will have a less positive QRS deflection in aVF.
A study of Analson et al. [15] showed that the probability of the latest mechanical ac-
tivation in the lateral wall is 35 %. This existence probability decreases in anterior and
posterior regions to 26 % and 23 % respectively, whereas the inferior wall (septum) in-
frequently shows the latest mechanical activity (16 %). The study has demonstrated that
optimal resynchronization could be obtained when the region with the latest activity de-
termined by echocardiography is paced. From this perspective, 3D echocardiography may
potentially identify the latest activated region for electrode pacing [24].
A recent study of Becker et al. [28] has investigated the efficacy of the CRT according to a
proper selection of the LV lead. This study sought: firstly to identify the LV segment with
latest mechanical contraction based on the myocardial deformation imaging method using
tracking procedure of acoustic markers in 2D echocardiographic images [80, 106]. Secondly
to determine the CRT efficacy for the LV lead position in the segment selected accord-
ing to its greatest mechanical delay. The study demonstrates a relative simple approach
to determine the LV position based on a detailed analysis of the myocardial contraction
sequence before and on CRT. The LV lead position determined by circumferential strain
analysis was found to be in high agreement with the anatomical LV lead position de-
fined by fluoroscopy. A great reduction of QRS duration has been demonstrated to be an
electrical marker of optimal CRT pacing [155]. This study evaluated concordance of the
segment with earliest peak strain after CRT and the segment having the latest peak strain
before CRT as a mechanical marker for optimal CRT. There was a significant relationship
between the distance of the assumed LV lead position defined by a detailed myocardial
deformation imaging analysis to the segment with greatest need for pacing and the im-
provement of LV function. Agreement of the assumed LV position and segment with latest
contraction prior to CRT resulted in greatest functional response.
A study of Helm et al. [118] has searched an optimal LV pacing site for hearts with de-
layed lateral contraction due to LBBB. The study was conducted in 10 canine hearts.
Hemodynamic pressure volume data were recorded and results for each pacing site were
derived from an average of 10 sequential cycles. These data were used to derive arterial
pulse pressure (dP/dtmax). Mechanical dyssynchrony was indexed by the circumferential
uniformity ratio estimate (CURE) [118, 119, 153]. The optimal pacing sites were at lateral
wall based on the maximal dP/dtmax response. The optimal pacing region was determined
using a cost function defined as the ratio of the mean benefit from pacing within a given
region divided by its relative size as a percentage of the LV surface. Very selective regions
may have the highest mean CRT response. The regions defining the optimal response more
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than 70 %, 80 % and 90 % are demonstrated in figure 3.5.
(a) (b)
Figure 3.5. Optimal LV pacing region with cost function: (a) Isoregions of 70 %, 80 % and 90 % corre-
sponding to maximal CRT response for different LV pacing sites. The maximal response is an average from
several electrodes yielding peak or nearly peak responses. (b) Cost function is calculated as the ratio of
the mean functional response divided by the size of territory (percent of LV free wall). Function is plotted
for regions providing varying percent levels of the maximal obtainable CRT benefit. The peak trade off
between response and region size was at more than 70 % level and was considered as optimal regions.
Optimal pacing region is achieved by minimal cost function and maximal cardiac response [118].
The main achievements in the study of Helm et al. [118] were:
1. The optimal LV pacing region is fairly broad and centered over the mid to apical lateral
LV wall
2. Reasonable concordance exists between regions that yield the most mechanical syn-
chrony and those achieved optimal LV systolic and diastolic performance
A summary of the studies in which different lead positions are investigated is demonstrated
in table 3.2.
Author Right electrode position Left electrode position
Kass et al. 1999 [139] RVA, midseptal free wall
Sogaard et al. 2002 [252] high inter-ventricular septum, free wall
RVOT
Teo et al. 2003 [264] RVA lateral, postolateral
*Verbeek et al. 2003 [278] RVA, RVOT anterolateral, posterolateral
Van Campen et al. 2006 [273] RVA, RVOT anterolateral, posterolateral
Yoshida et al. 2007 [291] RVA, (RVOT in case of Tri-V) lateral
Helm et al. 2007 [118] RVA entire free wall
RVA: right ventricular apex, LVA: left ventricular apex, RVOT: right ventricular outflow tract, Tri-V:
triangle ventricular pacing, * implemented on the dogs heart
Table 3.2. Several studies since 1999 on CRT in which various positions of the electrodes have been
investigated.
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3.3.3 Timing Delays
As discussed, a BVP device constitutes 3 electrodes: one sensing electrode in the right
atrium and two pacing electrodes in the left and right ventricle. When the sensing elec-
trode measures an excitation, either the left or the right electrode stimulates the ventricle
after a programmed delay (A-V delay). However the A-V delay varies according to each
patient, the relative timing of inter-ventricular delay (V-V delay) might result in a bet-
ter parameter setup for the BVP device (see right panel of figure 3.2). Compared to the
conventional simultaneous pacing, sequential pacing using V-V delay yields incremental
benefit from 25 % to 35 % in terms of contractility [160, 204, 274]. Several studies sug-
gested that cardiac function might be improved by proper time programming of the BVP
device [17, 42, 139, 186, 203, 207, 225, 250, 251, 270, 273, 277, 287].
Sogaard et.al [252] used tissue tracking and 3D echocardiography to evaluate the impact
of sequential CRT with individualized timing delay programming. Tissue tracking and 3D
echocardiography were carried out before and on the day after pacemaker implantation
for twenty consecutive patients with severe heart failure and LBBB. The adjustment of
A-V delay was performed during the simultaneous pacing according to the Ritter method
[226], which means choosing the longest A-V delay without truncation of the A-wave (see
section 2.4) by means of pulsed Doppler analysis of the transmitral flow. A similar study
proposed that the optimal A-V delay should provide the longest LV filling time without
early truncation of the A-wave by mitral valve closure [146]. The study has established
that the refinement of ventricular offset (V-V delay) achieved even more benefits in systolic
and diastolic function measured by TDI.
A recent study by Becker et al. [28] sought an optimal A-V delay using Doppler echocar-
diography. At first a long A-V delay was considered and this time was shortened step by
step until a maximal mitral inflow profile (maximal time velocity integral) was achieved
without reducing the A-wave duration. The study supposed a simultaneous pacing.
In a study of Boriani [43] a similar method is used to determine the appropriate A-V
delay by echcardiographic evaluation of the transmitral filling pattern. The goal was to
obtain the widest separation between E- and A-wave, preventing an early closure of the
mitral valve. In order to optimize the V-V delay, Doppler echocardiography was used to
obtain LV forward flow information or stroke volume. The stroke volume was derived from
measurements of the left ventricular outflow tract (LVOT) diameter and the velocity time
integral (VTI) of aortic flow. Stroke volume was calculated as:
Stroke volume =
pi
4
×LV OT×V TI (3.1)
52 Chapter 3. Cardiac Resynchronization Therapy
The results were similar to the study of Becker et al. [28] since the optimized value of V-V
delay in most patients was zero.
A summary of the studies in which different timing delays are investigated, is demon-
strated in table 3.3.
A recent study by Whinnett et al. [287] proved the importance of an optimal choosing of
timing delays (A-V, V-V delay) in CRT response by measuring the systolic blood pressure
using a finometer. The study optimized A-V intervals using a finometer for measuring beat-
to-beat changes in blood pressure. The technique was highly reproducible and indicated
that changes in A-V intervals had a more pronounced effect on systolic blood pressure at
higher paced atrial rates than at resting heart rates, with a parabolic relationship between
A-V intervals and systolic blood pressure.
Another method for determining timing delays has been recently proposed by Lunati et
al. [160] based on the observation that sequential ventricular pacing with an appropriate
V-V delay can further increase the mechanical efficacy of the heart. This method is based
on intracardial electrograms (IEGM) and estimates the V-V delay. The system measures
the conduction delays between all following IEGMs:
1. Sensed IEGM from atrium to the LV lead
2. Sensed IEGM from atrium to the RV lead
3. Sensed IEGM from RV pacing to the LV
4. Sensed IEGM from LV pacing to the RV
Author A-V delay (ms) V-V delay (ms)
Ritter et al. 1999 [226] 60, 120, 180, 240, 300 -
Sogaard et al. 2002 [252] avgd: 106.5 ± 26.6 L-R: 12, 20, 40, 60, 80
R-L: 12, 20, 40, 60, 80
Perego et al. 2003 [204] 80 - 160 L-R: 20, 40, 60
R-L: 20, 40, 0
Turner et al. 2004 [270] 90 - 110 -
Bruns et al. 2005 [51] 110 - 130 -
Whinnett et al. 2006 [287] 40, 60, 80, 120, 140, 160, 200 L-R:20, 40, 60
R-L: 20, 40
Boriani et al. 2006 [43] - L-R: 20, 40, 80
R-L: 20, 40, 80, 0
Becker et al. 2007 [28] 100 - 150 0
L-R: left before right, R-L: right before left, avgd: average delay
Table 3.3. Several studies since 1999 on CRT in which different timing delays have been investigated. Bold
values state the optimal values chosen by the authors. In some studies, no optimal values were achieved.
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The optimal V-V delay is defined by adding the correction factor to the difference be-
tween the atria and RV IEGM, with final multiplication by 0.5 (see equations 3.5 and 3.6
in section 3.4.3). The correction factor is assigned to the inter-ventricular conduction delay
between pacing in one ventricle to sensing from the other ventricle.
Figure 3.6, illustrates a summary of optimization methods for timing delays. According to
figure 3.6, several echocardiographic techniques have been developed in order to optimize
the A-V interval. In the Ritter method [225], A-V intervals are programmed to a short and
a sufficient long value in a way that the A-wave is not truncated (e.g. 60 ms and 160 ms).
Then the delay between QRS onset and the end of the A-wave (QA interval) is measured
at both setups. The optimized A-V delay values are gained through the following formulas:
AVopt = AVshort + [(AVlong +QAlong)− (AVshort +QAshort)] (3.2)
This could be simplified to:
AVopt = AVlong − (QAshort −QAlong) (3.3)
A simplified method has been described by Meluzin et al. [175], whereby a single Doppler
measurement at mitral inflow is required, with substraction of the interval between the
end of the A-wave and onset of the systolic component of mitral regurgitation, from the
programmed A-V interval with biventricular capture. The technique predicted settings
with maximal cardiac output (measured by catheterization). This approach relies on the
presence of mitral regurgitation.
On the iterative method a long A-V interval (e.g. 75 % of the intrinsic A-V interval) is
programmed and the A-V interval decremented in 20 ms steps, until A-wave truncation is
observed. The A-V interval may then be incremented in 10 ms steps to obtain the optimal
setting [66].
The aortic Velocity-Time Integral (VTI) Method includes the measurement of aortic VTI,
which is a surrogate of stroke volume and could be measured at different programmed A-V
delays. Continuous-wave Doppler may provide more stable measurements as compared to
pulsed-wave Doppler [132].
Recently, Jansen et al. [132] measured the LV dP/dtmax in order to optimize A-V intervals
in patients with CRT using the pulsed-wave transmitral VTI (maximal VTI of E- and A-
waves), diastolic filling time (maximal EA duration), the aortic VTI and Ritter’s formula.
Measurement of the maximal VTI of mitral inflow was the most accurate method, yield-
ing identical results to LV dP/dtmax in 29 of 30 patients. The diastolic filling time and
aortic VTI method performed worse (with concordant results in 20/30 and 13/30 patients
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Figure 3.6. Techniques used for optimization of timing delays [55]: (a) A-V delay optimization. (b) V-V
delay optimization. PEA: peak endocardial accleration, VTI: velocity time integral, TDI: tissue Doppler
imaging.
respectively) and the Ritter method performed worst, with results differing to invasive
measurements in all patients. Shortcomings of methods using VTI measurements are that
they are relatively time consuming and may have limited reproducibility in the clinical
setting.
Optimization of A-V intervals in patients with biventricular pacing by finger plethysmog-
raphy using a conventional pulse oxymetry probe was reported by Butter et al. [58]. This
technique correctly identified the optimal A-V interval that yielded maximum pulse pres-
sure (measured invasively).
Impedance cardiography has been used for optimizing A-V intervals and was found to
give similar results as echocardiography [45, 269]. As described by Braun et al. [45, 117],
two electrodes were placed at the inferior chest wall and at the neck respectively. Low-
amplitude high-frequency current was delivered via these surface electrodes and transtho-
racic impedance to this current flow was measured. Changes in transthoracic impedance
(mainly influenced by changes of systolic aortic blood flow) were measured by means of
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four additional surface electrodes: one pair placed bilaterally to the sternum and the sec-
ond pair bilaterally to the abdomen. Cardiac output was calculated on a beat-to-beat basis
from the transthoracic impedance signal (see figure 3.7). A-V interval values relate to the
atrio-RV stimulation interval and V-V intervals relate to inter-ventricular interval with
negative figures implying LV pre-excitation. Cardiac output is measured by impedance
cardiography at different V-V delays and A-V delays until the optimal values according
to maximal cardiac output are achieved.
Figure 3.7. Example of the impedance cardiography measurement acquired by the Task Force Monitor
System. There are two paced beats and one beat without pacing. From top to bottom: lead II of ECG, blood
pressure and the first derivative dZ/dt of the impedance [117]. DBP: diastolic blood pressure, SBP: systolic
blood pressure, B: aortic valve opening, dZ/dtmax: maximum of the first derivative of the impedance signal,
X: aortic valve closure.
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A number of treatment modalities still remain unsolved even though CRT suggests a ther-
apy in moderate to severe heart failure patients with prolonged QRS. Investigation of some
aspects of treatment modalities offers an improvement in hemodynamics.
Analysis of the BVP parameters in order to find the best locations for the electrode leads
in the left and right ventricle in concurrent with optimized timing delays are crucial to
reduce the number of non-responders to the therapy.
3.4 Optimization Methods Described in Literatures
In current clinical practice, there are several approaches for optimization of the BVP pa-
rameters; some using invasive measurements while others depend on measurements gained
non-invasively. Most of the established BVP optimization methods are summarized in a
review paper from Burri et al. [55].
The best value for the atrio-ventricular delay (A-V delay) is determined by approaches
based on three principles, each evaluating a different hemodynamic parameter: echocardio-
graphy, beat-to-beat blood pressure determination and electrical measurements. The first
method based on echocardiography is used often in daily clinical practice, either gauging
the E- and A-waves of the inflowing blood (Ritter Method [226], Mitral Inflow Method
[175]) or measuring the velocity-time-integral (VTI) of the aortic outflow or mitral inflow,
respectively.
The second A-V delay optimization approach presented in [55] is the measurement of beat-
to-beat changes in blood pressure using appropriate means, for instance finger plethys-
mography [58]. The third approach for A-V optimization utilizes electrical measurements,
including impedance cardiography [269], determination of the QRS width in ECG and
acceleration measurements of the ventricular wall using acceleration sensors placed at the
tip of a catheter. The latter two methods are provided as built-in algorithms in several
pacemaker models [55].
According to Burri et al. [55], the inter-ventricular stimulation delay (V-V delay) is opti-
mized in clinical practice by methods based on four non-invasive measurement principles,
while measuring the aortic pressure directly is negligible in clinical practice, since it is
invasive and difficult to perform. The non-invasive methods are discussed below.
The echocardiographic methods act as an important approach for V-V delay optimization,
including Tissue Doppler Imaging and aortic VTI measurement [224, 252]. The second al-
ternative is the evaluation of the ejection fraction using nuclear angiography [56]. Thirdly,
beat-to-beat blood pressure change measurements and finally the determination of ven-
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tricular wall acceleration could be used for optimization of V-V delay.
A recent study from Toggweiler et al. [268], investigates the eligibility of acoustic cardiog-
raphy for A-V and V-V delay optimization. The third and fourth heart sound are detected
and evaluated in strength. This data together with an ECG is used to calculate the elec-
tromechanical activation time, which is minimized in order to determine the optimal A-V
and V-V parameters. Results in study [268] show, that this method is also suitable for
clinical optimization.
The above mentioned optimization methods have some advantages and disadvantages.
The advantages are the non-invasive approach and the usability in daily clinical rou-
tine, especially for the echocardiography-based methods. Amongst others, some of the
disadvantages are the lack of temporal resolution of nuclear angiography and delivery of
suboptimal results of beat-to-beat blood pressure measurements for V-V optimization. A
common disadvantage of all methods presented is that an optimization of the pacing elec-
trode positioning is not performed [55, 268].
Electrode positioning influence on hemodynamic parameters was evaluated by van Campen
et al. [273], who tested 9 different pacing sites while keeping the A-V and V-V delay con-
stant. The optimal electrode setup was determined by measurement of cardiac index using
Doppler flow imaging during a trial with 48 patients. It was shown that an individual
adaptation of electrode positions improves the BVP efficacy [273].
Contrary to the methods described above, the optimization method presented in chapter
7 enables a pre-operative optimization of all three BVP parameters A-V delay, V-V delay
and electrode positioning, which are all computed automatically. This may lead to signif-
icantly improved therapy success.
3.4.1 Invasive Measurements
Several studies recommend an implantable hemodynamic monitor (IHM) to be a reliable
method for continuous measuring and recording of cardiac filling pressures in heart failure
(HF) Patients [8, 46, 51, 166, 254]. IHM consists of a pressure lead and a memory device,
which continuously records the heart rate, RV systolic/diastolic pressures in order to es-
timate the pulmonary artery diastolic pressure (ePAD). Furthermore, ePAD denotes the
pressure at time of pulmonary valve opening. An external pressure reference is used to
correct the barometric alteration of measured pressure. The maximum positive dP/dt of
the RV pressure curve stands for ePAD. The pressure lead sensor is usually placed in the
right ventricular high septum or right ventricular outflow tract (see figure 3.8).
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Figure 3.8. Chest X-ray of a patient under CRT with an IHM. CRT device is composed of three leads:
RA, RV and LV lead. The pressure sensor lead belongs to the IHM [51].
Hemodynamic sensors, including pressure sensors and chemical sensors (pH, temperature)
were tested in pacemakers. Most of them did not overcome the technological challenge
needing an implantable sensor overtime. Recently, the available technology in the field of
CRT is the peak endocardial acceleration (PEA) sensor [160]. During isovolumetric con-
traction and relaxation phases, myocardium generates mechanical vibrations which will
be transmitted to the PEA sensor located in the cardiac wall. The measured peak to peak
amplitude corresponds to the first heart sound, represents mitral valve closure which is
correlated with the LV dP/dtmax [209]. According to the concept of the first heart sound
detection, the PEA sensor is able to optimize the A-V delay [226]. In the CRT device, the
optimization procedure is automatically launched every week without an external inter-
vention. PEA can also be used to optimize the V-V delay.
Bruns et al. [51] measured the ePAD value for different A-V delays in order to find the op-
timal A-V delay. It was considered that the minimal ePAD maximizes the diastolic filling
time without truncation of the active left ventricular filling by the left atrium. Accordingly,
those A-V delays, which result in minimal ePAD, are the optimal ones.
In a study of Perego et al. [204], pressure signals were analyzed on beat by beat basis
in order to obtain maximum systolic rate of change of pressure dP/dtmax, the minimum
diastolic rate of pressure dP/dtmin, the maximum systolic pressure (SP) and end diastolic
pressure (EDP). For each protocol step and for each patient, LV dP/dtmax values were
compared by means of variance analysis, considering each beat as an individual case. In
the whole study population, optimized synchronous CRT was associated with a significant
increase in the maximal rate of LV pressure (LV dP/dtmax). The left ventricular EDP was
significantly reduced compared to the baseline. In a minority of patients, RV dP/dtmax
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changed in the opposite direction to LV dP/dtmax when timing delays were modified.
Despite these observations, optimization of A-V and V-V delay based on maximal LV
dP/dtmax was not associated with significant decrease in RV dP/dtmax. After pacing
setup, a positive correlation between LV dP/dtmax and LV dP/dtmin was observed (see
figure 3.9). In addition, the study underlined that RV dP/dtmax was a significantly weaker
measure of RV mechanical efficiency than LV dP/dtmax for the left ventricle.
Figure 3.9. Linear correlation between maximal systolic rate of LV pressure change (LV dP/dtmax) and
minimal diastolic rate of LV pressure change (LV dP/dtmin). The data from all the pacing steps of all
patients are normalized to baseline [204].
3.4.2 Echocardiography
Multiple echocardiographic modalities including Doppler echocardiography have been ap-
plied in almost all studies as a non-invasive clinical tool, to analyze the temporal course of
the LV contraction relying on the longitudinal motion [18, 25, 35, 65, 156, 203, 220, 255].
This ultrasound technique aimed to determine the level of dyssynchrony in LV contraction
and additionally predicting the effectiveness of CRT on symptoms, functional capacity, mi-
tral regurgitation and left ventricular reverse remodeling in patients [2, 25, 145, 237, 260].
Ahead of investigating the efficacy of the CRT, a baseline echocardiography is usually
carried out in order to assess the left ventricular ejection fraction, mitral regurgitation
severity and early to late transmitral flow velocity ratio (E/A) [273].
Although Doppler echocardiography is the preferred method for optimization of dual cham-
ber and biventricular pacemaker programming after the implantation, there is a lack of
guidelines for programming and the selection of appropriate echocardiographic method.
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Optimization by Doppler echocardiography resulted in an improvement in LVEF, aor-
tic velocity time integral (VTI) and maximum pressure increase [175, 268]. Optimization
using the aortic VTI leads to better results in comparison with mitral inflow method
[142, 175]. Systolic and diastolic parameters can also be obtained through conventional
Doppler echocardiography such as diastolic filling time, myocardial cardiace index, E/A
ratio, E-deceleration time, isovolumetric relaxation and pulmonary vein flow. Some of these
parameters can be measured in order to determine the efficacy of CRT [237, 260].
The time difference between the aortic and the pulmonary pre-ejection period can be esti-
mated by standard pulsed wave Doppler. The larger the difference between the aortic and
pulmonary pre-ejection period, the greater the chance of response to CRT independent of
QRS duration [97, 208].
Displacement imaging is a new tissue Doppler imaging (TDI) method which is used to
transform the Doppler velocity data to a quantitative display of wall displacement toward
the probe [235]. It has been demonstrated that left ventricular dyssynchrony can be quan-
tified using displacement imaging by measuring the time difference to peak longitudinal
systolic contraction of the septal and lateral mitral annulus [234].
Acoustic cardiography has been developed to measure diastolic heart sounds and systolic
time intervals with assistance of ECG. This leads to detection of the third and the fourth
heart sounds for measuring the electromechanical activation time (EMAT). EMAT is the
time between the onset of the QRS complex and the mitral valve component of the first
heart sound. Invasive studies indicate that EMAT and the third heart sound are correlated
with LV function [168, 229, 244, 303].
The TDI technique for identification of mechanical dyssynchrony can be elaborated by
measuring the time to peak myocardial sustained systolic (Ts) and diastolic velocity in dif-
ferent myocardial segments. Since typical appearance in heart failure patients is evidenced
by earliest activation in the basal anterior septum and latest in the basal lateral segments
[208], tissue Doppler imaging (TDI) and tissue tracking (TT) could be used to detect the
LV systolic performance moreover LV asynchrony (see figure 3.10) [200, 251, 252, 253].
The reduction of myocardium showing the delayed longitudinal contraction (DLC) pre-
dicts the improvement in LV systolic performance and reversion of LV remodeling during
CRT [251, 252, 253]. The hypothesis behind is that pre-activation of myocardium display-
ing DLC improves the overall response to CRT (see figure 3.11). Thus, TDI can be used
to optimize the lead positioning (see section 3.3.2). As described in section 3.3.3, echocar-
diography is very often used to determine the optimal A-V delay. It can be also used to
demonstrate and to assess the inter-ventricular and intra-ventricular resynchronization.
Strain rate analysis was carried out in each segment and motion toward the apex in di-
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astole was registered as DLC if negative strain rate analysis documented that the motion
reflected true shortening.
(a) (b)
Figure 3.10. Tissue tracking (TT) in a patient with LBBB. An irregular distribution of color-bands is
seen during systole (left panel), indicating poor systolic performance of the lateral wall. Systolic apical
displacement occurs only in the basal part of the lateral wall, whereas the remaining parts of the lateral
wall show no net apical displacement during systole (gray color). After adjusting the TT time interval to
left ventricular diastole (identified by aortic valve closure and mitral valve closure), the delayed longitudinal
shortening of the lateral wall can be visualized by the apical displacement during diastole (right panel)
[25].
Nowadays, the most commonly used tool for V-V delay optimization is either standard
echocardiography or tissue Doppler imaging. Both methods could be used to determine
the left ventricular outflow tract velocity-time integral (VTI) for calculation of stroke vol-
ume and myocardial performance index (MPI) and to assess dP/dt from the spectrum
of mitral regurgitation [42, 252, 274]. Echocardiographic methods, however, have several
limitations: they are time consuming, require two persons and are operator-dependent.
The optimal V-V delay varies over time and should be re-evaluated during follow-ups [82].
Therefore, in routine CRT pacemaker follow-up, there is a strong need for an easier, faster
and more cost-effective method of V-V delay optimization.
In the study of Teo et al. [264], echocardiography was performed pre-implant and post-
implant to assess the left ventricular function. Additionally, the optimal AV delay was
derived from the Doppler signal of the transmitral flow (Ritter method [226]). Further-
more, based on assessment of the site of latest activation in the LV, echocardiography can
guide LV lead positioning and may be used to optimize A-V delay and V-V delay. Finally,
echocardiography allows assessment of resynchronization and follow-up after CRT.
Since contraction of the ventricle myocardium is three dimensional, it includes longitudinal,
radial and circumferential movement. Most studies investigate the longitudinal movement,
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Figure 3.11. Apical long-axis view in patient with dilated cardiomyopathy and LBBB. One Doppler
sample (yellow) is positioned at high septal area and another (green) is in posterior wall. In each of the
2 points, strain rate analysis is carried out. First vertical line (right) shows onset of negative strain rate
(yellow curve), indicating active contraction in systole. Second vertical line indicates cessation of systole
where strain rate (yellow curve) becomes positive. Shortly before second line, negative strain rate is observed
in posterior wall (green curve) and this persists between second and third line, indicating active shortening
in early diastole, i.e. longitudinal contraction delay (DLC) [251].
which explains the LV movement along the basal apical axis. During systole, the left ven-
tricle condenses along its longitudinal axis, the base of the LV moving towards the apex.
This motion is overturned during diastole while the base moves away from the apex.
Helm et al. [119] demonstrated that longitudinal motion analysis might be less sensitive
to dyssynchrony since it follows different time courses than circumferential deformation
and is not an adequate CRT efficacy significant. Therefore, the technique developed by
Becker [28] using 2D echocardiographic analysis allows determination of circumferential
deformation parameters, which leads to an optimal analysis of cardiac asynchrony. The
distortion or circumferential deformation of the LV is the most complex motion since the
LV generates a wringing motion with clockwise rotation at the base and counterclockwise
rotation at the apex during systole.
The study of Becker et al. [28] investigated the impact of LV lead position in CRT us-
ing circumferential strain analysis, LVEF, LV end-systolic volume and LV end-diastolic
volume which were determined by manual tracing of end-systolic and end-diastolic en-
docardial borders in 2D echo images. End-systole was marked as aortic valve closure in
apical long axis views. Four parasternal short axis views (mitral valve level, papillary mus-
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cle level, apical level and an additional apical level which allowed just visualization of the
LV cavity) were acquired using 2D tissue harmonic imaging. The focus was adjusted to
the centre of the LV cavity to optimize myocardial tissue characterization of all segments
of the short axis views. The system followed acoustic markers accurately within the my-
ocardium during several consecutive frames [220, 255]. It was assumed that the natural
acoustic markers change their position from frame to frame in accordance with the sur-
rounding tissue motion. The system calculated mean strain values for whole predefined LV
segments. Regarding the width between endocardial and pericardial trace, a tracking set-
ting was selected which included as much myocardium as possible, but prevented inclusion
of tissue outside the myocardium. For analysis of LV myocardial deformation, the AHA
17 segments model was applied on the parasternal short axis views. For the parasternal
short axis views on the basal and papillary muscle level six segments were analysed, for
the short axis view on the apical level four segments were analysed and for the most apical
level only one segment was analysed. For each segment with adequate tracking quality,
circumferential strain was calculated as a mean over the whole segment.
Circumferential strain relates to circumferential deformation along the curvature of the
left ventricle in the parasternal short axis. The circumferential strain values over time for
each segment were given as strain-time curves (see figure 3.12). For each point on these
curves, the exact time after the QRS complex and the strain value are displayed on de-
mand. The segment having the latest peak negative circumferential strain before CRT in
relation to the QRS complex was determined (see figure 3.12). Strain-time curves before
CRT during intrinsic conduction and on active CRT one day after implantation were com-
pared to determine the segment with the maximal temporal difference in peak negative
circumferential strain (see figure 3.13). This segment was assumed to be the location of
the LV lead. The distance between the assumed LV lead position and the segment with
maximal baseline dyssynchrony was counted in number of segments referring to the four
apico-basal levels and up to six segments within one circumference. One distance step
was related either to the apico-basal level or to the circumferential level. Optimal position
of the LV lead was defined as a concurrence of segments or immediate neighboring (one
distance step) of the segment with maximal dyssynchrony and the segment with assumed
location of the LV lead.
Hence, there are several tasks performed by 2D echocardographic images [28]:
1. Circumferential strain analysis based on tracking of acoustic markers in parasternal
2D echocardiographic images can be used in CRT to describe the temporal course of
LV contraction.
2. Myocardial deformation imaging analysis allows an accurate assumption on the LV lead
position in CRT based on a detailed analysis of the myocardial contraction sequence.
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The distance between the assumed LV lead position and the
segment with maximal baseline dyssynchrony was counted in
number of segments referring to the four apico-basal levels and
up to six segments within one circumference. One distance step
was related either to the apico-basal level or to the circumferential
level. Optimal position of the LV lead was defined as concurrence of
segments or immediate neighbouring (!1 distance step) of the
segment with maximal dyssynchrony and the segment with
assumed location of the LV lead. Non-optimal position of the LV
lead was defined as a greater distance ("two distance steps)
between segment with maximal dyssynchrony and segment with
assumed LV lead position.
The physician performing the echocardiographic analysis and
classification of LV lead position as optimal or non-optimal were
blinded to possible difficulties during LV lead placement, anatomic
limitations, or substrate disparities.
Fluoroscopy
After CRT implantation, biplane fluoroscopy in orthogonal views
(LAO 608 and RAO 308) was performed. These loops were analysed
Figure 1 Upper panel: short axis view with circumferential strain display prior to cardiac resynchronization therapy at end-systole with inhomogeneous colour dis-
tribution due to dyssynchronous contraction. Lower panel: there are six circumferential strain tracings for the six evaluated segments within the circumference. The
dotted white line indicates the mean circumferential strain of all six segments. The time difference between segment with earliest and latest peak strain is marked.
Lead position dependent remodelling in CRT 1213
Figure 3.12. Upper panel: short axis view with circu fer ntial strain displ y prior to c r iac resynchro-
nization therapy at end-systole with inhomogeneous color distribution due to dyssynchronous contraction.
Lower panel: there are six circumferential strain tracings for the six evaluated segments within the cir-
cumference. The dotted white line indicates the mean circumferential strain of all six segments. The time
difference between segmen w th earlies and lat st peak strain is marked [28].
3. Search for concurrenc or neighborhood of the segment with as umed LV lead position
based on circumferential strain analysis. Since results of pacing the LV segment with
latest peak systolic strain show significantly greater improvement in LV function.
Hence, there are several tasks performed by 2D in order to investigate the mechanical
displacement [234, 235]:
1. Measurement of myocardial contraction and relaxation velocities based on the phase
shift of the ultrasound signal reflected from the contracting myocardium in order to
identify the dyssynchrony.
2. Evaluation of septal to lateral wall contraction delay (longitudinal contraction delay)
and assessing the distortion (circumferential deformation).
3. Calculation of the time-to-peak tissue displacement by time velocity integral (under-
lying TDI velocity integration).
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by two blinded readers to determine the anatomical location of the
LV lead tip. The RAO view was used to define the baso-apical
location of the lead tip. The LV was divided into four levels:
basal, medial, apical, and apex (Figure 3, left panel). The LAO
view was subsequently used to determine the location within the
circumference of that level. For this purpose, the 17 segment
scheme introduced by Cerqueira et al.21 was projected into the
LAO view (Figure 3, right panel).
Peak oxygen consumption
Patients underwent bicycle cardiopulmonary exercise testing
(10 W per min increments) at baseline and after 10+3 months
Figure 2 Upper panel: short axis view with circumferential strain display during cardiac resynchronization therapy at end-systole with homogenous colour
distribution due to synchronous contraction. Lower panel: circumferential strain tracings from the six evaluated segments within the circumference. The
time difference between segment with earliest and latest peak strain during cardiac resynchronization therapy is given in white. The tracing obtained prior
to cardiac resynchronization therapy from the segment with latest peak strain is added as interrupted purple line. The tracing of the segment during resyn-
chronization therapy is marked with a white arrow. The reduction in contraction delay with cardiac resynchronization therapy compared to prior to
therapy for this segment is marked as yellow distance. It was greatest among all 17 left ventricular-segments of this patient indicating the left ventricular
lead position.
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Figure 3.13. Upper panel: short axis view with circumferential strain display during cardiac resynchro-
nization therapy at end-systole with homogenous color distribution due to synchronous contraction. Lower
panel: circumferential strain tracings from the six evaluated segments within the circumference. The time
difference between segment with earliest and latest peak strain during cardiac resynchronization therapy is
given in white. The tracing obtained prior to cardiac resynchronization therapy from the segment with lat-
est peak strain is added as an interrupted purple line. The tracing of the segment during resynchronization
therapy is marked with a white arrow. The reduction in contra tio del y with cardiac re ynchronization
therapy compared to prior to therapy for this segment is marked as yellow distance. It was greatest among
all 17 left ventricular-segments of this patient indicating the left ventricular lead position [28].
Recently, tissue synchronization imaging (TSI) has been introduced by Van de Veire et
al. [73], which is a signal processing algorithm of tissue Doppler data to detect the peak
positive velocities for measuring the ventricular asynchrony. The value of TSI can predict
the acute response to CRT. TSI automatically calculates the time to peak myocardial
sustained systolic velocity (Ts) in every position in the image with reference to the QRS
interval. To prevent TSI system of measuring peak systolic velocities outside the ejection
phase, the tool is adjusted manually at the beginning and the end time intervals. The
beginning and end time are set at aortic valve opening and at aortic valve closure time
respectively.
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Amongst studies on LV function improvement after CRT, a study of Rajagopalan et al.
[218] investigated the RV function following CRT. The study showed the beneficial effects
of CRT on RV function in terms of increasing the myocardial velocities at the region of
interests (base, mid RV segments) using TDI. The improvement is verified by measuring
the increased LVEF.
3.4.3 Intracardial Electrogram (IEGM)
A novel method of determining optimal V-V delay using intracardiac electrogram (IEGM)
signals has recently been described [107, 160, 174]. This method assumes that optimal V-V
timing occurs when the paced activations RV and LV leads meet in the intra-ventricular
septum [149].
In this method, the delay in milliseconds (ms) between RV and LV intrinsic depolarization
(∆) is measured initially on the real-time IEGM from the LV and RV. Afterwards, the
different wave front velocities left to right (IVCD: pacing LV, sensing in RV and measuring
the distance between the two events in ms on IEGM) and right to left (IVCD: pacing RV,
sensing in LV) are measured and then the two values are subtracted one from the other:
 = IV CDLR − IV CDRL (3.4)
The optimal V-V timing is calculated:
Vopt = 0.5× (∆+ ) (3.5)
In most cases, the so-called correction coefficient () is equal or close to 0 ms and the
formula can be simplified to:
Vopt = 0.5×∆ (3.6)
As described in section 3.3.3, Lunati et al. [160] optimized the V-V delay according to the
IEGM method.
3.4.4 Blood Pressure Measurements
Acute changes in blood pressure are potentially a good measure of the effect of changing
pacing parameters on cardiac function. Whereas one may be concerned, in principle, that
a change in blood pressure would instead be a result of a change in peripheral vascular
tone, it is reassuring to remember that the stimulus for such a change in vascular tone
must be a change in cardiac performance. Additionally, addressing the early few seconds
after a change in pacing configuration allows us to focus on the primary cardiac effects
rather than any secondary (vascular) effects. Even if secondary vascular effects do occur,
they are likely to attenuate, rather than augment, the changes in blood pressure and so
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this approach cannot overestimate the immediate effects on cardiac function [287].
In the study of Whinnett et al. [287] beat-to-beat blood pressure was recorded during
adjustment of the A-V and V-V delay of the participants BVP device while paced at a rate
of 110 beats/min. Testing was performed at raised heart rates because previous work from
this unit has shown that, at higher heart rates, altering A-V delay had a more pronounced
effect on blood pressure and that the peak A-V delay became clearer at higher heart rates.
The systolic blood pressure was used as the hemodynamic target for optimization because
this would have increased two indications if cardiac output rose:
1. The rise in cardiac output would increase the mean arterial pressure
2. The rise in stroke volume would increase the pulsatility of blood pressure.
To minimise the effects of background variation in blood pressure, each tested A-V and
V-V delay was compared with an arbitrary fixed reference delay of A-V and V-V delay.
The applied algorithm was based on beat-by-beat blood pressure, measured non-invasively
with the finometer device, to assess the hemodynamic effect of simultaneously adjusting
A-V and V-V delays. The relative change in systolic blood pressure (SBPrel) was calcu-
lated by comparing the mean of the 10 beats immediately after a transition with the 10
beats immediately before (see figure 3.14).
Verbeek et al. [278] investigated the pacing results on inter-ventricular and intra-ventricular
asynchrony in the left ventricular function with the assist of measured pressures. The aim
of the study was to explore the mechanism of hemodynamic improvement during LV
based pacing of hearts with LBBB. The pacing was performed in canine hearts. Various
sites of LV were performed in different A-V delay in order to measure the maximum
rate of increase of LV pressure (dP/dtmax) and LV stroke work (SW). Inter-ventricular
delay was measured between upslope of LV and RV pressures. Intra-ventricular delay
was measured from endocardial electrical activation maps. Typical examples of pressure-
volume loops during pacing illustrate that pacing from various sites increased SW at
essentially unchanged end diastolic volume (see figure 3.15).
3.4.5 Electrocardiography
Traditionally, the duration of the QRS complex on surface electrocardiograms has been
used as a marker of LV dyssynchrony and consequently only patients with a wide QRS
complex (more than 120 ms) were included in large trials [257, 260]. However, recent data
indicated that the QRS duration does not adequately reflect LV dyssynchrony. The lack of
a relation between QRS duration and LV dyssynchrony has been reported not only in pa-
tients with wide QRS complex but also in patients with narrow QRS complex. Moreover,
various studies demonstrated that severe LV dyssynchrony might be present in 20 % to 50
% of patients with narrow QRS complex [39, 231, 296]. The fact that CRT may also be
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(a) (b)
(c) (d)
Figure 3.14. Example of the data acquired for measuring relative change in systolic blood pressure (SBP)
for the tested atrio-ventricular (A-V) and inter-ventricular (V-V) delays [287]: (a) Each tested A-V and V-
V delay was compared with the reference A-V and V-V delays (A-V 120 ms and V-V 0 ms); this reference
delay was returned to between each tested delay. (b) Thirty five different combinations of A-V and V-V
delay were measured, each time returning to the reference A-V and V-V delay. (c) To reduce the effect of
background noise the relative change in systolic blood pressure (SBPrel) (the mean of 10 beats before a
change and the 10 beats immediately after a change) was calculated and the mean for at least six replicate
transitions was established. (d) Constructing a surface plot of SBPrel for each patient tested was then
possible. LV: left ventricle; RV: right ventricle.
beneficial in heart failure patients with narrow QRS complex and severe LV dyssynchrony
is an important issue, since the majority of heart failure patients may not show prolonga-
tion of the QRS complex and recent observations suggested that QRS widening more than
120 ms may occur in only 30 % of heart failure patients [36]. Therefore, the majority of
heart failure patients have a narrow QRS complex and are currently not eligible for CRT.
However, preliminary data from studies suggested that heart failure patients with narrow
QRS complex may benefit from CRT.
Turner et al. [270] studied only the acute effects of CRT in a group of 20 heart failure
patients with a QRS duration of 120 ms. In these patients, CRT resulted in an acute hemo-
dynamic improvement, particularly in patients with a pulmonary capillary wedge pressure
more than 15 mmHg.
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For the whole group of experiments and all pacing sites
except the RV apex, maximum hemodynamic improvement
was obtained at intraVA values not significantly different
from pre-LBBB values, while interVA was incompletely
restored (range !2 to !32 ms), and the QRS duration did
not change significantly from LBBB values (Fig. 7). The
results for anterior and posterior wall pacing (data not
shown) were similar to those for lateral wall pacing.
DISCUSSION
The findings of the present study indicate that in canine
hearts with experimental LBBB, LV based pacing can
recover LV function in terms of LV dP/dtmax and SW.
Relative improvements in LV dP/dtmax (20% to 23%) were
in the same range as those observed in patients (1,3) and
occurred in the absence of changes in diastolic function
parameters. Maximum improvement of LV function is
consistently obtained at intra-ventricular resynchronization
of activation. This requires pacing with AV delays equal to
baseline PQ time for all LV sites, except for LV apex and
BiV pacing, which require AV delays shorter than PQ time
during baseline LBBB.
Hemodynamic effects of pacing during LBBB. The
present study extends the insights in effects of resynchroni-
zation therapy by providing data on the improvement of
LV dP/dtmax and SW in LBBB hearts during pacing at
different sites and at a large range of AV delays. Improve-
ments in LV dP/dtmax and SW were obtained at unchanged
diastolic function, indicating increased ventricular
contractility.
Because asynchronous electrical activation induces oppos-
ing contraction patterns within the LV wall (19,20), it is
most likely that electrical resynchronization increases con-
tractility by improving coherence of contraction of the
various myocardial regions. This idea is supported by more
uniform strain patterns observed during BiV pacing than
during RV pacing in canine hearts without conduction
abnormalities (17). The important role of better coherence
of LV contraction is further emphasized by the lack of
mitral regurgitation in our experimental LBBB model, as
determined using both color Doppler imaging and left atrial
pressure measurements. As a consequence, reduction of
mitral regurgitation, mentioned to contribute to the bene-
ficial effect of resynchronization therapy in patients, does
not contribute to the improvement of LV function in
experimental LBBB.
Intra-ventricular resynchronization. The importance of
intraVA for LV function is emphasized by the finding that
for different degrees of interVA the same optimal LV
function is obtained as long as intraVA is close to zero. This
result is independent from the pacing site and strategy
required to achieve intra-ventricular resynchronization (ex-
clusion of endogenous activation (LV apex and BiV pacing)
or fusion of endogenous and pacing induced activation (LV
anterior, lateral, and posterior wall pacing). Asynchrony
around the LV circumference appears especially relevant,
probably because it is considerably larger than asynchrony in
the longitudinal direction, an observation in agreement with
MRI tagging studies during ventricular pacing (17).
Observations on LV wall motion and velocity using
echocardiography and Tissue Doppler imaging in patients
suggest improved LV synchrony during biventricular pacing
(12,15,21). The requirement of intra-ventricular resynchro-
nization for optimal LV function is supported by MRI
tagging measurements of mechanical asynchrony in canine
hearts with pacing induced heart failure and experimental
LBBB (22). These investigators concluded, however, that
during optimal LV pacing electrical asynchrony persists, but
this is based mainly on extrapolation of electrical activation
measured during LV pacing with short AV delay. Endocar-
dial mapping data from the present study, with similar PQ
time ("100 ms) and optimal paced AV delay ("70 ms),
demonstrate that electrical asynchrony differs significantly
between short and intermediate AV delays (Fig. 3). There-
fore, their conclusion that fusion is absent during pacing at
optimal AV delay, based on electrical activation determined
during pacing at short AV delays, does not seem justified.
The discrepancy between our finding that the QRS
Figure 4. Pressure–volume loops measured with the conductance catheter, showing the short-term effect of pacing during left bundle branch block (LBBB)
for left ventricular (LV) apex (left panel) and LV lateral pacing (right panel) at paced atrioventricular delays of 40 and 90 ms. The results for anterior and
posterior wall pacing were comparable to those for lateral wall pacing.
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Figure 3.15. Pressure-volume loops measured with the conductance catheter, showing the short-term
effect of pacing during left bundle branch block (LBBB) for left ventricular (LV) apex (left panel) and LV
lateral pacing (right panel) at paced atrio-ventricular delays of 40 and 90 ms. The results for anterior and
posterior wall pacing were comp rable to those for lateral wall pacing [278].
In addition, Achilli et al. [5] studied the effects of CRT in a group of 14 heart failure pa-
tients with a QRS duration of 120 ms and comp red these effects with a control group of
38 heart failure patients with a QRS duration more than 120 ms. All patients had evidence
of LV dyssynchr ny on M-mode echocardiography in combination with inter-v ntricul r
dyssynchrony. The authors demonstrated that the clinical and functional benefit was sim-
ilar in heart failure patients with wide and narrow QRS complex.
There are studies suggesting the QRS interval as an unreliable marker of the underly-
ing mechanical dyssynchrony in he he rt, since the absence of correlation between LV
dP/dtmax and QRS duration has practical and theoretical implications. Several studies
have provided conflicting results about the role of QRS shorteni g as a p edictor of t e
hemodynamic results [59, 204, 298]. The results of Perego et al. [204] hypothesized that
the minimal QRS length is not necessarily associat d with the most efficie t mechan cal
ventricular activation.
Analson et al. [59] explai ed that the degree of QRS narrowing under biventricular pacing
was associated with symptomatic and functional improvement during follow-up in patients
with congestive heart failure.
Gianfranchi et al. [102] h s investigated the fusion band in ECG in order to optimize
the resynchronization. The study delivered an electrocardiographic fusion band by pro-
gramming the stimulator. The native electrocardi gram w s r orded and measured with
an intrinsic atrio-ventricular interval. Afterwards, atrio-ventricular interval was progres-
sively shorte ed by st ps of 20 ms down to 100 ms. Twelve le ds electrocardiogram we e
recorded at each step. The fusion band is the range of A-V intervals at which surface
electrocardiogram (mainly in V1 of Wilson lead) presents an intermediate morphology
between the native left bundle branch block (upper limit of the band) and the paced right
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bundle branch block (lower limit). The patient underwent echocardiographic examination
at each atrio-ventricular interval chosen inside the fusion band. The following parameters
were evaluated in order to verify the optimal results gained by electrocardiography: ejec-
tion fraction, diastolic filling time, E-wave deceleration time, aortic VTI and myocardial
performance index (MPI). All the echocardiographic parameters showed an improvement
inside the fusion band, with a plateau behaviour (see figure 3.16). As the fusion band in
this study was ranged from an atrio-ventricular delay of 200 ms to an atrio-ventricular
delay of 120 ms, an intermediate atrio-ventricular delay of 160 ms might guarantee the
persistence of fusion even during any possible physiological atrio-ventricular conduction
variation.
A recent study by Mohindra et al. [183] investigated the use of body surface potential
mapping and computer model simulations to optimize the CRT device. The outcome was
the influence of pacing locations on reducing dyssynchrony. Placing the LV pacing tip
on the posterobasal section of LV and pacing both leads simultaneously helps to greatly
reduce dyssynchrony without the need for optimal programming of the delay. This suggests
that in patients with optimal lead placement, programming of the V-V timing may not be
necessary [157, 183].
3.5 Conclusion and Unresolved Issues
Clinical trials of CRT have demonstrated considerable improvements in quality of life and
exercise capacity, but a significant number of non-responders have decreased the overall
benefits. The use of ECG criteria alone might result in selection of some patients who are
unlikely to benefit and also exclusion of potential responders. Assessment of the regional
left ventricular mechanical activation and viability with the echocardiography should be
considered before implantation of the BVP device and further studies are required to
refine the selection process. Once a decision has been made to proceed with the CRT then
appropriate placement of the leads and optimal programming of the device will maximize
the therapeutic effect. Several studies have shown that QRS duration is a relatively poor
predictor of the symptomatic response to CRT in an individual patient [207, 223] and
there is increasing evidence that the patients with ventricular dysfunction and normal QRS
can benefit [20]. Several studies have assessed various invasive and non-invasive methods
for optimizing the timing delays including beat-to-beat analysis of cardiac output and
hemodynamical techniques. Table 3.4 demonstrates a summary of methods used for CRT
optimization.
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ECG morphology at different AV intervalsFigure 1
ECG morphology at different AV intervals. Different ECG morphology corresponding to each programmed AV interval, 
including the basal ECG of the patient without ventricular pacing. With the progressive shortening of the programmed AV 
interval, QRS morphology (mainly in V1 lead) changes from LBBB to a RBBB-like trace at the shortest AV interval, correspond-
ing to a complete capture of both ventricles by LV pacing. Different degrees of ventricular fusion between RV spontaneous 
activation and LV pacing can be seen for AV intervals programmed in the range 200–120 ms.
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Figure 3.16. ECG morphology at different A-V intervals. Different ECG morphology corresponding to
each programmed A-V interval, including the basal ECG of the patient without ventricular pacing. With
the progressive short ning of the programmed A-V i terval, QRS mo phology (mainly in V1 lead) changes
from LBBB to a RBBB-like trace at the shortest A-V interval, corresponding to a complete capture of
both ventricles by LV pacing. Different degrees of ventricular fusion between RV spontaneous activation
and LV pacing can be seen for A-V intervals programmed in the range 200− 120 ms [102].
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Optimized parameters Techniques Measuring methods
Timing delays
Ritter method
Transmitral inflow
Iterative method
Echocardiography Diastolic filling time
Mitral VTI
Aortic VTI
Myocardial performance index
E/A ratio
Intracardial electrogram (IEGM) IVCD
Radionuclide ventriculography LVEF
Finger plethysmography Beat to beat blood pressure
changes
Impedance cardiography dZ/dt
Electrocardiography QRS duration analysis
PEA
ePAD
Invasive with implanted device LV dP/dt
EDP
SP
Finometer Blood pressure measurements
Electrode positions
Echocardiography Circumferential strain analysis
DLC analysis
Electrocardiography QRS duration analysis
Hemodynamic monitor (IHM)
Invasive with implanted device Pressure sensor
Chemical sensor
Table 3.4. Clinical methods used for optimization of CRT parameters.
The work presented in chapter 7 proposes a non-invasive optimization algorithm to find
the best electrode positioning sites and timing delays for BVP in patients with LBBB
and MI. This algorithm can be used to plan an optimal therapy for an individual patient.
The optimization algorithm is applied once on the activation time and other time on
ECG intervals to investigate the BVP parameter optimization. Furthermore, optimization
algorithms results are compared in this thesis.
4Human Heart Modeling
The present chapter describes the methodology for setting up a volumetric 3D heart model
from different image modalities. The construction of such a heart model consists of four
stages:
1. Anatomical modeling
2. Cellular electrophysiology modeling
3. Excitation propagation modeling
4. Pathological modeling
Since the optimization methods of the research in chapter 7 will be verified in chapter 9,
a simulation environment including a volume conductor model is provided. Therefore, an
anatomical torso model with conductivity values is used in order to validate the optimized
results by generating the corresponding ECG.
4.1 Anatomical Modeling of the Heart
Detailed anatomical models were achieved by segmentation of the MR data sets [84].
Thirteen 3D anatomical data sets were used. Ten of those were the segmented data sets
of patients suffering from left bundle branch block (LBBB) and myocardial infarction
(MI). The segmentation was done by using interactive deformable contours based on a
triangle mesh forming the borders of different parts of the organ. A detailed description
of the anatomical models including the geometrical characteristics and the pathological
symptoms of the corresponding patients is included in chapter 6.
4.1.1 Segmentation Algorithms
The goal of segmentation is to separate an image into homogeneous regions with respect
to one or more characteristics [22]. In medical imaging, segmentation is important for
extracting various features and parameters, such as longitudinal contraction delay between
two regions of interest in different slices of a 2D frame series. The aim of the study is to
classify the MR images to the anatomical regions such as left ventricle, right ventricle
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and blood vessels. Nowadays, a wide variety of segmentation techniques are available.
However, there is no standard segmentation technique that can provide satisfactory result
for all imaging application. Segmentation techniques are classified as follows [22]:
1. Region based techniques, which seek for a region fulfilling homogenous criterion.
2. Edge based techniques that look for edges between regions with different characteris-
tics.
Two and three dimensional deformable models have been used to segment, visualize and
quantify a variety of anatomical structures ranging in scale from the macroscopic to the mi-
croscopic. These include the brain, heart, arteries, kidney, lungs, stomach, liver and torso.
Segmenting manually 3D image volumes slice by slice is a difficult process and requires
good technical expertise in detecting the borders between different anatomical regions in
MR images, because mostly the MR images are not taken in frontal view with enough slices.
Applying a 2D active contour model to an initial slice and the propagation of the model
to neighboring slices can significantly improve the volume segmentation process. However,
the use of a true 3D deformable surface model can potentially result in even greater im-
provements in efficiency. Deformable surface models in 3D were first used in computer
vision [265]. Miller et al. [176] built a polygonal approximation to a sphere and deformed
the geometry of the balloon model until the surface of the balloon conforms to the ob-
ject surface of interest. The segmentation process is formulated as the minimization of a
cost function where the desired behavior of the balloon model is determined by a local
cost function associated with each model vertex. The cost function is a weighted sum of
three terms: a deformation potential, which expands the model vertices toward the object
border, an image term that identifies features such as edges and opposes the balloon ex-
pansion and a term that maintains the topology of the model by constraining each vertex
to remain close to the center of its neighbors.
The energy of a contour v(s), which in 2D is a function of x(s) and y(s) is defined as
equation 4.1. The energy function is a summation of internal deformation energy and an
external potential and should be minimized [22].
E(ν) = Ei(ν) + Ee(ν) (4.1)
Ei =
∫ 1
0
w1(s)
∣∣∣∣∣∂v∂s
∣∣∣∣∣
2
+ w2(s)
∣∣∣∣∣∂2v∂s2
∣∣∣∣∣
2
ds (4.2)
Ee(v) =
∫ 1
0
P (v(s))ds (4.3)
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where w1(s) controls the tension and w2(s) controls the rigidity. P (v(s)) denotes a scalar
potential function on the image plane. The contour v(s) that minimizes the energy E(ν)
must satisfy the Euler Lagrange equation [22]:
− ∂
∂s
(
w1
∂v
∂s
)
+
∂2
∂s2
(
w2
∂2v
∂s2
)
+∇P (v(s, t)) = 0 (4.4)
In the present study, the original mesh in the form of a sphere is created with a center
in the middle of the region of interest [232, 300]. The sphere radius has an average value
between the longest and shortest distance of the area boundary from the middle point.
This sphere itself contains a number of triangular meshes in order to reproduce the border
of the organ. This leads to ability of stretching and expanding interactively. The manual
segmentation offers the pull and push possibility, allowing the user to decide where the
next node of triangular mesh should be located. However, the placement of a new node
may change the neighborhood locations (see figure 4.1).
(a) (b)
Figure 4.1. Segmentation of left ventricle in short axis view: (a) Example of tracking the left ventricular
epicardium. (b) Three dimensional volume representing the left ventricle based on the selected mesh.
In order to speed up the process of manual segmentation for the ventricles, a semi auto-
matic algorithm is implemented for generating the endocardium from epicardium using
the assumption of no difference between their structural shape. After segmenting the epi-
cardium of the ventricle, the 2D slices of ventricle are investigated in the axial plane. The
center of gravity (COG) is obtained for each epicardial slice and considered as the refer-
ence point in the polar coordinates. Several pairs of points are selected in the epi- and
endocardium. Each pair of points and the COG are on a straight line. The reduction in
radial direction is computed by averaging the differences of each pairs. The reduction or
scaling coefficient is then multiplied by the epicardial points in each slice. This procedure
offers a simple way to generate the endocardium. The steps of generating the endocardium
is summarized as follows:
• Calculating the COG for each epicardial slice as a reference point
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• Selecting at least 3 pairs of points from the epi- and endocardium respectively in one
or different slices
• Calculating the average of the difference between epicardial and endocardial radii as a
multiplication coefficient
• Multiplying the epicardial points to the scaling coefficient
The cross section of the segmented ventricle is demonstrated in figure 4.2.
(a) (b)
Figure 4.2. Cross section of segmented left ventricle in axial view: (a) 2D view. (b) 3D view.
4.1.2 Three Dimensional Model
A 3D model is the next step after creating the volumetric mesh of the heart corresponding
to left and right ventricle including epicardium and endocardium. Each extracted seg-
ment is associated with a certain value selected by the user from a codebook containing
all organs with the corresponding values. The assignment of tissue values leads to the
identification of each organ using a numerical label as a tissue class that simplifies further
modeling steps. The classes’ assignment is useful for modeling the conduction system, since
the excitation propagation possibility in different tissues should be taken into account in
the electrophysiological properties of different tissues. A sample of segmented ventricles
with different tissue classes is demonstrated in figure 4.3.a.
The representation of the three dimensional image is based on the segmented volume
extracted from series of 2D MR images (figure 4.3.b). The voxel side length can differ,
according to the image resolution. Normally, due to the lack of sufficient slices in z axis
direction, an interpolation between slices is necessary, resulting in an isotropic cubic voxel
data set. This process is implemented prior to the segmentation.
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(a) (b)
Figure 4.3. A segmented ventricular model: (a) A slice of a segmented data set including left and right
ventricular myocardium with tissue classes 31 and 30 respectively. The tissue classes 44 and 43 are assigned
to the blood inside the left and right cavity respectively. (b) Three dimensional representation of the
ventricles.
4.1.3 Myocardium Fiber Orientation
Fiber orientation affects the excitation conduction in the heart. The extraction of my-
ocardial fiber orientation in this research is established by the software tool created by
Weiss [282] based on Streeter et al. [256]. Streeter proposed two angles for each transmu-
ral position within the myocardium in order to define the fiber orientation in Cartesian
coordinates (see figure 4.4):
1. Helix angle which depicts the fiber orientation rotation through the ventricular wall.
2. Transverse angle which depicts how the fibers are deflecting from the epicardial angle.
(a) (b)
Figure 4.4. (a) A transmural course of the LV myocardium (α1 as helix angle and α3 as transverse angle)
[256]. (b) View of three axial slices illustrating the fiber orientation.
No noticeable change in transverse angle was measured, despite a small change of 6◦ from
apex to base. The transverse angle was constantly varying from epicardium (-75.3◦) over
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0◦ in midmyocardium to 55.5◦ in endocardium [240, 256].
A rule-based algorithm, derived from anatomical studies by Streeter [256], was imple-
mented to define the fiber orientation in the ventricular myocardium model. The fiber
orientation is integrated to allow the assignment of anisotropic electrical properties to the
tissue.
4.1.4 AHA Classification of Left Ventricle
The left ventricular subdivision algorithm was based on a publication of American Heart
Association (AHA), proposing standardized myocardial segmentation for tomographic im-
ages in order to identify the region of investigation (see figure 4.5) [65]. The left ventricle
was subdivided into 17 segments.
(a) (b)
Figure 4.5. Subdivision of the left ventricle according to the AHA [65]: (a) Short axis view. (b) Long axis
view.
The subdivision algorithm can also be applied to the right ventricle. The 17 segments can
be enhanced to more segments in order to create more detailed standardized structure.
The software developed by Keller [140] is applied to the 3D model of the left ventricle in
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order to mark different locations specific for myocardial infarction (see figure 4.6).
(a) (b)
Figure 4.6. AHA standard subdivision of the patient left ventricle. Different colors are used to indicate
different segments. (a) Anterior. (b) Posterior.
Subdivision is done by a fully automatic algorithm. First, the long axis of the left ventricle
is determined using principal component analysis. Then, the left ventricle is subdivided
into 3 equal slices from basal to apical endocardium perpendicular to the long axis. The
apex is defined as the fourth slice. In the last step, these slices are subdivided into the
segments with equal angles. The segments are numbered from 1 to 17 according to AHA
suggestion shown in figure 4.5.
4.2 Modeling the Electrophysiology
The second step in constructing a cardiac ventricular model is the implementation of
electrophysiology. The electrophysiological behavior of myocytes was simulated by the ten
Tusscher ionic cell model [261]. The mathematical system derives the transmembrane volt-
age of a myocyte from a number of ionic currents. With such a model, both the amplitude
and the duration of the action potential (AP) can be calculated.
Additionally, a transmural heterogeneity of action potentials was included in the myocar-
dial model. The heterogeneity of AP is achieved by changing the certain electrophysiolog-
ical parameters, such as the slow delayed rectifier current (Iks) and transient potassium
outward current (Ito) from epi- to endocardium.
4.2.1 The Bidomain Model
The bidomain model considers two domains, respectively the intra- and extracellular space
each with a potential and a conductivity tensor. The Poisson’s equation describes the ionic
currents and concentration in both intra- and extracellular spaces considering no external
stimulus current [216].
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∇ · (σi∇φi) = AmIm (4.5)
∇ · (σe∇φe) = −AmIm (4.6)
where Am is defined to be the surface to volume ratio of the cell membrane and Im is
the transmembrane current density per unit area. φi and φe are the potential fields of the
intra- and extracellular space. The conductivity tensors of these spaces are σi and σe. This
leads to:
∇ · (σi∇φi) = −∇ · (σe∇φe) (4.7)
The transmembrane voltage (Vm) is assumed as a potential difference across the cell mem-
brane.
Vm = φi − φe (4.8)
The following equation yields with subtracting ∇ · (σi∇φe) from both sides of equation
4.7.
∇ · (σi∇Vm) = −∇ · ((σi + σe)∇φe) (4.9)
In addition, the transmembrane current (Im) is expressed according to Hodgkin and Huxley
[124] as follows (see figure 4.7):
Im = Cm
∂Vm
∂t
+ Imem (4.10)
Figure 4.7. The electrical equivalent circuit representing the cell membrane of Hodgkin and Huxley [124].
The conductive components are a function of potential difference across the cell membrane (Vm) and
the equilibrium potentials (E) of the ions. INa, IK and Il represent the sodium, potassium and leakage
currents, RNa, RK and Rl are the corresponding resistances and VNa, VK and Vl are the corresponding
Nernst potential [9].
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where Cm is the membrane capacitance and Imem is the sum of all ionic currents that are
calculated from the cellular models. According to equation 4.6 , the equation 4.9 can be
rewritten as follows:
∇ · (σi∇Vm) +∇ · (σi∇φe) = Am · (Cm∂Vm
∂t
+ Imem) (4.11)
4.2.2 The ten Tusscher Cell Model
Different cell models were developed for describing the atrial or ventricular electrophysi-
ology of a specific mammal, as illustrated in table 4.1.
In the human ventricular model of ten Tusscher, the complete ionic current Imem consists
of twelve components [261]:
Imem = INa+IK1+Ito+IKr+IKs+ICaL+INaCa+INaK+IpCa+IpK+IbCa+IbNa (4.12)
The description of the ionic currents components is in table 4.2.
Furthermore, a schematic of the ten Tusscher model is illustrated in figure 4.8. The intracel-
lular compartments and the ionic currents taken into account are displayed. Additionally,
a transmural heterogeneity of action potentials was considered.
Figure 4.8. Schematic description of the ventricular cell model based on ten Tusscher. It contains detailed
description of ion currents, pumps and exchangers in three cell compartments: myoplasm, sarcoplamatic
reticulum (SR) and junctional sarcoplasmic reticulum (JSR) [261].
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Year Author Specimen Species
1975 McAllister, Noble, Tsien [170] Purkinje fiber -
1977 Beeler, Reuter [30] Ventricular myocardium Mammalian
1980 Yanagihara, Noma, Irisawa [289] Sinoatrial node Rabbit
1982 Bristow, Clark [47] Sinoatrial node Rabbit
1983 Bristow, Clark [48] Sinoatrial node Rabbit
1984 Noble, Noble [195] Sinoatrial node Rabbit
1985 DiFrancesco, Noble [79] Purkinje fiber Mammalian
1987 Hilgemann, Noble [122] Atrial working
myocardium
Rabbit
1990 Earm, Noble [90] Atrial working
myocardium
Rabbit
1991 Luo, Rudy [161] Ventricular myocardium Mammalian
1994 Luo, Rudy [162, 163] Ventricular myocardium Guinea-pig
1994 Demir, Clark, Murphey, Giles [77] Sinoatrial node Rabbit
1996 Dokos, Celler, Lovell [81] Sinoatrial node Mammalian
1996 Lindblad, Murphey, Clark, Giles
[158]
Atrial working
myocardium
Rabbit
1996 Demir, O’Rourke, Tomaselli,
Marban, Winslow [78]
Ventricular myocardium Rabbit
1998 Courtemanche, Ramirez, Nattel [69] Atrial working
myocardium
Human
1998 Nygren, Fiset, Firek, Clark,
Lindblad, Clark, Giles [198]
Atrial working
myocardium
Human
1998 Jafri, Rice, Winslow [130] Ventricular myocardium Guinea-pig
1998 Noble, Varghese, Kohl, Noble [196] Ventricular myocardium Guinea-pig
1998 Priebe, Beuckelmann [214] Ventricular myocardium Human
1999 Demir, Clark, Giles [76] Sinoatrial node Rabbit
1999 Winslow, Rice, Jafri, Marba´n,
O’Rourke [288]
Ventricular myocardium Canine
2000 Ramirez, Nattel, Courtemanche
[219]
Atrial working
myocardium
Canine
2000 Zhang, Holden, Kodoma, Honjo,
Lei, Varghese, Boyett [301]
Sinoatrial node Rabbit
2001 Boyett, Zhang, Garny, Holden [44] Sinoatrial node Rabbit
2001 Pandit, Clark, Giles, Demir [201] Ventricular myocardium Rat
2001 Puglisi, Bers [215] Ventricular myocardium Rabbit
2002 Kneller, Ramirez, Chartier,
Courtemanche, Nattel [148]
Atrial working
myocardium
Canine
2002 Kurata, Hisatome, Imanishi,
Shibamoto [151]
Sinoatrial node Rabbit
2002 Bernus, Wilders, Zemlin,
Verschelde, Panfilov [33]
Ventricular myocardium Human
2004 Lovell, Cloherty, Celler, Dokos [159] Sinoatrial node Rabbit
2004 ten Tusscher, Noble, Noble, Panfilov
[261]
Ventricular myocardium Human
2004 Iyer, Mazhari, Winslow [129] Ventricular myocardium Human
2006 ten Tusscher II, Panfilov [262] Ventricular myocardium Human
Table 4.1. Ionic models of cardiac cells [241]
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Current Definition
Sodium currents
INa fast sodium influx
IbNa background sodium current
Potassium currents
IK1 inward rectifier current
IKr rapid delayed rectifier current
IKs slow delayed rectifier current
Ito transient potassium outward current
IpK plateau potassium current
Calcium currents
ICaL L-type calcium current
IbCa background calcium current
IpCa plateau calcium current
Mixed currents
INaK sodium/potassium pump current
INaCa sodium/calcium exchanger current
Table 4.2. Imem components according to the ten Tusscher cell model [261].
Figure 4.9 shows how the AP of myocytes changes from endo- to epicardium. The het-
erogeneity of AP is achieved by changing the model parameters of slow delayed rectifier
current (Iks) and transient potassium outward current (Ito) from epi- to endocardium.
The electrophysiological model of this work is based on the model of a human ventricular
myocyte provided by ten Tusscher et al. [261]. The model is adjusted for epicardial, endo-
cardial and midmyocardial cells to allow for the transmural heterogeneity of the human
ventricular myocardium [93]. The midmyocardial cells have the longest AP duration. Ac-
tion potential curves have been calculated for cells embedded into myocardial tissue using
the bidomain model [211, 283].
Figure 4.9. The simulated AP curves changing from endocardium to epicardium [94].
4.3 Modeling Excitation Propagation
The excitation conduction between two adjacent cells can be determined by either solving
the Poisson’s equation in bidomain model or by using simplified models, for generating
the excitation propagations according to a set of rules. An adaptive cellular automaton
(ACA), belonging to the rule-based heart models, was used in the present work.
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4.3.1 Adaptive Cellular Automaton (ACA)
The ACA model does not consider explicitly the ionic flow interaction between the intra-
and extracellular spaces in order to simulate the excitation propagation. Instead, the pre-
calculated APs derived from the ionic current equations based on the ten Tusscher model
are applied as a set of rules stored in a predefined library for the fast computation of
ventricular excitation. The calculation partition results in a greatly reduced computation
time in comparison to the bidomain model. The calculation time of the ACA used is ap-
proximately 4 minutes for the simulation of one heart beat on a PowerPC 2GHz. The
ACA computes the three dimensional excitation propagation according to the fiber orien-
tation, location of the cell and its recent course of transmembrane voltage. The ACA is
composed of a finite number of nodes. Each node corresponds to a set of heart myocytes
possessing the same properties in a small region of the heart. By a given time instant,
the state of each node in the cellular automaton changes depending on the states of a
finite number of neighboring nodes and the node’s own state in the previous time steps.
Different nodes may obey different criteria for state transition. The state of each node is
interpreted as transmembrane voltage at a given time instant. The criteria describing the
transition include the electrophysiological parameters, type of cardiac tissue, time course
of the transmembrane voltage during current and previous excitation, conduction velocity
and fiber orientation in myocardium.
The ACA developed by Werner, Sachse and Do¨ssel [285, 286] was applied in this work for
the heart model representing isotropic cubic voxels. The excitation is conducted between
the voxels (nodes) of the heart model if the following rules are satisfied (see figure 4.10):
1. Both nodes are excitable.
2. The excitation propagation between both nodes is permitted.
3. The node going to be excited, is not already excited and is in absolute refractory phase.
4. If the node is already in relative refractory phase, the produced action potential has a
smaller amplitude and duration compared to a not excited node.
The ACA uses precalculated action potential courses, which were calculated by cardiac cell
models. For each (node) tissue type, there are several action potential course possibilities,
depending on the various stimulus rates and different cardiac cell time states. If the cell
is stimulated during refractory period, there is no AP generated. If the stimulus occurs
during relative refractory period, the resulting AP has smaller amplitude and shorter
duration. With all these rules, the ACA selects the proper AP course for each node from
the precalculated AP courses. Also, the ACA excites the neighboring cells according to
the rule set.
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Figure 4.10. Cellular automaton function [239]: (a) Excitation initiation in one cell. (b) Propagation into
the neighboring cells and refractory phase of initial excited cell. (c) Refractory phase of the last neighboring
cells and the further conduction of excitation to the adjacent cells. (d) All the cells in refractory phase.
(e) Repolarization of the initial cell. (f) Repolarization of the neighboring cells which returns them to the
excitable cells.
4.3.2 Modeling the Excitation Conduction System
In order to simulate electrical excitation initiation and propagation, a pacemaker model
and an excitation conduction system are implemented into the cardiac model. The exci-
tation conduction system up to the left and right bundle is generated manually according
to an anatomical atlas. The right bundle branch usually originates from the most dis-
tal part of the His bundle as a single slender bundle and crosses through the muscular
inter-ventricular septum to the right ventricular endocardial septal wall [131]. The bun-
dle emerges at the right septal surface and continues to the moderator band, where it
branches into two different parts, one carrying excitation to the anterior papillary muscle,
and the other to the RV free wall. The left bundle branch (LBB) has a highly variable
anatomy in different individuals. The LBB consists of three main branches with multiple
interconnections, which ramify over the left ventricular septal wall and extend to the bases
of the anterior and posterior papillary muscles, carrying excitation to the septum and the
inferior and superior free wall [263].
In this research, the end points of Purkinje fibers are generated on the endocardium based
on a density given by the user. The program then automatically connects the end points
of the Purkinje fibers with the Tawara bundles using an optimal tree. The algorithm is
based on Graph theory with minimization of the cost function [284]. Figure 4.11 shows a
generated conduction system for a patient data set.
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Figure 4.11. Simulated excitation conduction system of the ventricles starting from AV node to Purkinje
fibers.
4.4 Modeling Pathologies
The pathologies simulated in this study were a total left bundle branch block (LBBB) in
conjunction with reduced intra-ventricular conduction velocities and myocardial infarction
(MI).
4.4.1 Myocardial Infarction: Allocation in AHA Segments
Myocardial infarction consists of necrotic tissue in the center and a surrounding transition
zone of ischemic tissues with gradually changing properties. This results in a change of
excitation propagation ability for cardiac cells. In the study, the myocardial infarction is
modeled by a spherical area of about 30− 50 voxel volume including the necrotic tissues
with excitation propagation velocity of zero in the center and a surrounding ischemic area
with slower conduction velocity [134]. Since, the center of the infarction consists of dead
necrotic tissue showing no electrical activity. The necrotic center is surrounded by an is-
chemic area, with gradually increasing electrical activity (see figure 4.12.a).
According to figure 4.12.a, the diagram shows the dependency of excitation propagation
velocity and excitation amplitude dependent on the normalized distance from infarction
center. In the center, propagation velocity and excitation amplitude are 0. Starting from
distance factor 0.5, propagation velocity and excitation amplitude increase up to the nor-
mal value. Figure 4.12.b illustrates a cross section of the ventricles with simulated infarc-
tion, which shows activation of the myocardium. The area of infarction is clearly visible
with no activation.
In order to simulate several infarction locations, the AHA recommendation for ventricular
classification was implemented. This standard ventricular classification enables an abstract
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(a) (b)
Figure 4.12. Myocardium infarction: (a) Modeling a myocardial infarction by adapting the excitation
amplitude factor and the propagation velocity factor to the normalized distance from infarction center
[134] . In the center of the infarction there is a necrotic area showing no electrical activity (factor 0). The
necrotic area is surrounded by an ischemic area with gradually increasing activity (factor increasing up to
1). (b) An axial cross section of the ventricles with the myocardial infarction through a delayed activation
(gray spot) and no activation (black spot).
description of infarction location and later allocation of corresponding optimal electrode
positions. An excitation propagation velocity of zero and a slower conduction velocity were
assigned to the necrotic and ischemic area at the corresponding AHA segment, respectively.
Therefore, AHA segments enable a standard description of nomenclature, allocation of MI
and additionally the corresponding optimal lead positioning [177]. The 17 AHA segments
are assigned to the territories of the coronary arteries, according to AHA proposal. This
is considered to make sense, due to the coronary arteries’ vital role in oxygen supply.
4.4.2 Left Bundle Branch Block: Simulation of Blockage in the Excitation
Conduction System
The LBBB pathology was modeled by setting a disconnection in the excitation conduction
system after the bundle of His. Moreover the LBBB was modeled by adjusting the cellular
automaton parameters in a way that the electrical excitation transmission failed along the
left bundle branch. The LBBB could also be modeled by setting the excitation conduction
velocity to zero along the left bundle.
4.4.3 Reduction of Intra-ventricular Conduction Velocity
In patients with Congestive Heart Failure (CHF), heart tissue shows a larger amount of
fibrotic tissue. In order to model this, the ventricular excitation conduction velocity was
simulated with 100 %, 80 % and 60 % of the physiological case.
88 Chapter 4. Human Heart Modeling
Inter-ventricular delay can be modeled by reducing the electrical conduction velocity in
both ventricles. In LBBB patients, in addition the excitation of left ventricle is delayed.
Hence, in order to simulate the total inter-ventricular delay, a disconnection of excitation
conduction and a reduction of conduction velocity in the left ventricle were performed. In
this work, namely the intra-ventricular conduction velocity was set to 100 %, 80 % and
60 % of physiological value.
5Forward and Inverse Problems of Electrocardiography
The most important aim in electrocardiography is to increase the information about car-
diac electrical activity, which is extracted by non-invasive measurements on the body
surface. The general objective of the forward and inverse problems of electrocardiography
is a better qualitative and quantitative understanding of the heart’s electrical activity. To
this end, an equivalent source model, in conjunction with a specified volume conductor is
usually taken into account as the subject’s torso.
The forward problem of electrocardiography refers to the computation of the body surface
potentials starting from either equivalent current dipoles representing the electrical activ-
ity of the heart or from known potentials on the epicardium. In general, two approaches
are used in order to solve the forward problem [110]: surface methods and volume methods
In surface based methods, an isotropic conductivity is considered into different regions of
the torso hence only the boundaries between different regions are isolated and characterized
in the numerical torso. If an anisotropic region such as skeletal muscle should be included
into the torso model, the first step is converting it to an approximately isotropic region
before forward calculation. These computations involve the solution of integral equations
for the potentials of the discrete surfaces of the torso model (Boundary Element Method).
In volume based methods, the entire three dimensional torso model is represented numeri-
cally by a combination of tetrahedral or hexahedral elements. Volume based methods may
be subdivided into finite differences, finite element and finite volume methods.
In comparison to others, surface methods utilize simpler torso models with fewer elements.
However the matrix characterizing the set of equations to be solved is fully populated, since
the principal integral equations couple the potential of each element to the potential of
other elements [110]. Nevertheless, in volume methods the potential at each point is ex-
pressed only in terms of potentials at its nearest neighbors.
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In contrast to the forward problem, which can be solved uniquely to a constant potential,
the inverse problem does not possess a mathematically unique solution and considers the
reconstruction of cause by its effects. The cardiac sources should be computed from the
measured BSPM on the body surface. The primary cardiac sources cannot be uniquely
determined as long as the active cardiac region containing these sources is inaccessible
for potential measurements. This is because the electric field that these sources generate
outside any closed surface completely enclosing them, may be duplicated by equivalent
single-layer (monopole) or double-layer (dipole) current sources on the closed surface it-
self. Many equivalent sources, and hence inverse solutions, are thus possible. However, once
an equivalent source is selected, its parameters can usually be determined uniquely from
the body-surface potentials [202].
Since one of the major applications of the forward problem is simulating the cardiac
pathologies with computer heart models, this chapter describes the forward problem of
electrocardiography. Modeling of the generated bioelectric fields from cardiac sources in
the tissues and surface of the human body is incorporated with ECG and the standard
leads (see chapter 2). The simulation of electrocardiograms, which were used in this work
under idealized conditions, will be described later. In addition, the solutions of forward
and inverse problem will be declared.
5.1 Solution of Forward Problem of Electrocardiography
The construction of geometry models of the heart and torso is essential to solve the forward
and inverse problem of electrocardiography. Once the geometry models containing torso,
lungs, heart, stomach, liver etc. are available, a numerical approach is required to solve
the field problem. As discussed at the beginning of this chapter, the numerical methods
are classified to [85, 242, 247]:
1. Surface approach, which is based on integral function technique. The typical algorithm
is the boundary element method (BEM) [4, 96, 101, 136].
2. Volume approach, which is based on differential equations techniques. The typical
algorithms include finite element method (FEM) [135, 136], finite difference method
(FDM) [194] and finite volume method (FVM) [113].
In the surface approach, the interfaces of different conductivity regions are detected for
modeling. Therefore, this approach can considerably reduce the number of unknown vari-
ables. However, it is very difficult to handle anisotropic regions, while the volume approach
is very suitable to model the inhomogeneous areas. These two approaches have their own
advantages and can be applied to different problems. In the BEM, the BE mesh is critical
and directly influences the solution accuracy [54, 96, 101, 242].
5.1. Solution of Forward Problem of Electrocardiography 91
Since the computation of BSPM and ECG in this research is performed via finite element
based human body model, this section provides a brief description on volume approach
method.
As discussed in section 4.2.1, the bidomain model is a macroscopic way to consider the
cellular electrophysiology of the myocyte with dividing the region in two subspaces (intra
and extracellular) while considering potential and conductivity for each subspace [94].
The conductivity tensor σ which contains the conductivity of myocyte tissue is defined as
follows:
σS =
σSl 0 00 σSt 0
0 0 σSt
 (5.1)
for S = i, is referred to the intracellular domain
for S = e, is referred to the extracellular domain
where σSl and σSt are respectively the longitudinal and transversal scalar conductivities
according to the fiber direction of the myocardiun tissues. This is due to the anisotropic
characteristic of the excitation propagation along the fibers. The anisotropy ratio R is
defined as a ratio between the longitudinal and transversal conductivity [233]:
R =
σSl
σSt
(5.2)
The bidomain equations for extra and intracellular spaces are defined as follows [94, 233]:
∇.(σi∇ϕi) = f (5.3)
∇.(σe∇ϕe) = −f (5.4)
where σi and σe are conductivity tensors of intra and extracellular space. ϕi and ϕe are
respectively intra and extracellular potential. The current source density f is related to
the divergence of the impressed current density Js as follows:
f = ∇ · Js (5.5)
Adding equation 5.3 and 5.4 together with considering the transmembrane voltage as
Vm = ϕi − ϕe, the following equation is obtained:
∇.((σi + σe)∇ϕe) = −∇.(σi∇Vm) (5.6)
substitution of following parameters as
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σi + σe = σ (5.7)
∇.(σi∇Vm) = f (5.8)
leads to the Poisson equation of:
∇.(σ∇ϕ) = −f in Γ (5.9)
where Γ is a finite domain of volume conductor. The boundaries are taken as the zero
reference potential and the area between body surface and air to satisfy the Dirichlet
and Neumann boundary conditions respectively [94]. The equation 5.9 can be discretized
by finite element method with tetrahedral unstructured grids and an adaptive mesh re-
finement. The linear system equations achieved by finite element approximation can be
solved by numerical solution algorithms iteratively. In the current work using the forward
solver software of IBT, Cholesky decomposition and conjugate gradient method are used
in order to solve the forward problem [94, 104, 249]. The finite element model leads to size
reduction of the problem. Since the computation of the body surface is resulted from heart
sources, a high resolution geometry should be considered in the heart region. Therefore,
more nodes and vertices are assigned to the heart geometry whereas less nodes are consid-
ered for homogeneous regions. The current source density is computed by interpolation of
the transmembrane voltages to the finite element grid [94]. An example of finite element
model is demonstrated in figure 5.1.
(a) (b)
Figure 5.1. The Meet Man finite element model: (a) torso. (b) heart.
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5.2 Solution of Inverse Problem of Electrocardiography
As already mentioned, the inverse problem does not possess a unique solution. This diffi-
culty is solved by using simplified models for the cardiac current sources and regularization
techniques. These models introduce implicit constraints, enabling model parameters to be
uniquely computed from the surface potentials. Therefore, the solution of the inverse prob-
lem will lead to recover an approximation of the electrical activity of the equivalent source
based on the measured potentials on the torso surface. The different solutions to the inverse
problem may be presented according to the type of the heart model whose parameters are
being sought.
To stabilize inverse solutions against sensitivity to small perturbations in the input, addi-
tional constraints based on supplementary a priori information, must be imposed on the
solution. Straightforward least-squares solutions will not give reliable results due to the
presence of the common small singular value decomposition (SVD). Even truncated SVD
solutions are not very effective because of the lack of a clear distinction between significant
and insignificant singular values [86, 94, 202].
The most common approach to this problem is a technique known as Tikhonov regular-
ization: the least-squares residual error cost function is supplemented by a second term
that penalizes for large values of a chosen property of the solution. Thus, a tradeoff is con-
structed between fidelity to the data (small residual error) and fidelity to the constraint
represented by the second term (small regularization error). This tradeoff is controlled by
a multiplicative weight known as the regularization parameter. Among areas of recent de-
velopment have been the incorporation of more constraints, and especially, temporal and
spatial ones. Inverse solutions in general clinical application will need to incorporate such
sophisticated techniques to impose physiologically realistic constraints as precisely as possi-
ble. Such solutions hold the promise of greatly improved characterizations, quantification,
and localization of cardiac abnormalities from non-invasive body surface measurements
[202].
As discussed in section 4.2.1, the bidomain model gives a linear relationship between the
distributions of TMV within the myocardium and the BSPM. To solve the inverse problem,
a simplified finite element model is constructed. Different conductivities for various geom-
etry elements are considered. The transfer matrix in the following equation is computed
by a series of forward computations [94],
A.−→x = −→y (5.10)
where A ∈ Rm×n is the transfer matrix describing the relationship between cardiac sources
and BSPM. −→x ∈ Rn is the vector of cardiac sources and −→y ∈ Rm is the vector of measured
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BSPM [94, 249]. A random column vector
−→
N can be added to the left part of equation
5.10 where each component corresponds to a Gaussian random variable that models the
additive zero mean Gaussian noise added to the measure. In general, at least one solu-
tion exists because the number of recorded samples on the body surface is larger than
the quantity of epicardial potential nodes. The opposite situation will lead directly to an
extremely undeterminated system of equations, providing a non-unique solution.
Hence, from an algebraic point of view, at least m uncorrelated samples leading to m
linear independent equations will be enough to solve the problem. However, the proximity
between them and the fact that they are recording a common electrical source cause an
important correlation and similarity between observed signals in the electrodes. But de-
spite this dependence, they stay linearly independent, with infinite precision, even with no
noise, due to the Gauss’ Law. More observed data is expected to add some new informa-
tion into the problem. Nevertheless, as the body surface is finite, the more samples, the
more correlation between them. So the quantity of information incorporated by each new
sample decreases as a function of the total of observed points [202].
The relation between epicardial and ECG potentials is concentrated in the forward matrix.
When a matrix suffers from all the former problems, it is called an ill-conditioned matrix.
The degree of ill-conditioning can be numerically determined as the proportion of the
largest and smallest singular value of the SVD decomposition of the forward matrix. This
classification can also be interpreted from SVD point of view, through the degree of ill-
conditioning. There are two important classes of problems to consider, and many practical
problems belong to one of these two classes.
1. Rank-deficient problems which are characterized by the matrix A having a cluster
of small singular values, and there is a well-determined gap between large and small
singular values.
2. Ill-posed problems, where all the singular values of A, as well as the SVD components
of the solution, on average, decay gradually to zero.
For discrete ill-posed problems, the goal is to find a balance between the residual norm and
the size of the solution that matches the errors in the data as well as one’s expectations
to the computed solution.
Further examples of regularization methods are generalized singular value decomposition
(GSVD), Tikhonov regularization zero, first and second order. Tikhonov regularization is
applied in IBT inverse solver software. The Tikhonov regularization solution is obtained
by minimizing the objective function as [94, 216]:
−→x λ = argmin−→x (||A
−→x −−→y ||22 + λ2||L−→x ||22). (5.11)
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The regularization term L−→x incorporates the a priori information about the solution −→x .
L is a linear operator. It is assumed that the measurement noise is uncorrelated and has
a diagonal covariance matrix.
Summarizing, the degree of ill-posedness in the inverse problem will cause an ill-conditioned
inverse problem. Anyway, in both interpretations the consequence is that the system re-
mains ambiguous, so multiple solutions are possible, and small perturbations of the ob-
served data can cause an arbitrary large perturbation of the solution. The mathematical
treatment of this kind of systems, like ill-conditioned systems is the challenge of the reg-
ularization techniques.
5.3 Optimization Based Approach
An alternative approach for solving the inverse problem of electrocardiography is the
optimization based method. The electrophysiological model parameters are varied until
the simulated ECG gets similar to the measured ECG. As it will be demonstrated in
chapter 9, the parameters of the cellular automaton (CA) such as myocardial excitation
conduction velocity and infarction position are iteratively varied until the measured and
simulated ECG are as similar as possible. The comparison between the measured and
simulated ECG was performed as follows [94]:
1. Both data sets were normalized, so that the difference between the maximal and min-
imal values is 1.
2. The simulated ECG was interpolated to the sample rate of the measured one.
3. The difference between the measured and simulated signals was calculated in terms of
root mean square error (ERMS).
4. The resulting ERMS were averaged using all channels. The averaged ERMS in each
ECG channel is used as the criterion of optimization using Powell and downhill simplex
methods [212].

Part II
Data and Methodology

6Patient Data
Several MR data sets were acquired from University Hospital Mannheim and University
Hospital Heidelberg. The individual models were generated by segmentation of imaging
data (MRI, CT) in order to obtain the patients’ anatomy. The model of the left ventricle
was subdivided into 17 segments according to the American Heart Association (AHA)
suggestion, which simplifies the determination of MI position in accordance with the cor-
responding coronary artery.
The 3D ventricular model was extracted from a series of segmented short axis 2D MR data
sets for each patient. The segmentation was done by using interactive deformable contours
based on a triangle mesh forming the borders of different parts of the organ. The cardiac
conduction system including the bundle of His, left and right bundle and Purkinje fibers
were implemented into the ventricles. The electrophysiological properties of the heteroge-
neous ventricle and the pathophysiological properties according to the patient symptoms
(ischemic cardiomyopathy and left bundle branch block) were implemented into the ven-
tricular model. The 3D volume conductor model of the thorax was extracted from a series
of frontal axis 2D MR data sets for each patient. The segmentation was done by using
interactive deformable contours based on a triangle mesh forming the borders of different
organs. The tetrahedral mesh of the thorax was created including the heart and the other
organs.
Multichannel ECG measurements with the Biosemi device of the patients’ pre- and post-
implantation at University Hospital Mannheim were completed. Figure 6.1 illustrates the
steps from data acquisition to heart and torso model creation.
6.1 Patients Heart Model
Nine data sets including ten MR data sets and one CT data set were acquired from pa-
tients mostly suffering from LBBB and MI. One data set was acquired from a patient
with extrasystole. Two additional data sets from a healthy person and the Visible Man
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Figure 6.1. The steps of generating the patient model: (1) Segmented ventricles extracted from axial MR
data. (2) 3D ventricular model with the conduction system. (3) Subdivided left ventricular model based on
AHA standard. (4) Distribution of the simulated transmembrane voltage. (5) Distribution of the simulated
epicardial potential. (6) Fontal MR data set. (7) Segmented Torso from MR data set. (8) Volume conductor
model. (9) 3D Torso model with standard ECG electrodes. (10) Distribution of the simulated BSPM.
were used in the work. The individual models were generated by segmentation of the 2D
data set in diastole and interpolating the slices in case of MR data to increase the z-axis
resolution.
The description of the segmented models is demonstrated in table 6.1. The ventricular
models and AHA segmented models are demonstrated in figures 6.2 to 6.14.
P-ID Gender/age Cardiac pathology Res. (mm3) Dimension Size
1 male LBBB, MI (sim. only) 1×1×1 145×126×197 3599446
2 male (62) LBBB, ischemic .39×.39×.39 381×361×224 30809440
3 male (65) LBBB, MI 1×1×1 180×164×137 4044496
4 male (76) LBBB, DCMP, ischemic 1×1×1 179×163×154 4493514
5 male (80) LBBB, MI, ischemic 1×1×1 155×157×130 3163806
6 male (25) LBBB, MI (sim. only) .5×.5×.5 265×210×230 12799756
7 male (50) LBBB, MI 1×1×1 218×188×147 6024904
8 female (70) LBBB, MI 1×1×1 166×138×110 2520136
9 male (54) LBBB, MI 1×1×1 145×165×150 3589006
10 male (46) LBBB, MI 1×1×1 192×163×180 5633536
11 male(80+) LBBB,MI 1×1×1 200×200×200 8000256
12 female (70+) ventricular asynchrony 1×1×1 200×200×200 8000256
13 female(40+) extrasystole 1×1×1 160×140×140 3136256
The first and the sixth data sets are referred respectively to the Visible Man and a healthy subject in
which the pathologies were simulated. P-ID: patient-ID, Res: resolution, LBBB: left bundle branch block,
MI: myocardial infarction, DCMP: dilated cardiomyopathy. For patient 2, the data set was achieved from
a high resolution CT in which no interpolation was needed. Ventricular models 9 and 10 are related to the
work of Farina [94].
Table 6.1. Overview of the 13 different data sets used in this study.
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(a) (b)
(c) (d)
Figure 6.2. Patient-1: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
(a) (b)
(c) (d)
Figure 6.3. Patient-2: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
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(a) (b)
(c) (d)
Figure 6.4. Patient-3: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
(a) (b)
(c) (d)
Figure 6.5. Patient-4: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
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(a) (b)
(c) (d)
Figure 6.6. Patient-5: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
(a) (b)
(c) (d)
Figure 6.7. Patient-6: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
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(a) (b)
(c) (d)
Figure 6.8. Patient-7: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
(a) (b)
(c) (d)
Figure 6.9. Patient-8: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view. (c)
Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based on
AHA in posterior view.
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(a) (b)
(c) (d)
Figure 6.10. Patient-9: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view.
(c) Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based
on AHA in posterior view.
(a) (b)
(c) (d)
Figure 6.11. Patient-10: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view.
(c) Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based
on AHA in posterior view.
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(a) (b)
(c) (d)
Figure 6.12. Patient-11: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view.
(c) Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based
on AHA in posterior view.
(a) (b)
(c) (d)
Figure 6.13. Patient-12: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view.
(c) Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based
on AHA in posterior view.
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(a) (b)
(c) (d)
Figure 6.14. Patient-13: (a) Ventricular model in anterior view. (b) Ventricular model in posterior view.
(c) Subdivided ventricular model based on AHA in anterior view. (d) Subdivided ventricular model based
on AHA in posterior view.
6.2 Patients Torso Model
The torso model of the thorax was generated by segmentation of the 2D frontal axis
data sets of thorax. Further, the volume conductor was achieved by selecting a proper
number of nodes and assigning the related conductivity tensor. The information of the
generated volume conductors of four patients are shown in table 6.2. The torso models are
demonstrated in figures 6.15 to 6.18.
ID Number of nodes Number of tetrahedra Distance between nodes
Patient-10 162841 991472 2 mm
Patient-11 44678 283641 2 mm
Patient-12 81612 503765 2 mm
Patient-13 93570 583647 2 mm
Torso model 10 is related to the work of Farina [94].
Table 6.2. Overview of the 4 different volume conductor models used in this study.
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(a) (b)
(c) (d)
Figure 6.15. Patient-10: (a) MR data set in frontal axis. (b) Segmented torso. (c) Volume conductor
model. (d) Inner organs model.
(a) (b)
(c) (d)
Figure 6.16. Patient-11: (a) MR data set in frontal axis. (b) Segmented torso. (c) Volume conductor
model. (d) Inner organs model.
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(a) (b)
(c) (d)
Figure 6.17. Patient-12: (a) MR data set in frontal axis. (b) Segmented torso. (c) Volume conductor
model. (d) Inner organs model.
(a) (b)
(c) (d)
Figure 6.18. Patient-13: (a) MR data set in frontal axis. (b) Segmented torso. (c) Volume conductor
model. (d) Inner organs model.
6.3 Multichannel ECG Measurements of Patients
Multichannel ECGs were measured on several patients at University Hospital Mannheim
before pacemaker implantation. The multichannel ECGs after implantation were mea-
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sured on three of those patients who underwent MR tomography. A tracking system (FAS-
TRACK) was used to localize the electrode positions. The post processing of the measured
ECGs including denoising, baseline wander cancellation and averaging in time which was
performed will be described in chapter 7. A sample of recorded ECG is illustrated in figure
6.19.
(a)
(b)
(c)
Figure 6.19. Patient-13: (a) One channel of recorded ECG. (b) Averaging over the time of different ECG
cycles in one channel after baseline wander cancellation. (c) Denoised and baseline corrected ECG channel.
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Measuring 64 channels ECG on the patients before implantation lead to BSPM of 64 po-
sitions. The BSPM was interpolated on the surface of the mesh in torso model in order to
compute the epicardial potential distribution. The inverse solution results in a better pa-
rameter setting of the patient heart model. Comparing 64 measured ECGs with simulated
computer ECGs for patients after implantation gave evidence on the applicability of the
computer model of heart and thorax.

7Optimization Algorithms and Methodology
As discussed in chapter 4, an optimization environment including an anatomical model of
the heart, cellular electrophysiology, excitation propagation and pathological model was
setup in order to find the optimal CRT parameters. A simulation environment including
a volume conductor model (anatomical torso model and conductivity values) is used to
validate the method results by generating the corresponding ECG.
The aim of BVP is to maximize patient’s cardiac output, in order to improve the hemo-
dynamic parameters of the patient as described in chapter 3. Ideally, a computerized
optimization of BVP would use a model of the cardiac contraction in order to calculate
the cardiac output. Since these models require an extensive calculation time and were not
available at the time of this analysis, an alternative approach is used. If the temporal and
spatial excitation propagation of the pathological heart with pacing is as close as possible
to the physiological excitation propagation, it is assumed that the cardiac output will be
optimal. Thus, the activation times for each cardiac cell (isochrones) are computed for
physiological, pathological and therapeutic case (pathology with pacing). The optimiza-
tion strategies based on isochrones are presented in sections 7.2. The purpose of the work
is classified in two strategies: the first is outlined in chapter 8 and the second in chapter 9.
The structure of the first strategy is:
1. Construction of an individual patient heart model considering the LBBB and MI ex-
tracted from MR data sets according to the description from chapter 4.
2. Assessement of the optimal pacing configurations as well as the best electrode setup and
timing delays in the course of two electrophysiologically based optimization algorithms.
3. Comparison of the results obtained from the two optimization methods and reconcile-
ment of the derived results.
The results of the two optimization algorithms may differ. In this case, a trade off between
optimal results could be performed, ensuring a proper selection of pacing parameters.
The structure of the second strategy is:
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1. Creation of an individual patient torso model considering the inner organs such as
heart, lungs, liver.
2. Solution of the inverse problem by setting the patient model parameters to achieve
a personalized model of the pathology by measuring the multichannel ECG from a
patient before implantation.
3. Calculation of the BSPM for the patient under therapy based on the optimal BVP
setup.
4. Extraction of the 12 standard ECG channels.
5. Verification of the optimal pacing results with respect to comparison of measured
ECG of the patient after implantation with the simulated ECG for optimal pacing
parameters.
7.1 Implementation of BVP into the Models
As discussed in chapter 3, biventricular cardiac pacemakers stimulate the right and left
ventricle either simultaneously or sequentially as a means to resynchronize ventricular
contraction. Standard atrial and ventricular pacing leads are placed on the right atrium
(sensing electrode), right ventricle (right stimulation electrode) and left ventricle (left
stimulation electrode), respectively. To accomplish ventricular resynchronization in clinical
practice, the left ventricular lead is implanted via the coronary sinus to achieve perma-
nent epicardial stimulation from lateral or posterolateral vein. The right ventricular lead
is implanted on the apex of the right ventricle.
In the present research, the lead positions to investigate, were chosen interactively to ob-
tain equally spaced positions covering the whole surface of the left ventricle. Different
pathologies according to 17 infarction positions and 3 reduced conduction velocities were
simulated. For each pathology, 36 lead positioning setups in parallel with various A-V (60 to
260ms) and V-V delays (-30 to 70ms) were investigated [177, 178, 179, 180, 181, 182, 221].
Overall 36 electrode setups were investigated. Eight different electrode positions were
chosen in the anterior (A, B, C, D) and posterior (I, J, K, L) branches of coronary sinus.
Four positions were chosen in the left ventricular free wall (E, F, G, H) based on several
studies [16]. The right ventricular electrodes were placed in the apex (X), upper (U) and
middle (M) septal wall (see figure 7.1).
7.2 Optimization of BVP
The optimization strategy used was based on the assumption that the optimal cardiac
output was given during sinus rhythm if no pathological changes in the electrophysiology
were present. Thus, the aim of the pacing therapy was to achieve a cardiac activation as
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(a) (b)
Figure 7.1. The electrode positions chosen for the patient-4 heart model. The electrodes A, B, C and D
are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located respectively at the right ventricular upper septum, middle
septum and apex.
close to the sinus rhythm as possible. For this purpose, the isochrones representing the
excitation front, i.e. the time of activation for each cardiac cell, represented by a voxel
in the anatomical data set model, were computed for one cardiac cycle. The activation
time or isochrone, was defined as the time of action potential initiation. The isochrones
as cardiac output for physiology, pathology, pacing and the differences between them are
represented in figure 7.2.
(a) (b) (c)
(d) (e) (f)
Figure 7.2. Isochrones of the excitation for a cardiac model: (a) Physiology. (b) Pathology. (LBBB and
MI) (c) Error between physiology and pathology. (d) Physiology. (e) Pathology with therapy (pacing) (f)
Error between physiology and pacing.
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7.2.1 Optimization of Pacing Parameters Based on Isochrones
The activation times for each cardiac cell (isochrones) were computed for the physiological,
pathological and therapeutic case (pathology with pacing). The difference of the isochrones
was expressed as a root mean square error (ERMS) [178, 179, 221]. Hence, the ERMS was
a measure for the difference between physiological and pathological excitation propaga-
tion. In the present research, the ERMS was minimized in order to find a pacing setup
delivering temporal and spatial excitation propagation as close as possible to the natural
physiological state.
The ERMS was a function of three variables: A-V delay, V-V delay and electrode position-
ing. The smallest error yields the optimal pacemaker setups with respect to the cardiac
activation.
ERMS =
√√√√ 1
N
N∑
i=1
(xi − ei)2 (7.1)
xi : the activation time of voxel i in physiological case
ei : the activation time of voxel i in pathological/pacing case
The method was independent from QRS duration, a measure often used for BVP opti-
mization in clinical practice. The steps of the optimization algorithm can be described as
follows:
1. Calculation of the ERMS.path for the isochrones between the physiological and patho-
logical case.
2. Calculation of the ERMS.pace for the isochrones between the physiological and pacing
case.
3. Determination of the minimal error with pacing (ERMS.pace), expected to be smaller
than the error without pacing (ERMS.path) for the isochrones.
7.2.2 Optimization of Pacing Parameters Based on QRS Duration
The method based on isochrones optionally provides a measure of QRS duration in parallel
with the first optimization algorithm by calculating the QRS duration from the time
difference between the last and the first activated cell. Measuring the QRS duration yields
an additional confirmation of the algorithm based on isochrones computation. This method
mimics the clinical procedure used nowadays to optimize CRT (see section 3.4.5). In the
first optimization method, the activation times in each cardiac cell were computed for
physiological (case 1), pathological (case 2) and therapeutical state (case 3). Since the
ECG of a patient with a LBBB is characterized by a QRS complex with the duration of
more than 120 ms, the QRS duration is computed for case 1 to 3. The QRS duration is
calculated as the difference of the activation time of the first and last activated cardiac
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cell (see figure 7.3). With this second optimization method, the optimal CRT parameters
are those leading to minimal QRS duration difference between case 1 and 3.
tQRS = tact,last − tact,first (7.2)
tact : the activation time of the corresponding voxel
tQRS : the QRS duration time
terror = tQRS,path(pace) − tQRS,phys (7.3)
terror : the difference time between physiological
and pathological/pacing case
The steps of the optimization algorithm are as follows:
1. Calculation of the QRS durations for the physiological and pathological case.
2. Calculation of the QRS duration for pacing case.
3. Finding the minimal difference of QRS duration between physiological and pacing case.
In order to calculate the QRS duration without ECG simulation, the minimal and the
maximal value of the isochrones matrix are explored. The QRS duration is established
from the difference of the achieved values, corresponding to the activation time of the
early activated cardiac cell and the last activated cardiac cell respectively.
(a) (b) (c)
Figure 7.3. QRS duration in the isochrones of the excitation for a cardiac model: (a) Physiology. (b)
Pathology (LBBB and MI). (c) Pacing.
It must be considered, that every evaluation of the ERMS or QRS function requests a
simulation with the computer heart model, leading to long computation time. So it is
important, that the minimization algorithm needs the smallest possible number of function
evaluations. The conventional, gradient-based minimization algorithms need at least 9
function evaluations for one iteration step. Hence, it was decided to use the downhill
simplex algorithm (DSA) for optimization in this work [222]. The DSA uses a simplex (in
this case a triangle) starting at arbitrary values of ERMS . The simplex moves in the two
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dimensional parameter space including A-V and V-V delays for each electrode positioning
towards the minimum. A more detailed description of the DSA is included in section 7.3.
7.3 Downhill Simplex Algorithm
The downhill simplex algorithm (DSA) was proposed by Nelder & Mead [213]. Since DSA
does not compute derivatives but relies only on function evaluations, it is a promising
candidate to speed up the calculation process for timing delay optimization.
The first point must be chosen manually or randomly to start the DSA. The DSA algorithm
is supposed to make its own way downhill through the unimaginable complexity of an N-
dimensional topography, until it encounters local minimum. The downhill simplex starts
with N+1 points, defining an initial simplex. If there is one initial point P0 then the other
N points can be expressed by
Pi = P0 + aiei (7.4)
where ei are N unit vectors, and ai are constants that characterize the length scale for
each vector direction [248].
The DSA implements a series of steps. Most steps include moving the highest point (the
point of simplex where the function is largest) through the opposite face of the simplex
to a supposed lower point (Pmirror). These steps are called reflections, and they are con-
structed to conserve the volume of the simplex. An example of DSA applying on a 2D
function is illustrated in figure 7.4.
In case, the value of the function in point Pmirror is between the second highest and lowest
value of the vertices of the simplex, then the highest point is changed to Pmirror (figure
7.4.b). When the value of function in point Pmirror is lower than or equal to in the lowest
point of the simplex the value is checked in point Pmirror.expand to see if the function drops
further in direction of Pmirror. The lower of points Pmirror and Pmirror.expand replaces then
the highest point of the simplex. If point Pmirror is greater, then the simplex expands
in direction to Pmirror.expand, thus its volume grows (figure 7.4.c). When the value of the
function in point Pmirror is higher than or equal to the value in the highest point of the
simplex, the value is checked in point Pcontract and the triangle compresses in one dimen-
sion along the last expansion direction (figure 7.4.d). While the Pcontract is still higher
than the initial highest value, the contraction would be two dimensionally performed that
means the two other nodes are contracted (figure 7.4.e).
The DSA is a numerical method to minimize a multidimensional function without using
the gradient of the function. So a minimum can be found with fewer calculations compared
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to the conventional methods.
The optimization process is started with 3 arbitrary values for A-V and V-V, since the
DSA needs three starting points. The parameter representing the efficacy of BVP either
ERMS or QRS difference is calculated for this three start values. The DSA estimates new
values for A-V and V-V delay. Then, another parameter representing the efficacy of the
optimization method is calculated. This way, the program iterates to an optimal set of
parameters. The iteration process is terminated by the user termination criterion, when
the optimized values are satisfactory.
highest value
Pmirror
Pmirror.expand
Pcontract
(1D) Contraction (2D)
(a)
highest value
Pmirror
Pmirror.expand
Pcontract
(1D) Contraction (2D)
(b) (c)
highest value
Pmirror
Pmirror.expand
Pcon ract
(1D) Contraction (2D)
(d)
highest value
Pmirror
Pmirror.expand
P ontract
(1D) Contraction (2D)
(e)
Figure 7.4. Steps of performing DSA [213, 222]. (a) The initial simplex in triangular form. (b) Resulting
Pmirror from reflection of the highest value. (c) Resulting Pmirror.expand from expansion of highest value.
(d) Resulting Pcontract from one dimensional contraction of highest value. (e) Resulting two dimensional
contraction of two other values.
7.4 Statistical Analysis and Student’s t Test
Many populations encountered in clinical practice are well approximated by the normal
distribution, so this assumption will lead to confidence interval procedures of wide appli-
cability.
In most studies discussed in chapter 3, statistical analysis was performed on patients who
underwent CRT. Continuous data were expressed as mean ± standard deviation (SD)
[17, 28, 63, 139, 203, 207, 252, 264, 273, 287, 294]. Therefore, investigation by variance
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analysis or Student’s t test was appropriate in clinical studies.
In a study of Becker et al. [29], a comparison of parametric variables before and after CRT
in a form of fitted covariance model was implemented. In a study of Cazeau et al. [63],
all analysis were based on the intention-to-treat principle. Baseline characteristics were
assessed with the use of the chi-square test for dichotomous variables and Student’s t test
or Wilcoxon’s nonparametric test for quantitative or categorical variables.
Pitzalis et al. [207] presented the data as mean values ± SD. The continuous variables were
compared using Student’s t test for dependent (intragroup comparisons) and independent
(intergroup comparisons) variables, and frequencies by means of the Fisher’s exact test.
Survival was analyzed using the Cox proportional hazards model, and expressed as haz-
ard ratios (HR) and confidence intervals (CI). In study of van Campen et al. [273], data
sets were presented similar to Pitzalis et al. [207] study. Groups were compared using the
two-sided t test for unpaired data, and the data of the whole group were compared using
the two-sided t test for paired data.
Considering a normal distribution with unknown mean and unknown variance for a pop-
ulation leads to a t distribution with n-1 freedom degrees [184]. The random variable T is
calculated as:
T =
X − µ
S/
√
n
(7.5)
where X1, X2, ....Xn are random samples from a normal distribution with unknown mean
µ and unknown variance σ2, standard deviation S and the sample size n.
The t probability density function is:
f(x) =
Γ [(k + 1)/2]√
pikΓ (k/2)
· 1
[(x2/k) + 1](k+1)/2
−∞ < x <∞ (7.6)
where k is the number of degrees of freedom. The mean and variance of the t distribution
are zero and k/(k − 2)(for k > 2), repectively.
Several t distributions are shown in figure 7.5. The general appearance of the t distribution
is similar to the standard normal distribution in that both distributions are symmetric and
the maximum ordinate value is reached when the mean is zero. However, the t distribution
has heavier tails than the normal, which means more probability in the tails than the
normal distribution.
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Figure 7.5. Probability density functions of several t distributions [184].
Defining tα,k as value of the random variable T with k degrees of freedom, an area of α as
a probability can be detected in figure 7.6.
Knowing the distribution of the test statistic under the null hypothesis allows accurate
calculation of probability values (p-values).
A t test is any statistical hypothesis test in which the test statistic has a Student’s t-
distribution if the null hypothesis is true. It is applied when sample sizes are small. The t
tests are divided to dependent and independent type:
1. Independent t test consists of two groups with no relationship.
2. Dependent t test consists of a matched sample where two groups are matched on a
particular variable.
The compared groups may have similar or different sample sizes and variances. For each
condition, the random variable T is calculated from a specific equation defined in table
7.1.
Figure 7.6. Percentage points of the t distribution [184].
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Type of t test Assumption Random variable T
Independent
1-sample X−µ
S/
√
n
2-samples
equal sample sizes
X1−X2r
S21+S
2
2
n
unequal
equal variance
X1−X2r
(n1−1)s21+(n2−1)s22
n1+n2−2 (
1
n1
+ 1
n2
)
unequal variance X1−X2r
S21
n
+
S22
n2
Dependent repeated samples XD−µ
SD/
√
N
X1, X2: random samples, µ: mean, n: sample size, S: standard deviation, XD: average of differences
between all pairs, SD: standard devation of differences between all pairs.
Table 7.1. Calculation of random variable T based on t test type.
7.5 Compatibility of the Computer Model with Clinical Data
The computation of BSPM corresponding to a given distribution of transmembrane volt-
ages within the heart was used to verify the results obtained from the optimization al-
gorithms based on electrophysiological heart models. The ECG was calculated for the
physiological, pathological and therapeutical cases with optimal pacing suggested by the
optimization method for those patient models with available MR data sets of the torso.
The QRS duration of each channel was computed and then compared to the corresponding
QRS duration of the physiological case in order to determine the efficacy of the optimiza-
tion method. To measure the QRS duration a wavelet-based segmentation method was
applied to the ECG signals in order to detect the R peak and the QRS complex.
In addition, for those patient models with available MR data sets of torso and multichan-
nel ECGs before and after implantation, an optimization strategy was performed. The
optimization included setting the cellular automaton parameters, such as changing the
conduction velocity in different segments to get a similar simulated ECGs as the mea-
sured one. Goal of this parameter optimization is to achieve a personalized model of the
pathology, in which the 64 simulated ECG channels will be as similar as possible to the
measured one. A high correlation coefficient between measured and simulated channel is
a good indicator of the success of the method. Further investigations were performed to
measure the influence of the pacemaker timing changes on the BSPM of the patient af-
ter the implantation. This provided valuable information to verify our CRT optimization
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method. Therefore, preprocessing was performed on the ECGs in order to detect the R
peaks and measure the QRS duration as the indicator of pacing efficacy in LBBB patients.
7.5.1 Baseline Wander Correction
Removal of baseline wander is necessary in order to minimize undesired changes in beat
morphology. Baseline wander is caused by patient movement, breathing and other un-
desired artifacts. Linear filtering, polynomial fitting and wavelet transforms are methods
used to remove the baseline wander. The wavelet transform is applied to the ECG signals
in order to decompose them to the low and high scales coefficients.
Based on the study of Mozaffary et al. [187], the wavelet transform of the ECG signal is
computed. In each scale, the wavelet coefficients energy for both coarse and detail levels
are calculated. Once comparing the energies of coarse and detailed levels, the branch of
the tree with the higher energy is chosen. The higher energy branches will be followed
until a point is reached where energy difference exceeds a preset threshold level. In this
point, the binary tree is completed and the baseline wander signal is identified. Using the
obtained wavelet coefficients, the inverse wavelet transform is calculated after substracting
the baseline wander from the wavelet coefficients. Thus, a baseline wander free ECG signal
is achieved.
The implemented program at IBT [41] utilizing mother wavelet Daubechies (db11) is ap-
plied to the measured ECGs (see figure 7.7). The decomposition level was 10 according to
the sample rate of 2048 Hz.
7.5.2 Denoising
The implemented program at IBT is applied on ECG signals, including the following steps
[41]:
1. Applying discrete wavelet transform (DWT) with Daubechies mother wavelet (db1) to
the signal in order to determine the approximated and detailed coefficients.
2. Selecting a threshold according to Donoho’s thresholding method [41, 83].
tr = σ
√
2 log(n) (7.7)
where n is the length of the noise signal and σ is the standard deviation of the noise.
Since the σ is often unknown, an estimation of σ would be as follows:
σˆ =
1
0.6745
MAD (7.8)
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(a)
(b)
Figure 7.7. Baseline wander cancellation in measured ECG: (a) Initial ECG signal. (b) Reconstructed
ECG signal after baseline wander removal.
where MAD is the median absolute deviation of the appropriately normalized fine
scale wavelet coefficients.
3. Applying soft thresholding to the detailed wavelet coefficients.
4. Applying inverse DWT to reconstruct the ECG signal.
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A block diagram showing the steps of the denoising system is demonstrated in figure 7.8.
A noisy and denoised ECG signal are illustrated in figure 7.9
Wavelet
Transform
MAD
Estimator
Threshold
selection
Soft
Thresholding
Inverse
Wavelet
Transform
noisy ECG
denoised ECG
Wavelet
Transform
MAD
Estimator
Threshold
selection
Soft
Thresholding
Inverse
Wavelet
Transform
noisy ECG
denoised ECG
Figure 7.8. Block diagram of a simple wavelet shrinkage denoising system [83].
(a)
(b)
Figure 7.9. Noise removal in measured ECG signal: (a) Noisy measured ECG signal (b) Denoised ECG
signal with mother wavelet db1.
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7.5.3 QRS Detection
The ECG signal can be segmented to the P wave, QRS complex and T wave. The aim
of the optimization algorithm in the research is to decrease the QRS duration after im-
plantation. Therefore the QRS complex should be detected properly both for pre- and
post-implantation data.
The implemented IBT software utilizes the Haar wavelet because of its similar function
to the derivative operator. For measured ECGs, the R peaks are detected and translated
to overlap each other. Averaging of the ECG cycles over time is performed to obtain an
averaged ECG signal (see figure 7.10).
The ECG signal is decomposed using wavelet transform. The number of decomposition
levels depends on the region of interest. Since the QRS complex is carried by frequencies
between 5-25 Hz, a decomposition level of 6 is chosen although it can be changed due to
the sample rate frequency.
Table 7.2 demonstrates the frequency range of different decomposed signal levels. The lo-
cal maximum and minumum of the proper level is searched with comparing the values to
a threshold obtained from energy of wavelet coefficients over a certain time period [41].
sample rate level 1 level 2 level 3 level 4 level 5 level 6
(Hz) (Hz) (Hz) (Hz) (Hz) (Hz) (Hz)
2048 512 - 1024 256 - 512 128 - 256 64 - 128 32 - 64 16 - 32
1024 256 - 512 128 - 256 64 - 128 32 - 64 16 - 32 8 - 16
512 128 - 256 64 - 128 32 -64 16 - 32 8 - 16 4 - 8
Table 7.2. Frequency contents of different levels with respect to the sample rate [41].
The application of the Haar wavelet results in an enhancement of slopes and extremum
points. The changes in sign of the ECG signal can be determined by a derivative operator
or by zero-crossing in the wavelet coefficients. The closest zero-crossing to the obtained
maximum within the region of interest is determined as the location of the R peak. De-
tection of the Q and S points is similar to the R peak due to the zero crossing in the
corresponding level. Finding a minimum followed by a maximum or vice versa depends to
the morphology of the measured signal, where the ECG lead was located (see figure 7.11).
For ECGs measured after implantation, a proper thresholding is performed based on
wavelet coefficients in order to eliminate the stimulus from ECG signal (see figure 7.12).
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(a)
(b)
(c)
Figure 7.10. Time averaging in measured ECG signal: (a) Sequence of measured ECG. (b) Time averaging
of different ECG cycles (The red ECG signal is the averaged one). (c) A sequence constructed by averaged
ECG signal.
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(a)
(b)
Figure 7.11. Peak detection in ECG signal before implantation: (a) ECG signal sequence. (b) QRS
detection.
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(a)
(b)
(c)
Figure 7.12. Stimulus artifact removal in ECG signal: (a) ECG signal sequence including the stimulus
artifact for a patient after pacemaker implantation. (b) Stimulus artifact removal. (c) QRS detection.

Part III
Results and Conclusion

8Results of Simulation
Different pathologies according to 17 infarction positions and 3 reduced conduction ve-
locities were simulated. For each pathology, 36 lead positioning setups in parallel with
various A-V (60 to 260 ms) and V-V delays (-30 to 70 ms) were investigated as discussed
in section 7.1. For each infarction, the optimal electrode setup and optimal timing delays,
which lead to minimal ERMS , were identified due to the first optimization method (ERMS
based algorithm) described in section 7.2.1. Furthermore, the optimal setup parameters
were discovered due to the second optimization method (QRS duration based algorithm)
described in section 7.2.2.
8.1 Results for Patient Data Sets
The electrode positioning setup is demonstrated for each patient ventricular model. The
results of the optimal pacing parameters for all data sets with respect to the lowest error
are included in this section. In addition, an illustration of minimal error assoiciated with
36 electrode setups related to each MI position is presented for each patient data set. All
optimal results for V-V delays are positive values which is expected, due to the LBBB.
The natural exitation of the left ventricle is delayed in case of LBBB, requiring an earlier
stimulation. Positive values show the pre-stimulation of the left ventricle. The physiological
excitation conduction velocity is assumed to be 1000 mm/s [285].
8.1.1 Patient-1
The electrode positioning setup is demonstrated in figure 8.1. The results of both optimiza-
tion methods are summarized in tables 8.1 - 8.6 for the several conduction velocities. The
minimal errors associated with each electrode setup for each MI position are illustrated in
figures 8.2 - 8.7.
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(a) (b)
Figure 8.1. The electrode positions chosen for the Patient-1 heart model. The electrodes A, B, C and D
are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
With both optimization methods the most frequently found optimal electrode positions
were in the anterior branches of coronary sinus close to the base and RV upper septal
(electrode pairs UA and UB). In case of 80 % of conduction velocity when the infarction
is located in AHA7, the best electrode setup indicated by the first optimization method is
UD. At the same conduction velocity when the infarction is located in AHA16, the best
electrode setup suggested by the second optimization method is UL. Both optimization
methods yield similar results for the optimal timing delays as 160 ms for A-V delay and
70 ms for V-V delay.
Although DSA optimization reduces the number of computations, still more than 200
simulations with the first optimization method and more than 500 simulations with the
second optimization method must be performed for each pathological case. A maximum
improvement of up to 26 %, the reduction percentage of ERMS and an improvement of up
to 77 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 86.05 69.42 19.32 UA 160.00 70.00 228
AHA2 87.80 72.50 17.42 UB 160.00 70.00 222
AHA3 85.06 70.26 17.39 UA 160.00 70.00 216
AHA4 85.47 72.01 15.74 UA 160.00 70.00 216
AHA5 87.36 70.66 19.11 UA 160.00 70.00 222
AHA6 89.22 71.40 19.97 UA 160.00 70.00 228
AHA7 86.85 72.05 17.03 UA 160.00 70.00 234
AHA8 89.57 75.17 16.07 UA 160.00 70.00 456
AHA9 88.49 71.36 19.35 UA 160.00 70.00 186
AHA10 87.42 70.01 19.91 UA 160.00 70.00 192
AHA11 87.84 70.44 19.80 UA 160.00 70.00 222
AHA12 88.69 72.19 18.60 UA 160.00 70.00 228
AHA13 89.66 70.22 21.68 UA 160.00 70.00 228
AHA14 89.51 70.15 21.62 UA 160.00 70.00 222
AHA15 82.53 69.63 15.63 UA 160.00 70.00 210
AHA16 80.12 70.08 12.53 UA 160.00 70.00 222
AHA17 80.86 70.09 13.31 UA 160.00 70.00 228
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.1. Results of the first optimization method for Patient-1 with 100 % conduction velocity.
Figure 8.2. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 85.93 70.63 17.80 UB 160.00 70.00 234
AHA2 86.51 73.01 15.60 UB 160.00 70.00 228
AHA3 85.94 70.13 18.39 UB 160.00 70.00 216
AHA4 89.19 74.61 16.34 UA 160.00 70.00 216
AHA5 89.97 70.71 21.40 UA 160.00 70.00 222
AHA6 81.36 70.06 13.88 UA 160.00 70.00 228
AHA7 85.03 70.83 16.69 UD 120.00 49.84 246
AHA8 88.28 70.08 20.61 UB 160.00 70.00 268
AHA9 88.26 70.11 20.56 UA 160.00 70.00 210
AHA10 89.14 72.41 18.76 UA 160.00 70.00 210
AHA11 85.06 70.00 17.70 UA 160.00 70.00 222
AHA12 89.88 72.06 19.82 UA 160.00 70.00 228
AHA13 88.22 70.55 20.02 UA 160.00 70.00 228
AHA14 86.66 70.10 19.10 UA 160.00 70.00 228
AHA15 90.23 75.64 16.16 UA 160.00 70.00 210
AHA16 86.72 70.31 18.92 UA 160.00 70.00 234
AHA17 89.75 72.71 18.98 UA 160.00 70.00 228
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.2. Results of the first optimization method for Patient-1 with 80 % conduction velocity.
Figure 8.3. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 86.26 71.86 16.69 UB 160.00 70.00 234
AHA2 85.20 72.28 15.16 UB 160.00 70.00 228
AHA3 89.62 72.91 18.64 UB 160.00 70.00 222
AHA4 89.36 73.38 17.88 UB 160.00 70.00 222
AHA5 83.11 70.23 15.49 UB 160.00 70.00 228
AHA6 85.75 72.59 15.34 UB 160.00 70.00 228
AHA7 89.88 73.06 18.71 UB 160.00 70.00 246
AHA8 82.43 74.49 9.63 UB 160.00 70.00 268
AHA9 88.55 72.85 17.72 UB 160.00 70.00 222
AHA10 87.33 72.95 16.47 UB 160.00 70.00 210
AHA11 82.78 70.18 15.22 UB 160.00 70.00 222
AHA12 82.52 69.23 16.10 UB 160.00 70.00 228
AHA13 88.46 65.24 26.24 UB 160.00 70.00 240
AHA14 88.97 70.05 21.26 UB 160.00 70.00 234
AHA15 88.12 70.19 20.34 UB 160.00 70.00 216
AHA16 88.44 70.18 20.64 UB 160.00 70.00 234
AHA17 89.33 75.07 15.96 UB 160.00 70.00 234
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.3. Results of the first optimization method for Patient-1 with 60 % conduction velocity.
Figure 8.4. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 128 49 61.72 UA 160.00 70.00 529
AHA2 121 43 64.46 UB 160.00 70.00 540
AHA3 123 52 57.72 UA 160.00 70.00 591
AHA4 124 53 57.26 UA 160.00 70.00 582
AHA5 119 48 59.66 UA 160.00 70.00 561
AHA6 105 34 67.62 UA 160.00 70.00 471
AHA7 104 33 68.27 UA 160.00 70.00 550
AHA8 117 46 60.68 UA 160.00 70.00 598
AHA9 123 47 61.79 UA 160.00 70.00 562
AHA10 122 51 58.20 UA 160.00 70.00 569
AHA11 112 41 63.39 UA 160.00 70.00 530
AHA12 103 32 68.93 UA 160.00 70.00 571
AHA13 102 40 60.78 UA 160.00 70.00 517
AHA14 107 36 66.36 UA 160.00 70.00 545
AHA15 114 39 65.79 UA 160.00 70.00 577
AHA16 102 31 69.61 UA 160.00 70.00 563
AHA17 112 40 64.28 UA 160.00 70.00 527
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.4. Results of the second optimization method for Patient-1 with 100 % conduction velocity.
Figure 8.5. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 160 34 77.50 UB 160.00 70.00 454
AHA2 150 46 69.33 UB 160.00 70.00 561
AHA3 153 43 71.89 UB 160.00 70.00 589
AHA4 154 42 72.72 UA 160.00 70.00 559
AHA5 149 47 68.45 UA 160.00 70.00 554
AHA6 127 41 67.71 UA 160.00 70.00 468
AHA7 123 37 69.91 UB 160.00 70.00 617
AHA8 146 50 65.75 UB 160.00 70.00 568
AHA9 152 46 69.73 UA 160.00 70.00 595
AHA10 151 52 65.56 UA 160.00 70.00 600
AHA11 139 53 61.87 UA 160.00 70.00 576
AHA12 126 40 68.25 UA 160.00 70.00 590
AHA13 110 30 72.72 UA 160.00 70.00 580
AHA14 134 48 64.17 UA 160.00 70.00 583
AHA15 142 52 63.38 UA 160.00 70.00 576
AHA16 126 39 69.04 UL 160.00 70.00 556
AHA17 139 53 61.87 UA 160.00 70.00 570
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.5. Results of the second optimization method for Patient-1 with 80 % conduction velocity.
Figure 8.6. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 211 96 54.50 UB 160.00 70.00 499
AHA2 196 77 60.71 UB 160.00 70.00 434
AHA3 201 84 58.21 UB 160.00 70.00 455
AHA4 205 98 52.20 UB 160.00 70.00 442
AHA5 197 97 50.76 UB 160.00 70.00 484
AHA6 167 67 59.88 UB 160.00 70.00 414
AHA7 156 47 69.87 UB 160.00 70.00 577
AHA8 185 68 63.24 UB 160.00 70.00 540
AHA9 199 94 52.76 UB 160.00 70.00 496
AHA10 200 100 50.00 UB 160.00 70.00 472
AHA11 185 85 54.05 UB 160.00 70.00 529
AHA12 160 60 62.50 UB 160.00 70.00 522
AHA13 144 44 69.44 UB 160.00 70.00 521
AHA14 176 76 56.82 UB 160.00 70.00 482
AHA15 186 86 53.76 UB 160.00 70.00 549
AHA16 165 65 60.61 UB 160.00 70.00 491
AHA17 182 82 54.95 UB 160.00 70.00 454
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.6. Results of the second optimization method for Patient-1 with 60 % conduction velocity.
Figure 8.7. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRSpathology without pacing.)
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8.1.2 Patient-2
The electrode positioning setup is demonstrated in figure 8.8. The results of both optimiza-
tion methods are summarized in tables 8.7 - 8.12 for the several conduction velocities. The
minimal errors associated with each electrode setup for each MI position are illustrated
in figures 8.9 - 8.14. Both optimization methods mostly found the optimal left electrode
(a) (b)
Figure 8.8. The electrode positions chosen for the Patient-2 heart model. The electrodes A, B, C and D
are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
position in the lateral wall of the left ventricle or anterior branches of coronary sinus close
to the base (electrode E, G and C). The optimal RV electrode varied according to the
underlying pathology (electrode U, M and X). The best timing delays range assessed by
the first optimization method is 120− 160 ms for the A-V delay and 48− 70 ms for V-V
delay. However the timing delays achieved by the second optimization method is always
the same values of 160 ms for A-V delay and 70 ms for V-V delay. The first optimization
delivers a number between 317 to 533 simulations for each pathological case. More than
500 simulations with the second optimization method are performed for each pathological
case. A maximum improvement of up to 39 %, the reduction percentage of ERMS and an
improvement of up to 91 %, the reduction percentage of ErrorQRS , can be achieved.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 18.69 13.92 25.54 UE 160.00 70.00 367
AHA2 19.30 14.94 22.58 XC 140.00 57.58 414
AHA3 19.56 15.57 20.40 MC 140.31 60.23 359
AHA4 20.41 16.53 19.01 UE 160.00 70.00 390
AHA5 21.30 17.27 18.91 ME 160.00 70.00 337
AHA6 19.97 15.33 23.22 UE 160.00 70.00 388
AHA7 19.23 14.72 23.46 UE 160.00 70.00 357
AHA8 20.07 15.87 20.95 UE 160.00 70.00 356
AHA9 19.99 16.13 19.28 XE 130.00 49.81 355
AHA10 20.07 16.04 20.06 UG 140.00 57.58 386
AHA11 21.12 17.09 19.08 UE 160.00 70.00 336
AHA12 22.50 18.38 18.31 ME 160.00 70.00 339
AHA13 19.25 14.65 23.90 UE 160.00 70.00 373
AHA14 19.05 14.27 25.09 ME 160.00 70.00 358
AHA15 20.68 16.66 19.42 UE 160.00 70.00 355
AHA16 21.64 17.73 18.06 UE 160.00 70.00 317
AHA17 19.45 14.85 23.65 ME 160.00 70.00 353
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.7. Results of the first optimization method for Patient-2 with 100 % conduction velocity.
Figure 8.9. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 20.67 14.24 31.13 UG 140.00 57.58 478
AHA2 21.23 15.09 28.93 XC 125.00 52.56 459
AHA3 21.35 15.82 25.87 XC 127.50 54.31 482
AHA4 22.12 16.57 25.09 XE 130.00 52.15 495
AHA5 23.11 17.47 24.43 XE 130.00 49.81 447
AHA6 22.02 15.62 29.06 UG 140.00 57.58 461
AHA7 21.19 15.04 29.05 UG 140.00 57.58 460
AHA8 21.97 16.13 26.58 UG 140.00 57.58 452
AHA9 21.78 16.20 25.59 ME 125.00 51.00 449
AHA10 21.80 16.15 25.92 MG 126.09 50.74 478
AHA11 22.93 17.35 24.36 UG 140.00 57.58 433
AHA12 24.34 18.62 23.48 UG 140.00 57.58 408
AHA13 21.27 14.91 29.87 XE 131.25 48.04 499
AHA14 21.09 14.58 30.86 UG 140.00 57.58 453
AHA15 22.45 16.80 25.16 UG 140.00 57.58 427
AHA16 23.38 17.98 23.11 UG 140.00 57.58 421
AHA17 21.43 15.11 29.48 UG 140.00 57.58 428
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.8. Results of the first optimization method for Patient-2 with 80 % conduction velocity.
Figure 8.10. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 24.12 14.68 39.15 XE 125.00 51.00 554
AHA2 24.68 15.65 36.57 MG 125.00 51.00 533
AHA3 24.50 16.34 33.30 MG 120.00 49.84 529
AHA4 25.12 17.11 31.89 ME 120.00 49.84 534
AHA5 26.32 17.89 32.03 XE 125.00 51.00 513
AHA6 25.60 16.01 37.47 XE 125.00 51.00 529
AHA7 24.58 15.44 37.21 XE 125.00 51.00 544
AHA8 25.30 16.50 34.76 XE 125.00 51.00 521
AHA9 24.92 16.84 32.43 UG 120.00 49.84 502
AHA10 24.84 17.04 31.40 MG 120.00 49.84 536
AHA11 26.12 17.68 32.31 XE 125.00 51.00 516
AHA12 27.57 19.00 31.09 XE 125.00 51.00 501
AHA13 24.76 15.37 37.93 XE 123.75 52.27 526
AHA14 24.60 14.98 39.11 XE 125.00 51.00 556
AHA15 25.54 17.25 32.48 MG 120.00 49.84 505
AHA16 26.46 18.32 30.76 ME 120.00 49.84 502
AHA17 24.85 15.55 37.43 XE 120.00 49.84 546
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.9. Results of the first optimization method for Patient-2 with 60 % conduction velocity.
Figure 8.11. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
8.1. Results for Patient Data Sets 145
Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 69 12 82.60 UE 160.00 70.00 547
AHA2 72 10 86.11 UE 160.00 70.00 525
AHA3 101 22 78.21 UG 160.00 70.00 471
AHA4 103 10 90.29 ME 160.00 70.00 501
AHA5 91 8 91.20 ME 160.00 70.00 527
AHA6 75 21 72.00 UE 160.00 70.00 567
AHA7 68 8 88.23 UE 160.00 70.00 567
AHA8 68 10 85.29 UE 160.00 70.00 514
AHA9 120 25 79.16 UE 160.00 70.00 333
AHA10 92 8 91.30 UE 160.00 70.00 478
AHA11 69 12 82.60 ME 160.00 70.00 583
AHA12 74 8 89.18 ME 160.00 70.00 531
AHA13 68 8 88.23 UE 160.00 70.00 529
AHA14 68 8 88.23 ME 160.00 70.00 556
AHA15 81 24 70.37 UE 160.00 70.00 531
AHA16 68 23 66.17 UE 160.00 70.00 493
AHA17 68 15 77.94 ME 160.00 70.00 555
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.10. Results of the second optimization method for Patient-2 with 100 % conduction velocity.
Figure 8.12. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 94 37 60.64 UG 160.00 70.00 491
AHA2 99 38 61.61 UG 160.00 70.00 441
AHA3 137 42 69.34 UG 160.00 70.00 457
AHA4 140 25 82.14 UG 160.00 70.00 433
AHA5 122 27 77.86 UG 160.00 70.00 535
AHA6 103 27 73.78 UG 160.00 70.00 548
AHA7 93 22 76.34 UG 160.00 70.00 505
AHA8 94 25 73.40 UG 160.00 70.00 490
AHA9 164 50 69.51 UG 160.00 70.00 298
AHA10 127 30 76.37 UE 160.00 70.00 466
AHA11 94 22 76.59 ME 160.00 70.00 490
AHA12 99 22 77.77 UE 160.00 70.00 490
AHA13 93 22 76.34 UG 160.00 70.00 497
AHA14 93 22 76.34 UE 160.00 70.00 499
AHA15 116 42 63.79 UE 160.00 70.00 391
AHA16 93 30 67.74 UE 160.00 70.00 492
AHA17 93 29 68.82 UG 160.00 70.00 501
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.11. Results of the second optimization method for Patient-2 with 80 % conduction velocity.
Figure 8.13. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 134 57 56.20 UG 160.00 70.00 499
AHA2 138 65 52.89 UG 160.00 70.00 387
AHA3 194 82 57.73 UG 160.00 70.00 330
AHA4 199 72 63.81 UG 160.00 70.00 349
AHA5 173 70 59.53 UG 160.00 70.00 362
AHA6 147 58 60.54 UG 160.00 70.00 487
AHA7 133 49 63.15 UG 160.00 70.00 510
AHA8 133 62 53.38 UG 160.00 70.00 441
AHA9 230 110 52.17 UF 160.00 70.00 241
AHA10 186 80 56.98 UE 160.00 70.00 402
AHA11 140 59 57.85 UG 160.00 70.00 429
AHA12 138 51 63.04 UG 160.00 70.00 458
AHA13 133 50 62.40 UG 160.00 70.00 543
AHA14 133 60 54.88 UG 160.00 70.00 468
AHA15 171 86 49.70 UE 160.00 70.00 336
AHA16 133 70 47.36 UG 160.00 70.00 417
AHA17 133 63 52.63 UG 160.00 70.00 493
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.12. Results of the second optimization method for Patient-2 with 60 % conduction velocity.
Figure 8.14. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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8.1.3 Patient-3
The electrode positioning setup is demonstrated in figure 8.15. The results of both opti-
mization methods are summarized in tables 8.13 - 8.18 for the several conduction velocities.
The minimal errors associated with each electrode setup for each MI position are illus-
trated in figures 8.16 - 8.21. Both optimization methods mostly found the optimal left
(a) (b)
Figure 8.15. The electrode positions chosen for the Patient-3 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
electrode position in the lateral wall of the left ventricle (electrode G and H). The optimal
right electrode position is mostly in the RV apex (electrode X) only in case of 60 % of
conduction velocity, the position is changed to the middle septal (electrode M), which is
attained with the first optimization method. The best timing delays range mostly achieved
is 160ms for the A-V delay and 70ms for V-V delay. Merely the timing delays achieved by
the first optimization method, vary between 120− 140 ms for A-V delay and 51− 59 ms
for V-V delay once the conduction velocity is set to 60 %. In case of 80 % of the conduction
velocity when the infarction is located in AHA8 and AHA9 the timing delays determined
by the first algorithm is different 140− 150 ms for A-V delay and 64.57 ms, 60.70 ms for
V-V delay.
DSA optimization delivers a number between 307 to 554 simulations for each pathological
case. A maximum improvement of up to 59 %, the reduction percentage of ERMS and an
improvement of up to 89 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 18.21 11.55 36.57 XG 160.00 70.00 483
AHA2 20.19 15.84 21.54 XG 160.00 70.00 463
AHA3 22.93 17.57 23.37 XH 160.00 70.00 465
AHA4 22.06 17.04 22.75 XG 160.00 70.00 456
AHA5 24.55 17.50 28.71 XG 160.00 70.00 461
AHA6 24.88 17.90 28.05 XG 160.00 70.00 456
AHA7 17.83 11.51 35.44 XG 160.00 70.00 480
AHA8 23.99 17.55 26.84 XH 160.00 70.00 420
AHA9 25.88 18.22 29.59 XH 160.00 70.00 441
AHA10 24.37 18.02 26.05 XG 160.00 70.00 434
AHA11 26.60 18.28 31.27 XG 160.00 70.00 451
AHA12 25.38 18.13 28.56 XG 160.00 70.00 454
AHA13 23.91 17.78 25.63 XG 160.00 70.00 455
AHA14 24.21 17.75 26.68 XH 160.00 70.00 438
AHA15 23.71 17.89 24.54 XG 160.00 70.00 451
AHA16 24.78 17.72 28.49 XH 160.00 70.00 451
AHA17 27.59 17.69 35.88 XG 160.00 70.00 444
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.13. Results of the first optimization method for Patient-3 with 100 % conduction velocity.
Figure 8.16. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 21.93 11.09 47.61 XH 160.00 70.00 432
AHA2 23.36 12.02 48.63 XH 160.00 70.00 418
AHA3 25.70 17.05 33.65 XH 160.00 70.00 401
AHA4 25.23 16.25 35.59 XH 160.00 70.00 425
AHA5 27.49 17.35 36.88 XH 160.00 70.00 397
AHA6 27.69 17.23 37.77 XH 160.00 70.00 393
AHA7 21.57 11.01 48.95 XH 160.00 70.00 432
AHA8 26.57 17.55 33.94 XH 150.00 64.57 398
AHA9 28.28 18.53 34.47 XH 140.00 60.70 391
AHA10 27.22 17.29 36.48 XH 160.00 70.00 414
AHA11 29.30 17.99 38.60 XH 160.00 70.00 391
AHA12 28.12 17.81 36.66 XH 160.00 70.00 388
AHA13 27.04 16.94 37.35 XH 160.00 70.00 402
AHA14 27.00 17.33 35.81 XH 160.00 70.00 384
AHA15 26.64 17.20 35.43 XH 160.00 70.00 384
AHA16 27.74 17.25 37.81 XH 160.00 70.00 405
AHA17 30.14 16.91 43.89 XH 160.00 70.00 369
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.14. Results of the first optimization method for Patient-3 with 80 % conduction velocity.
Figure 8.17. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 28.36 11.04 61.07 XH 130.00 52.15 554
AHA2 29.05 12.06 58.48 XH 140.00 59.14 523
AHA3 30.86 13.55 56.09 XH 140.00 59.14 501
AHA4 30.98 12.37 60.07 XH 130.00 55.27 526
AHA5 32.92 17.23 47.66 XH 140.00 59.14 503
AHA6 32.97 17.35 47.37 XH 140.00 59.14 503
AHA7 27.96 11.80 57.79 XH 130.00 52.15 548
AHA8 31.40 17.29 44.93 MH 125.00 51.00 514
AHA9 32.90 17.84 45.77 MH 120.00 49.84 505
AHA10 32.58 17.47 46.37 XH 130.00 55.27 500
AHA11 34.43 17.84 48.18 XH 140.00 59.14 493
AHA12 33.28 17.54 47.29 XH 140.00 59.14 505
AHA13 32.73 13.37 59.15 MH 130.00 53.71 519
AHA14 32.18 17.68 45.33 XH 140.00 59.14 496
AHA15 32.10 17.59 45.20 XH 120.00 49.84 505
AHA16 33.21 17.45 47.45 XH 140.00 59.14 502
AHA17 35.02 17.53 49.94 XH 140.00 59.14 469
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.15. Results of the first optimization method for Patient-3 with 60 % conduction velocity.
Figure 8.18. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
152 Chapter 8. Results of Simulation
Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 93 10 89.24 XG 160.00 70.00 437
AHA2 108 22 79.62 XG 160.00 70.00 463
AHA3 106 12 88.67 XH 160.00 70.00 393
AHA4 100 30 70.00 XG 160.00 70.00 448
AHA5 91 28 69.23 XG 160.00 70.00 431
AHA6 92 10 72.82 XG 160.00 70.00 483
AHA7 90 10 88.88 XG 160.00 70.00 439
AHA8 104 20 80.76 XH 160.00 70.00 489
AHA9 107 12 88.78 XH 160.00 70.00 401
AHA10 90 30 66.66 XG 160.00 70.00 441
AHA11 92 25 72.82 XG 160.00 70.00 465
AHA12 98 20 79.59 XG 160.00 70.00 488
AHA13 93 22 76.34 XG 160.00 70.00 473
AHA14 97 22 77.31 XH 160.00 70.00 426
AHA15 98 24 77.51 XG 160.00 70.00 409
AHA16 99 22 77.77 XH 160.00 70.00 456
AHA17 100 22 78.00 XG 160.00 70.00 436
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.16. Results of the second optimization method for Patient-3 with 100 % conduction velocity.
Figure 8.19. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 127 35 72.44 XH 160.00 70.00 457
AHA2 145 45 68.96 XH 160.00 70.00 454
AHA3 143 38 73.42 XH 160.00 70.00 377
AHA4 130 55 57.69 XH 160.00 70.00 440
AHA5 121 50 58.67 XH 160.00 70.00 449
AHA6 126 35 72.22 XH 160.00 70.00 463
AHA7 121 35 71.07 XH 160.00 70.00 451
AHA8 141 45 68.08 XH 160.00 70.00 459
AHA9 146 45 69.17 XH 160.00 70.00 344
AHA10 123 65 47.15 XH 160.00 70.00 432
AHA11 121 49 59.50 XH 160.00 70.00 459
AHA12 121 40 66.94 XH 160.00 70.00 470
AHA13 121 42 65.28 XH 160.00 70.00 454
AHA14 121 42 65.28 XH 160.00 70.00 435
AHA15 122 47 61.47 XH 160.00 70.00 458
AHA16 122 42 65.57 XH 160.00 70.00 483
AHA17 121 43 64.46 XH 160.00 70.00 421
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.17. Results of the second optimization method for Patient-3 with 80 % conduction velocity.
Figure 8.20. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 183 70 61.74 XH 160.00 70.00 363
AHA2 205 90 56.09 XH 160.00 70.00 342
AHA3 201 85 57.71 XH 160.00 70.00 323
AHA4 182 100 45.05 XH 160.00 70.00 343
AHA5 173 90 47.97 XH 160.00 70.00 365
AHA6 179 70 60.89 XH 160.00 70.00 389
AHA7 172 70 59.30 XH 160.00 70.00 350
AHA8 199 90 54.77 XH 160.00 70.00 349
AHA9 208 95 54.32 XH 160.00 70.00 307
AHA10 176 125 28.97 XH 160.00 70.00 380
AHA11 175 78 55.42 XH 160.00 70.00 413
AHA12 174 75 53.44 XH 160.00 70.00 394
AHA13 175 81 53.71 XH 160.00 70.00 408
AHA14 174 81 53.44 XH 160.00 70.00 389
AHA15 175 85 51.42 XH 160.00 70.00 372
AHA16 176 79 55.11 XH 160.00 70.00 410
AHA17 175 84 52.00 XH 160.00 70.00 355
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.18. Results of the second optimization method for Patient-3 with 60 % conduction velocity.
Figure 8.21. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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8.1.4 Patient-4
The electrode positioning setup is demonstrated in figure 8.22. The results of both opti-
mization methods are summarized in tables 8.19 - 8.24 for the several conduction velocities.
The minimal errors associated with each electrode setup for each MI position are illustrated
in figures 8.23 - 8.28.
(a) (b)
Figure 8.22. The electrode positions chosen for the Patient-4 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
Both optimization methods mostly found the optimal left electrode position in the lateral
wall of the left ventricle (electrode G, H and rarely F). The optimal right electrode posi-
tion is mostly in upper or middle septal area (electrode U and M). The best timing delays
range assessed by the first optimization method is 110− 160 ms for the A-V delay and
46.72− 70 ms for V-V delay. The best timing delays range mostly achieved by the second
optimization is overall 160 ms for the A-V delay and 70 ms for V-V delay.
DSA optimization delivers a number between 313 to 551 simulations for each pathological
case. A maximum improvement of up to 36 %, the reduction percentage of ERMS and an
improvement of up to 76 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 24.26 20.62 15.02 UG 160.00 70.00 395
AHA2 25.61 21.63 15.54 UG 160.00 70.00 408
AHA3 25.33 21.64 14.57 UG 160.00 70.00 395
AHA4 24.82 21.67 12.69 UG 160.00 70.00 398
AHA5 26.71 23.29 12.79 UG 160.00 70.00 371
AHA6 27.90 24.37 12.64 UG 160.00 70.00 385
AHA7 25.52 22.09 13.46 UG 160.00 70.00 388
AHA8 28.54 25.12 11.98 UG 160.00 70.00 413
AHA9 28.08 24.89 11.38 UG 160.00 70.00 383
AHA10 28.53 25.99 8.92 UH 160.00 70.00 371
AHA11 29.65 26.75 9.80 UG 160.00 70.00 370
AHA12 30.01 26.94 10.22 UG 160.00 70.00 367
AHA13 29.24 26.07 10.85 UH 160.00 70.00 376
AHA14 26.73 22.67 15.19 UG 160.00 70.00 398
AHA15 29.26 26.45 9.60 UH 160.00 70.00 375
AHA16 29.51 26.44 10.41 UG 160.00 70.00 392
AHA17 31.15 27.99 10.14 UG 160.00 70.00 386
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.19. Results of the first optimization method for Patient-4 with 100 % conduction velocity.
Figure 8.23. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
8.1. Results for Patient Data Sets 157
Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 28.31 21.36 24.56 UH 150.00 66.13 407
AHA2 29.89 22.56 24.52 UH 160.00 70.00 416
AHA3 29.34 22.39 23.70 UH 150.00 66.13 414
AHA4 28.57 22.41 21.57 UH 160.00 70.00 427
AHA5 30.52 23.96 21.50 UH 150.00 66.13 424
AHA6 31.82 25.12 21.08 UH 160.00 70.00 419
AHA7 29.40 22.78 22.51 UH 150.00 66.13 406
AHA8 32.27 25.89 19.78 UH 160.00 70.00 414
AHA9 31.62 25.68 18.78 UG 130.00 55.27 408
AHA10 31.73 26.81 15.52 UF 120.00 46.72 384
AHA11 33.07 27.42 17.09 UH 160.00 70.00 414
AHA12 33.56 27.59 17.79 UH 160.00 70.00 418
AHA13 32.94 26.68 19.02 UH 160.00 70.00 419
AHA14 30.80 23.47 23.81 UH 160.00 70.00 415
AHA15 32.61 27.41 15.93 MH 120.00 49.84 359
AHA16 33.01 26.60 19.41 UH 160.00 70.00 388
AHA17 34.42 28.82 16.27 UH 160.00 70.00 383
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.20. Results of the first optimization method for Patient-4 with 80 % conduction velocity.
Figure 8.24. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 36.08 22.91 36.49 MH 120.00 46.72 550
AHA2 38.12 24.03 36.96 MH 120.00 46.72 540
AHA3 37.11 23.89 35.61 MH 120.00 46.72 555
AHA4 35.90 23.81 33.67 MH 120.00 46.72 551
AHA5 37.97 25.36 33.19 MH 120.00 46.72 529
AHA6 39.44 26.43 32.99 MH 120.00 46.72 521
AHA7 36.94 24.25 34.36 MH 120.00 46.72 539
AHA8 39.65 27.19 31.44 MH 120.00 46.72 523
AHA9 38.65 26.97 30.21 UH 120.00 46.72 522
AHA10 38.23 27.95 26.89 MH 110.00 42.85 524
AHA11 39.94 28.69 28.19 MH 120.00 46.72 509
AHA12 40.71 28.81 29.23 MH 120.00 46.72 521
AHA13 40.25 27.90 30.68 MH 120.00 46.72 508
AHA14 38.58 24.80 35.72 UH 120.00 46.72 531
AHA15 39.36 28.27 28.19 MH 110.00 42.85 545
AHA16 40.03 28.54 28.71 MH 120.00 46.72 481
AHA17 41.09 29.98 27.04 MH 120.00 46.72 506
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.21. Results of the first optimization method for Patient-4 with 60 % conduction velocity.
Figure 8.25. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 81 30 62.95 UG 160.00 70.00 530
AHA2 88 29 67.04 UG 160.00 70.00 541
AHA3 88 28 68.18 UG 160.00 70.00 491
AHA4 107 25 76.63 UG 160.00 70.00 502
AHA5 100 40 60.00 UG 160.00 70.00 415
AHA6 90 38 57.71 UG 160.00 70.00 465
AHA7 81 30 62.96 UG 160.00 70.00 524
AHA8 81 25 69.13 UG 160.00 70.00 495
AHA9 86 31 63.95 UG 160.00 70.00 484
AHA10 104 32 69.23 UH 160.00 70.00 453
AHA11 93 42 54.83 UG 160.00 70.00 388
AHA12 81 40 50.61 UG 160.00 70.00 493
AHA13 81 38 53.08 UH 160.00 70.00 528
AHA14 81 30 62.96 UG 160.00 70.00 513
AHA15 88 35 60.22 UH 160.00 70.00 538
AHA16 87 42 51.72 UG 160.00 70.00 464
AHA17 80 32 60.00 UG 160.00 70.00 514
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.22. Results of the second optimization method for Patient-4 with 100 % conduction velocity.
Figure 8.26. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 112 42 62.50 UH 160.00 70.00 450
AHA2 124 58 53.22 UH 160.00 70.00 460
AHA3 123 57 53.65 UH 160.00 70.00 400
AHA4 148 56 62.16 UH 160.00 70.00 423
AHA5 137 78 43.06 UH 160.00 70.00 388
AHA6 125 75 40.00 UH 160.00 70.00 413
AHA7 112 40 64.28 UH 160.00 70.00 452
AHA8 112 50 55.35 UH 160.00 70.00 452
AHA9 124 60 51.61 UH 160.00 70.00 381
AHA10 144 58 59.72 UH 160.00 70.00 386
AHA11 131 75 42.74 UH 160.00 70.00 366
AHA12 115 73 36.52 UH 160.00 70.00 398
AHA13 112 65 41.96 UH 160.00 70.00 441
AHA14 112 60 46.42 UH 160.00 70.00 454
AHA15 128 62 51.56 UH 160.00 70.00 380
AHA16 125 76 39.20 UH 160.00 70.00 398
AHA17 112 60 46.42 UH 160.00 70.00 402
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.23. Results of the second optimization method for Patient-4 with 80 % conduction velocity.
Figure 8.27. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
8.1. Results for Patient Data Sets 161
Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 166 90 45.78 UH 160.00 70.00 429
AHA2 183 100 45.35 UH 160.00 70.00 452
AHA3 185 100 45.94 UH 160.00 70.00 387
AHA4 215 98 54.41 UH 160.00 70.00 334
AHA5 198 128 35.35 UH 160.00 70.00 361
AHA6 185 125 48.00 UH 160.00 70.00 433
AHA7 166 89 46.38 UH 160.00 70.00 418
AHA8 166 100 66.00 UH 160.00 70.00 435
AHA9 184 108 41.30 UH 160.00 70.00 348
AHA10 212 110 48.11 UH 160.00 70.00 313
AHA11 194 137 29.38 UH 160.00 70.00 365
AHA12 170 129 24.12 UH 160.00 70.00 396
AHA13 168 113 32.74 UH 160.00 70.00 444
AHA14 166 103 37.95 UH 160.00 70.00 424
AHA15 195 106 45.64 UF 160.00 70.00 385
AHA16 188 131 30.32 UH 160.00 70.00 370
AHA17 166 108 34.94 UH 160.00 70.00 409
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.24. Results of the second optimization method for Patient-4 with 60 % conduction velocity.
Figure 8.28. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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8.1.5 Patient-5
The electrode positioning setup is demonstrated in figure 8.29. The results of both opti-
mization methods, specific to several conduction velocities are summarized in tables 8.25
- 8.30. The minimal errors associated with each electrode setup for each MI position are
illustrated in figures 8.30 - 8.35.
(a) (b)
Figure 8.29. The electrode positions chosen for the Patient-5 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
Both optimization methods found the optimal left electrode position in the lateral wall
of the left ventricle (electrode E). The optimal right electrode position is mostly in upper
septal area or in the RV apex (electrode U and X). The best timing delays range evaluated
by the first optimization method is 120− 160 ms for the A-V delay and 46.72− 70 ms for
V-V delay. The best timing delays range achieved by the second optimization is overall
160 ms for the A-V delay and 70 ms for V-V delay. It is noticeable that the all resulted
parameters from second optimization method are the same, independent of conduction
velocities and MI locations.
DSA optimization delivers a number between 250 to 565 simulations for each pathological
case. A maximum improvement of up to 39 %, the reduction percentage of ERMS and an
improvement of up to 96 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 26.60 20.38 23.37 UE 160.00 70.00 440
AHA2 25.68 19.68 23.35 UE 160.00 70.00 436
AHA3 25.21 19.47 22.78 XE 140.00 60.70 414
AHA4 25.47 20.34 20.13 ME 140.00 60.70 427
AHA5 24.79 18.20 26.57 UE 160.00 70.00 421
AHA6 23.59 17.03 27.81 UE 160.00 70.00 436
AHA7 29.79 23.51 21.07 UE 140.00 60.70 454
AHA8 29.26 23.66 19.14 UE 160.00 70.00 392
AHA9 26.73 21.73 18.73 ME 120.00 49.84 454
AHA10 31.10 27.09 12.88 UE 150.00 64.57 418
AHA11 29.52 24.05 18.52 UE 160.00 70.00 400
AHA12 28.61 22.88 20.00 ME 140.00 60.70 477
AHA13 27.99 22.60 19.27 UE 160.00 70.00 456
AHA14 29.12 23.43 19.54 UE 160.00 70.00 443
AHA15 31.34 27.06 13.66 ME 140.00 57.58 414
AHA16 30.05 25.10 16.46 UE 160.00 70.00 446
AHA17 33.18 28.53 14.01 UE 160.00 70.00 427
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.25. Results of the first optimization method for Patient-5 with 100 % conduction velocity.
Figure 8.30. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 20.51 16.34 20.33 UE 160.00 70.00 381
AHA2 20.93 17.31 17.29 UE 160.00 70.00 383
AHA3 21.14 17.65 16.50 UE 160.00 70.00 395
AHA4 20.57 16.50 19.78 UE 160.00 70.00 384
AHA5 20.32 16.29 19.83 UE 160.00 70.00 402
AHA6 21.01 17.15 18.37 UE 160.00 70.00 387
AHA7 22.63 18.67 17.49 UE 160.00 70.00 360
AHA8 21.94 18.28 16.68 UE 160.00 70.00 384
AHA9 21.02 17.20 18.01 UE 140.00 57.58 386
AHA10 22.80 18.64 18.24 UE 160.00 70.00 330
AHA11 22.98 19.47 15.27 UE 160.00 70.00 422
AHA12 24.15 20.72 14.20 UE 160.00 70.00 383
AHA13 22.85 18.60 18.59 UE 160.00 70.00 391
AHA14 21.86 18.29 16.33 UE 160.00 70.00 382
AHA15 18.14 13.23 28.50 UE 160.00 70.00 322
AHA16 18.31 13.52 26.16 UE 160.00 70.00 374
AHA17 21.29 17.46 17.98 UE 160.00 70.00 364
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.26. Results of the first optimization method for Patient-5 with 80 % conduction velocity.
Figure 8.31. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 31.94 20.87 34.67 XE 120.00 49.84 534
AHA2 30.91 20.19 34.67 XE 120.00 49.84 525
AHA3 30.26 19.94 34.12 XE 120.00 49.84 508
AHA4 30.05 20.80 30.79 XE 120.00 49.84 542
AHA5 30.26 18.74 38.06 XE 120.00 49.84 554
AHA6 28.92 17.57 39.27 XE 120.00 46.72 565
AHA7 34.87 23.91 31.44 XE 120.00 46.72 489
AHA8 34.10 24.08 29.39 XE 120.00 49.84 505
AHA9 31.28 22.93 26.68 UE 100.00 38.98 526
AHA10 34.83 27.53 20.95 XE 120.00 49.84 509
AHA11 34.31 24.48 28.66 XE 120.00 49.84 500
AHA12 33.80 23.31 31.03 XE 120.00 46.72 497
AHA13 32.78 22.98 29.88 XE 120.00 46.72 520
AHA14 33.92 23.81 29.81 XE 120.00 49.84 503
AHA15 35.22 27.42 22.15 XE 120.00 46.72 497
AHA16 34.47 25.51 26.00 XE 125.00 51.00 470
AHA17 37.46 28.87 22.94 XE 120.00 46.72 485
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.27. Results of the first optimization method for Patient-5 with 60 % conduction velocity.
Figure 8.32. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 61 2 96.72 UE 160.00 70.00 549
AHA2 61 11 81.97 UE 160.00 70.00 487
AHA3 81 9 88.89 UE 160.00 70.00 460
AHA4 88 11 87.50 UE 160.00 70.00 424
AHA5 61 13 78.68 UE 160.00 70.00 500
AHA6 58 13 77.58 UE 160.00 70.00 533
AHA7 64 10 84.37 UE 160.00 70.00 513
AHA8 58 12 79.31 UE 160.00 70.00 517
AHA9 80 20 75.00 UE 160.00 70.00 467
AHA10 83 18 78.31 UE 160.00 70.00 464
AHA11 69 18 73.91 UE 160.00 70.00 528
AHA12 63 10 76.19 UE 160.00 70.00 458
AHA13 57 10 82.45 UE 160.00 70.00 561
AHA14 57 11 80.70 UE 160.00 70.00 509
AHA15 60 3 85.96 UE 160.00 70.00 471
AHA16 57 8 95.00 UE 160.00 70.00 536
AHA17 57 3 94.74 UE 160.00 70.00 497
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.28. Results of the second optimization method for Patient-5 with 100 % conduction velocity.
Figure 8.33. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 92 25 72.83 UE 160.00 70.00 536
AHA2 93 36 61.29 UE 160.00 70.00 444
AHA3 116 39 66.38 UE 160.00 70.00 297
AHA4 124 42 66.13 UE 160.00 70.00 408
AHA5 89 38 57.30 UE 160.00 70.00 490
AHA6 86 10 88.37 UE 160.00 70.00 565
AHA7 95 20 78.94 UE 160.00 70.00 538
AHA8 89 37 58.42 UE 160.00 70.00 475
AHA9 116 51 56.03 UF 160.00 70.00 374
AHA10 120 40 66.66 UE 160.00 70.00 386
AHA11 100 42 58.00 UE 160.00 70.00 434
AHA12 92 39 57.60 UE 160.00 70.00 502
AHA13 86 14 83.72 UE 160.00 70.00 534
AHA14 86 20 76.74 UE 160.00 70.00 535
AHA15 93 29 68.81 UE 160.00 70.00 480
AHA16 85 38 55.29 UE 160.00 70.00 536
AHA17 86 20 76.74 UE 160.00 70.00 500
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.29. Results of the second optimization method for Patient-5 with 80 % conduction velocity.
Figure 8.34. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 144 59 59.03 UE 160.00 70.00 398
AHA2 144 75 47.92 UE 160.00 70.00 326
AHA3 173 91 47.40 UE 160.00 70.00 250
AHA4 185 83 55.13 UE 160.00 70.00 308
AHA5 137 80 41.60 UE 160.00 70.00 400
AHA6 131 50 61.83 UE 160.00 70.00 436
AHA7 143 52 63.64 UE 160.00 70.00 431
AHA8 136 71 47.79 UE 160.00 70.00 356
AHA9 174 97 44.25 UF 160.00 70.00 346
AHA10 181 83 54.14 UE 160.00 70.00 402
AHA11 152 84 41.44 UE 160.00 70.00 389
AHA12 142 82 42.25 UE 160.00 70.00 402
AHA13 130 50 61.54 UE 160.00 70.00 444
AHA14 131 53 59.54 UE 160.00 70.00 413
AHA15 148 61 58.78 UE 160.00 70.00 340
AHA16 130 78 40.00 UE 160.00 70.00 422
AHA17 130 60 53.84 UE 160.00 70.00 433
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.30. Results of the second optimization method for Patient-5 with 60 % conduction velocity.
Figure 8.35. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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8.1.6 Patient-6
The electrode positioning setup is demonstrated in figure 8.36. The results of both opti-
mization methods are summarized in tables 8.31 - 8.36 for the several conduction velocities.
The minimal errors associated with each electrode setup for each MI position are illustrated
in figures 8.37 - 8.42.
(a) (b)
Figure 8.36. The electrode positions chosen for the Patient-6 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
The first optimization methods mostly found the optimal left electrode position in the
posterolateral or lateral wall of the left ventricle (electrode K and G). However the second
optimization method found the optimal left electrode position in anterior, posterolateral
and lateral wall (electrode B, K, G). The optimal right electrode position is mostly in
upper or middle septal area (electrode U and M). The best timing delays range evaluated
by the first optimization method is either 120 ms for the A-V delay and 49.84 ms for V-V
delay or 160 ms and 70 ms respectively. The best timing delays range achieved by the
second optimization is overall 160 ms for the A-V delay and 70 ms for V-V delay.
DSA optimization delivers a number between 326 to 514 simulations for each pathological
case. A maximum improvement of up to 39 %, the reduction percentage of ERMS and an
improvement of up to 84 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 18.00 15.80 12.20 MK 120.00 49.84 514
AHA2 19.00 16.65 12.36 MK 120.00 49.84 510
AHA3 19.50 17.01 12.76 MK 120.00 49.84 510
AHA4 18.07 15.55 13.94 MK 120.00 49.84 502
AHA5 17.80 15.30 14.04 MK 120.00 49.84 484
AHA6 19.02 16.04 15.66 MK 120.00 49.84 505
AHA7 20.41 17.81 12.73 UK 125.00 50.61 516
AHA8 20.03 17.10 14.62 MK 120.00 49.84 502
AHA9 19.06 16.55 13.16 MK 120.00 49.84 497
AHA10 20.63 17.33 15.99 MK 120.00 49.84 507
AHA11 21.02 18.00 14.36 MK 120.00 49.84 499
AHA12 22.30 19.60 12.10 MK 120.00 49.84 505
AHA13 20.70 17.59 15.02 MK 120.00 49.84 508
AHA14 19.50 17.33 11.12 MK 120.00 49.84 506
AHA15 15.05 12.31 18.20 MK 120.00 49.84 510
AHA16 15.22 12.88 15.37 MK 120.00 49.84 510
AHA17 19.08 16.00 16.14 MK 120.00 49.84 499
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.31. Results of the first optimization method for Patient-6 with 100 % conduction velocity.
Figure 8.37. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 20.50 16.22 20.87 UG 160.00 70.00 458
AHA2 20.81 17.01 18.26 UG 160.00 70.00 461
AHA3 21.01 17.32 17.56 UG 160.00 70.00 461
AHA4 20.36 16.25 9.62 UG 160.00 70.00 460
AHA5 20.05 16.29 18.75 UG 160.00 70.00 456
AHA6 20.95 17.12 18.28 UG 160.00 70.00 459
AHA7 22.45 18.23 18.79 UG 160.00 70.00 432
AHA8 21.88 18.14 17.09 UG 160.00 70.00 450
AHA9 20.34 17.00 16.42 UG 160.00 70.00 454
AHA10 22.22 18.21 18.04 UG 160.00 70.00 456
AHA11 22.36 19.52 12.70 UG 160.00 70.00 456
AHA12 24.15 20.44 15.36 UG 160.00 70.00 458
AHA13 22.27 18.21 18.23 UG 160.00 70.00 459
AHA14 21.00 18.14 13.61 UG 160.00 70.00 445
AHA15 17.89 13.36 25.32 UG 160.00 70.00 459
AHA16 17.94 13.80 23.07 UG 160.00 70.00 456
AHA17 20.55 17.51 14.79 UG 160.00 70.00 458
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.32. Results of the first optimization method for Patient-6 with 80 % conduction velocity.
Figure 8.38. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 25.20 17.78 29.44 UK 120.00 49.84 498
AHA2 25.25 17.92 29.02 UK 120.00 49.84 487
AHA3 25.25 18.00 28.71 UK 120.00 49.84 493
AHA4 25.00 17.72 32.00 UK 120.00 49.84 486
AHA5 24.85 16.92 31.91 UK 120.00 49.84 485
AHA6 25.32 17.72 30.01 UK 120.00 49.84 488
AHA7 27.22 18.71 31.26 UK 160.00 70.00 489
AHA8 26.60 18.30 31.20 UK 120.00 49.84 485
AHA9 24.36 18.25 25.08 UK 120.00 49.84 484
AHA10 27.54 18.80 31.73 UK 120.00 49.84 481
AHA11 27.25 19.27 29.28 UK 120.00 49.84 483
AHA12 27.98 20.12 28.09 UK 120.00 49.84 486
AHA13 27.11 18.53 31.64 UK 120.00 49.84 491
AHA14 25.75 18.02 30.01 UK 120.00 49.84 490
AHA15 23.12 14.05 39.23 UK 120.00 49.84 490
AHA16 23.24 14.20 38.89 UK 120.00 49.84 495
AHA17 25.19 17.80 29.33 UK 120.00 49.84 482
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.33. Results of the first optimization method for Patient-6 with 60 % conduction velocity.
Figure 8.39. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 105 20 80.95 UK 160.00 70.00 484
AHA2 124 35 71.77 UK 160.00 70.00 467
AHA3 217 71 67.28 UK 160.00 70.00 469
AHA4 156 62 60.26 UK 160.00 70.00 505
AHA5 146 58 60.27 UK 160.00 70.00 510
AHA6 113 52 53.98 UK 160.00 70.00 479
AHA7 110 20 81.82 UK 160.00 70.00 477
AHA8 121 37 69.42 UK 160.00 70.00 485
AHA9 158 59 62.66 UK 160.00 70.00 476
AHA10 151 45 70.20 UK 160.00 70.00 456
AHA11 121 48 60.33 UK 160.00 70.00 480
AHA12 116 36 68.97 UK 160.00 70.00 489
AHA13 105 20 80.95 UK 160.00 70.00 483
AHA14 105 35 66.67 UK 160.00 70.00 489
AHA15 121 47 61.16 UK 160.00 70.00 489
AHA16 105 30 71.43 UK 160.00 70.00 480
AHA17 105 42 60.00 UK 160.00 70.00 476
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.34. Results of the second optimization method for Patient-6 with 100 % conduction velocity.
Figure 8.40. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 90 15 83.33 UB 160.00 70.00 473
AHA2 109 30 72.47 UB 160.00 70.00 451
AHA3 202 66 67.32 UB 160.00 70.00 461
AHA4 141 57 59.57 UB 160.00 70.00 452
AHA5 131 53 59.54 UB 160.00 70.00 411
AHA6 98 47 52.04 UB 160.00 70.00 465
AHA7 95 15 84.21 UB 160.00 70.00 462
AHA8 106 32 69.81 UB 160.00 70.00 441
AHA9 143 54 62.23 UB 160.00 70.00 452
AHA10 136 40 70.58 UB 160.00 70.00 432
AHA11 106 43 59.43 UL 160.00 70.00 439
AHA12 101 31 69.30 UB 160.00 70.00 422
AHA13 90 15 83.33 UB 160.00 70.00 437
AHA14 90 30 66.66 UB 160.00 70.00 442
AHA15 106 42 60.37 UB 160.00 70.00 446
AHA16 90 25 72.22 UB 160.00 70.00 445
AHA17 90 37 54.63 UB 160.00 70.00 498
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.35. Results of the second optimization method for Patient-6 with 80 % conduction velocity.
Figure 8.41. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 125 49 60.80 UG 160.00 70.00 429
AHA2 144 65 54.86 UG 160.00 70.00 429
AHA3 237 101 57.38 UG 160.00 70.00 453
AHA4 176 92 47.72 UG 160.00 70.00 385
AHA5 166 88 46.98 UG 160.00 70.00 460
AHA6 133 82 38.34 UG 160.00 70.00 422
AHA7 130 50 61.53 UG 160.00 70.00 402
AHA8 141 67 52.48 UG 160.00 70.00 326
AHA9 178 89 50.00 UG 160.00 70.00 442
AHA10 171 75 56.14 UG 160.00 70.00 419
AHA11 141 78 44.68 UG 160.00 70.00 413
AHA12 136 66 51.47 UG 160.00 70.00 416
AHA13 125 48 61.60 UG 160.00 70.00 408
AHA14 125 65 48.00 UG 160.00 70.00 446
AHA15 141 77 45.39 UG 160.00 70.00 425
AHA16 125 60 52.00 UG 160.00 70.00 418
AHA17 125 72 42.40 UG 160.00 70.00 420
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.36. Results of the second optimization method for Patient-6 with 60 % conduction velocity.
Figure 8.42. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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8.1.7 Patient-7
The electrode positioning setup is demonstrated in figure 8.43. The results of both opti-
mization methods are summarized in tables 8.37 - 8.42 for the several conduction velocities.
The minimal errors associated with each electrode setup for each MI position are illustrated
in figures 8.44 - 8.49.
(a) (b)
Figure 8.43. The electrode positions chosen for the Patient-7 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
Both optimization methods mostly found the optimal left electrode position in the lat-
eral wall of the left ventricle (electrode E and F). The optimal right electrode position is
mostly in upper or middle septal area (electrode U and M) expect in the case of 60 % of
conduction velocity the best position is in RV apex (electrode X). The best timing delays
range evaluated by the first optimization method is between 120− 160 ms for the A-V
delay and 49.81− 70 ms for the V-V delay. The best timing delays range achieved by the
second optimization is overall 160 ms for the A-V delay and 70 ms for V-V delay.
DSA optimization delivers a number between 301 to 540 simulations for each pathological
case. The maximum possible improvement is of 39 %, for the reduction of ERMS and 82
%, for the decrease in ErrorQRS .
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 23.67 17.92 24.30 UE 160.00 70.00 404
AHA2 21.01 14.23 32.29 UE 160.00 70.00 438
AHA3 20.75 14.60 29.63 UE 160.00 70.00 410
AHA4 22.18 16.50 25.63 UE 160.00 70.00 377
AHA5 26.09 20.70 20.65 UE 160.00 70.00 381
AHA6 24.91 19.38 22.21 UE 160.00 70.00 396
AHA7 24.18 18.12 25.07 UE 160.00 70.00 365
AHA8 24.60 18.96 22.92 UE 160.00 70.00 364
AHA9 22.97 17.63 23.22 ME 130.00 55.27 411
AHA10 26.23 21.70 17.27 UE 160.00 70.00 354
AHA11 27.15 22.18 18.33 UE 160.00 70.00 404
AHA12 26.73 21.28 20.41 UE 160.00 70.00 359
AHA13 26.67 21.78 18.33 UE 160.00 70.00 347
AHA14 24.28 18.64 23.25 UE 160.00 70.00 374
AHA15 26.78 22.09 17.51 UE 160.00 70.00 389
AHA16 26.43 21.51 18.60 UE 160.00 70.00 364
AHA17 26.34 21.27 19.27 UE 160.00 70.00 358
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.37. Results of the first optimization method for Patient-7 with 100 % conduction velocity.
Figure 8.44. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 26.54 18.33 30.92 ME 140.00 60.70 455
AHA2 24.22 14.71 39.27 UE 140.00 57.58 501
AHA3 23.77 15.02 36.80 UE 140.00 57.58 464
AHA4 24.99 16.91 32.31 UE 140.00 57.58 467
AHA5 28.87 21.06 27.07 ME 140.00 57.58 435
AHA6 27.71 19.75 28.74 UE 140.00 57.58 462
AHA7 27.10 18.52 31.66 UE 140.00 57.58 407
AHA8 27.49 19.32 29.70 UE 140.00 57.58 438
AHA9 25.68 18.26 28.91 ME 120.00 52.97 458
AHA10 28.59 22.01 23.00 XE 130.00 49.81 405
AHA11 29.74 22.53 24.27 UE 140.00 57.58 426
AHA12 29.49 21.63 26.66 UE 140.00 57.58 442
AHA13 29.26 22.15 24.28 ME 140.00 57.58 434
AHA14 27.10 19.02 29.80 UE 140.00 57.58 429
AHA15 29.18 22.43 23.13 UE 140.00 57.58 420
AHA16 28.96 21.84 24.60 UE 140.00 57.58 436
AHA17 28.95 21.60 25.38 ME 140.00 57.58 420
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.38. Results of the first optimization method for Patient-7 with 80 % conduction velocity.
Figure 8.45. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 31.83 19.13 39.91 XE 120.00 49.84 519
AHA2 29.97 15.54 48.15 XE 125.63 51.63 540
AHA3 29.20 15.96 45.34 XE 123.75 52.27 504
AHA4 30.12 17.77 41.01 XE 125.00 51.00 493
AHA5 34.09 21.75 36.20 XE 120.00 49.84 504
AHA6 32.94 20.43 37.97 XE 125.00 51.00 516
AHA7 32.47 19.28 40.62 XE 125.00 51.00 514
AHA8 32.77 20.01 38.94 XE 125.00 51.00 492
AHA9 30.71 19.75 35.69 MF 120.00 49.84 506
AHA10 33.05 22.78 31.07 ME 120.00 52.97 503
AHA11 34.57 23.15 33.03 XE 120.00 49.84 488
AHA12 34.63 22.31 35.57 XE 125.00 51.00 508
AHA13 34.14 22.79 33.25 XE 120.00 49.84 501
AHA14 32.32 19.76 38.86 ME 125.00 51.00 493
AHA15 33.71 23.04 31.66 XE 125.00 51.00 458
AHA16 33.73 22.47 33.37 XE 120.00 49.84 480
AHA17 33.85 22.26 34.24 XE 125.00 51.00 486
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.39. Results of the first optimization method for Patient-7 with 60 % conduction velocity.
Figure 8.46. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 96 38 60.42 UE 160.00 70.00 488
AHA2 100 29 71.00 UE 160.00 70.00 490
AHA3 123 21 82.93 UE 160.00 70.00 482
AHA4 126 23 81.75 UE 160.00 70.00 356
AHA5 106 39 63.20 UE 160.00 70.00 487
AHA6 97 38 60.82 UE 160.00 70.00 488
AHA7 96 20 79.16 UE 160.00 70.00 512
AHA8 95 25 73.68 UE 160.00 70.00 471
AHA9 114 38 66.66 MC 160.00 70.00 425
AHA10 124 30 75.80 UE 160.00 70.00 373
AHA11 102 38 62.74 UE 160.00 70.00 526
AHA12 101 38 62.37 UE 160.00 70.00 465
AHA13 95 30 68.42 UE 160.00 70.00 508
AHA14 94 20 78.72 UE 160.00 70.00 489
AHA15 95 30 68.42 UE 160.00 70.00 409
AHA16 95 35 63.15 UE 160.00 70.00 523
AHA17 95 24 74.73 UE 160.00 70.00 502
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.40. Results of the second optimization method for Patient-7 with 100 % conduction velocity.
Figure 8.47. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
8.1. Results for Patient Data Sets 181
Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 128 48 62.50 UE 160.00 70.00 423
AHA2 133 51 61.65 UE 160.00 70.00 409
AHA3 164 45 72.56 UE 160.00 70.00 419
AHA4 166 49 70.48 UE 160.00 70.00 370
AHA5 140 70 50.00 UE 160.00 70.00 386
AHA6 130 58 55.38 UE 160.00 70.00 475
AHA7 128 45 64.84 UE 160.00 70.00 432
AHA8 126 53 57.94 UE 160.00 70.00 426
AHA9 151 70 53.64 UF 160.00 70.00 390
AHA10 164 59 64.02 UE 160.00 70.00 301
AHA11 133 70 47.36 UE 160.00 70.00 432
AHA12 132 62 53.03 UE 160.00 70.00 479
AHA13 126 58 53.96 UE 160.00 70.00 438
AHA14 126 46 63.49 UE 160.00 70.00 475
AHA15 130 53 59.23 UE 160.00 70.00 389
AHA16 126 68 46.03 UE 160.00 70.00 421
AHA17 126 50 60.31 UE 160.00 70.00 455
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.41. Results of the second optimization method for Patient-7 with 80 % conduction velocity.
Figure 8.48. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 182 87 52.20 UE 160.00 70.00 399
AHA2 189 88 53.44 UE 160.00 70.00 385
AHA3 225 87 61.33 UE 160.00 70.00 393
AHA4 231 102 55.84 UE 160.00 70.00 401
AHA5 196 120 38.77 UE 160.00 70.00 372
AHA6 183 98 46.44 UE 160.00 70.00 381
AHA7 179 70 60.89 UE 160.00 70.00 415
AHA8 179 97 45.81 UE 160.00 70.00 358
AHA9 216 121 43.98 UF 160.00 70.00 359
AHA10 231 117 49.35 UE 160.00 70.00 303
AHA11 185 120 35.13 UE 160.00 70.00 371
AHA12 183 110 39.89 UE 160.00 70.00 362
AHA13 178 110 38.20 UE 160.00 70.00 387
AHA14 178 90 49.43 UE 160.00 70.00 414
AHA15 191 98 48.69 UE 160.00 70.00 372
AHA16 150 110 26.66 UE 160.00 70.00 385
AHA17 178 98 44.94 UE 160.00 70.00 393
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.42. Results of the second optimization method for Patient-7 with 60 % conduction velocity.
Figure 8.49. The minimal ErrorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The average of optimal electrode setups is demonstrated with a green line while the blue line
shows the ErrorQRS pathology without pacing.)
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8.1.8 Patient-8
The electrode positioning setup is demonstrated in figure 8.50. The results of both opti-
mization methods are summarized in tables 8.43 - 8.48 for the several conduction velocities.
The minimal errors associated with each electrode setup for each MI position are illustrated
in figures 8.51 - 8.56.
(a) (b)
Figure 8.50. The electrode positions chosen for the Patient-8 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
Both optimization methods mostly found the optimal left electrode position in the lateral
wall of the left ventricle (electrode E, F ,G and H). The optimal right electrode position
achieved by the first optimization method is in middle septal area or RV apex (electrode
M and X) however the position is changed to the upper septal area (electrode U) with
the second optimization method. The best timing delays range evaluated by the first op-
timization method is in the range of 120− 160 ms for the A-V delay and 49.84− 70 ms.
The best timing delays range achieved by the second optimization is overall 160 ms for
the A-V delay and 70 ms for V-V delay.
DSA optimization delivers a number between 245 to 554 simulations for each pathological
case. A maximum improvement of up to 62 %, the reduction percentage of ERMS and an
improvement of up to 88 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 18.21 11.50 36.84 XG 160.00 70.00 483
AHA2 20.19 15.64 22.53 XG 160.00 70.00 463
AHA3 22.93 17.00 25.86 XH 160.00 70.00 465
AHA4 22.06 16.50 25.20 XG 160.00 70.00 456
AHA5 24.55 17.00 30.75 XG 160.00 70.00 461
AHA6 24.88 18.00 27.65 XG 160.00 70.00 456
AHA7 17.83 11.00 38.30 XG 160.00 70.00 480
AHA8 23.99 18.00 24.96 XH 160.00 70.00 420
AHA9 25.88 18.00 30.44 XH 160.00 70.00 441
AHA10 24.37 18.00 26.13 XG 160.00 70.00 434
AHA11 26.60 18.50 30.45 XG 160.00 70.00 451
AHA12 25.38 18.50 27.10 XG 160.00 70.00 454
AHA13 23.91 16.80 29.73 XG 160.00 70.00 455
AHA14 24.21 16.80 30.60 XH 160.00 70.00 438
AHA15 23.71 18.11 23.61 XG 160.00 70.00 451
AHA16 24.78 18.00 27.36 XH 160.00 70.00 451
AHA17 27.59 17.00 38.38 XG 160.00 70.00 444
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.43. Results of the first optimization method for Patient-8 with 100 % conduction velocity.
Figure 8.51. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode setups is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 21.93 11.89 45.78 XH 160.00 70.00 432
AHA2 23.36 12.00 48.63 XH 160.00 70.00 418
AHA3 25.70 17.00 33.85 XH 160.00 70.00 401
AHA4 25.23 16.60 34.20 XH 160.00 70.00 425
AHA5 27.49 17.70 35.61 XH 160.00 70.00 397
AHA6 27.69 17.50 36.80 XH 160.00 70.00 393
AHA7 21.57 11.00 49.00 XH 160.00 70.00 432
AHA8 26.57 17.70 33.38 XH 150.00 64.57 398
AHA9 28.28 18.30 34.65 XH 140.00 60.70 391
AHA10 27.22 17.80 34.60 XH 160.00 70.00 414
AHA11 29.30 18.30 37.54 XH 160.00 70.00 391
AHA12 28.12 18.00 35.98 XH 160.00 70.00 388
AHA13 27.04 17.00 37.13 XH 160.00 70.00 402
AHA14 27.00 17.50 35.18 XH 160.00 70.00 384
AHA15 26.64 17.50 34.30 XH 160.00 70.00 384
AHA16 27.74 17.50 36.91 XH 160.00 70.00 405
AHA17 30.14 17.00 43.59 XH 160.00 70.00 369
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.44. Results of the first optimization method for Patient-8 with 80 % conduction velocity.
Figure 8.52. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode setups is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 28.36 11.11 60.82 XH 130.00 52.15 554
AHA2 29.05 12.26 57.79 XH 140.00 59.14 523
AHA3 30.86 13.00 57.87 XH 140.00 59.14 501
AHA4 30.98 12.50 59.65 XH 130.00 55.27 526
AHA5 32.92 17.20 47.75 XH 140.00 59.14 503
AHA6 32.97 17.30 47.52 XH 140.00 59.14 503
AHA7 27.96 12.22 56.29 XH 130.00 52.15 548
AHA8 31.40 17.25 45.06 MH 125.00 51.00 514
AHA9 32.90 18.80 42.85 MH 120.00 49.84 505
AHA10 32.58 17.25 47.05 XH 130.00 55.27 500
AHA11 34.43 18.80 45.39 XH 140.00 59.14 493
AHA12 33.28 17.30 48.01 XH 140.00 59.14 505
AHA13 32.73 12.50 61.80 MH 130.00 53.71 519
AHA14 32.18 17.50 45.61 XH 140.00 59.14 496
AHA15 32.10 17.50 45.48 XH 120.00 49.84 505
AHA16 33.21 17.45 47.45 XH 140.00 59.14 502
AHA17 35.02 17.51 50.00 XH 140.00 59.14 469
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.45. Results of the first optimization method for Patient-8 with 60 % conduction velocity.
Figure 8.53. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode setups is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 56 18 67.85 UE 160.00 70.00 526
AHA2 67 10 85.07 UG 160.00 70.00 527
AHA3 121 19 84.29 UG 160.00 70.00 304
AHA4 87 10 88.50 UE 160.00 70.00 428
AHA5 81 19 76.54 UE 160.00 70.00 457
AHA6 61 18 70.49 UE 160.00 70.00 484
AHA7 58 18 68.96 UE 160.00 70.00 480
AHA8 67 10 85.07 UE 160.00 70.00 499
AHA9 83 18 78.31 UF 160.00 70.00 464
AHA10 82 10 87.80 UE 160.00 70.00 486
AHA11 65 12 81.53 UE 160.00 70.00 470
AHA12 70 15 78.57 UE 160.00 70.00 512
AHA13 56 10 82.14 UG 160.00 70.00 486
AHA14 56 10 82.14 UE 160.00 70.00 528
AHA15 61 10 83.60 UG 160.00 70.00 482
AHA16 56 10 82.14 UE 160.00 70.00 492
AHA17 56 10 82.14 UE 160.00 70.00 487
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.46. Results of the second optimization method for Patient-8 with 100 % conduction velocity.
Figure 8.54. The minimal errorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode setups is demonstrated with a green line while the blue line shows the
errorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 82 29 64.63 UE 160.00 70.00 528
AHA2 96 30 68.75 UH 160.00 70.00 512
AHA3 165 44 73.33 UG 160.00 70.00 273
AHA4 120 40 66.66 UE 160.00 70.00 418
AHA5 114 44 61.40 UE 160.00 70.00 510
AHA6 88 38 56.81 UE 160.00 70.00 504
AHA7 85 30 64.70 UE 160.00 70.00 487
AHA8 94 28 70.21 UE 160.00 70.00 471
AHA9 118 42 64.40 UF 160.00 70.00 455
AHA10 115 35 69.56 UE 160.00 70.00 498
AHA11 93 39 58.06 UE 160.00 70.00 496
AHA12 92 25 72.82 UF 160.00 70.00 512
AHA13 82 10 87.80 UE 160.00 70.00 501
AHA14 82 25 69.51 UE 160.00 70.00 467
AHA15 91 29 68.13 UE 160.00 70.00 459
AHA16 82 20 75.60 UE 160.00 70.00 458
AHA17 82 29 64.63 UE 160.00 70.00 483
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.47. Results of the second optimization method for Patient-8 with 80 % conduction velocity.
Figure 8.55. The minimal errorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode setups is demonstrated with a green line while the blue line shows the
errorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 125 45 64.00 UF 160.00 70.00 440
AHA2 144 65 55.55 UF 160.00 70.00 394
AHA3 237 100 57.80 UH 160.00 70.00 245
AHA4 176 95 46.02 UH 160.00 70.00 412
AHA5 166 94 43.37 UF 160.00 70.00 362
AHA6 133 93 30.07 UF 160.00 70.00 393
AHA7 130 45 65.38 UF 160.00 70.00 448
AHA8 141 65 53.90 UF 160.00 70.00 381
AHA9 178 85 52.24 UF 160.00 70.00 377
AHA10 171 75 56.14 UE 160.00 70.00 416
AHA11 141 79 43.97 UF 160.00 70.00 373
AHA12 136 70 48.52 UF 160.00 70.00 384
AHA13 125 45 64.00 UF 160.00 70.00 408
AHA14 125 70 44.00 UF 160.00 70.00 386
AHA15 141 75 46.80 UF 160.00 70.00 305
AHA16 125 55 56.00 UF 160.00 70.00 398
AHA17 125 70 44.00 UF 160.00 70.00 428
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.48. Results of the second optimization method for Patient-8 with 60 % conduction velocity.
Figure 8.56. The minimal errorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode setups is demonstrated with a green line while the blue line shows the
errorQRS pathology without pacing.)
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8.1.9 Patient-9
The electrode positioning setup is demonstrated in figure 8.57. The results of both opti-
mization methods are summarized in tables 8.49 - 8.54 for the several conduction velocities.
The minimal errors associated with each electrode setup for each MI position are illustrated
in figures 8.58 - 8.63.
(a) (b)
Figure 8.57. The electrode positions chosen for the Patient-9 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
Both optimization methods mostly found the optimal left electrode position in the lateral
wall or posterolateral of the left ventricle (electrode E, F, G, H and K). The optimal right
electrode position achieved by the first optimization method is mostly in upper or middle
septal area (electrode U and M) however the position is fixed in the upper septal area
(electrode U) with the second optimization method. The best timing delays range evalu-
ated by the first optimization method is in the range of 110− 160 ms for the A-V delay
and 42.85− 70 ms. The best timing delays range achieved by the second optimization is
overall 160 ms for the A-V delay and 70 ms for V-V delay.
DSA optimization delivers a number between 326 to 555 simulations for each pathological
case. A maximum improvement of up to 36 %, the reduction percentage of ERMS and an
improvement of up to 83 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 24.26 20.62 15.02 UG 160.00 70.00 395
AHA2 25.61 21.63 15.54 UG 160.00 70.00 408
AHA3 25.33 21.64 14.57 UG 160.00 70.00 395
AHA4 24.82 21.67 12.69 UG 160.00 70.00 398
AHA5 26.71 23.29 12.79 UG 160.00 70.00 371
AHA6 27.90 24.37 12.64 UG 160.00 70.00 385
AHA7 25.52 22.09 13.46 UG 160.00 70.00 388
AHA8 28.54 25.12 11.98 UG 160.00 70.00 413
AHA9 28.08 24.89 11.38 UG 160.00 70.00 383
AHA10 28.53 25.99 8.92 UH 160.00 70.00 371
AHA11 29.65 26.75 9.80 UG 160.00 70.00 370
AHA12 30.01 26.94 10.22 UG 160.00 70.00 367
AHA13 29.24 26.07 10.85 UH 160.00 70.00 376
AHA14 26.73 22.67 15.19 UG 160.00 70.00 398
AHA15 29.26 26.45 9.60 UH 160.00 70.00 375
AHA16 29.51 26.44 10.41 UG 160.00 70.00 392
AHA17 31.15 27.90 10.43 UG 160.00 70.00 386
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.49. Results of the first optimization method for Patient-9 with 100 % conduction velocity.
Figure 8.58. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 28.31 21.36 24.56 UH 150.00 66.13 407
AHA2 29.89 22.56 24.52 UH 160.00 70.00 416
AHA3 29.34 22.39 23.70 UH 150.00 66.13 414
AHA4 28.57 22.41 21.57 UH 160.00 70.00 427
AHA5 30.52 23.96 21.50 UH 150.00 66.13 424
AHA6 31.82 25.12 21.08 UH 160.00 70.00 419
AHA7 29.40 22.78 22.51 UH 150.00 66.13 406
AHA8 32.27 25.89 19.78 UH 160.00 70.00 414
AHA9 31.62 25.68 18.78 UG 130.00 55.27 408
AHA10 31.73 26.81 15.52 XF 120.00 46.72 384
AHA11 33.07 27.42 17.09 UH 160.00 70.00 414
AHA12 33.56 27.59 17.79 UH 160.00 70.00 418
AHA13 32.94 26.68 19.02 UH 160.00 70.00 419
AHA14 30.80 23.47 23.81 UH 160.00 70.00 415
AHA15 32.61 27.41 15.93 MH 120.00 49.84 359
AHA16 33.01 27.16 17.71 UH 160.00 70.00 388
AHA17 34.42 28.82 16.27 UH 160.00 70.00 383
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.50. Results of the first optimization method for Patient-9 with 80 % conduction velocity.
Figure 8.59. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 36.08 22.91 36.49 MH 120.00 46.72 550
AHA2 38.12 24.03 36.96 MH 120.00 46.72 540
AHA3 37.11 23.89 35.61 MH 120.00 46.72 555
AHA4 35.90 23.81 33.67 MH 120.00 46.72 551
AHA5 37.97 25.36 33.19 MH 120.00 46.72 529
AHA6 39.44 26.43 32.99 MH 120.00 46.72 521
AHA7 36.94 24.25 34.36 MH 120.00 46.72 539
AHA8 39.65 27.19 31.44 MH 120.00 46.72 523
AHA9 38.65 26.97 30.21 UH 120.00 46.72 522
AHA10 38.23 27.95 26.89 MH 110.00 42.85 524
AHA11 39.94 28.69 28.19 MH 120.00 46.72 509
AHA12 40.71 28.81 29.23 MH 120.00 46.72 521
AHA13 40.25 27.90 30.68 MH 120.00 46.72 508
AHA14 38.58 24.80 35.72 UH 120.00 46.72 531
AHA15 39.36 28.27 28.19 MH 110.00 42.85 545
AHA16 40.03 28.54 28.71 MH 120.00 46.72 481
AHA17 41.09 29.98 27.04 MH 120.00 46.72 506
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.51. Results of the first optimization method for Patient-9 with 60 % conduction velocity.
Figure 8.60. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 44 15 65.90 UK 160.00 70.00 479
AHA2 64 12 81.25 UH 160.00 70.00 420
AHA3 68 12 82.35 UK 160.00 70.00 399
AHA4 70 18 74.28 UK 160.00 70.00 455
AHA5 55 18 67.27 UK 160.00 70.00 473
AHA6 37 13 64.86 UK 160.00 70.00 590
AHA7 39 15 61.53 UK 160.00 70.00 394
AHA8 59 12 79.66 UK 160.00 70.00 451
AHA9 66 22 66.66 UK 160.00 70.00 490
AHA10 74 22 70.27 UH 160.00 70.00 501
AHA11 62 10 83.87 UK 160.00 70.00 418
AHA12 39 8 79.48 UK 160.00 70.00 383
AHA13 34 15 55.88 UG 160.00 70.00 455
AHA14 48 10 79.16 UK 160.00 70.00 492
AHA15 50 18 64.00 UE 160.00 70.00 526
AHA16 79 20 74.68 UH 160.00 70.00 505
AHA17 39 10 74.35 UH 160.00 70.00 511
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.52. Results of the second optimization method for Patient-9 with 100 % conduction velocity.
Figure 8.61. The minimal errorQRS achieved by the second optimization method versus AHA segments
1 to 17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
errorQRS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 76 18 76.31 UK 160.00 70.00 492
AHA2 103 30 70.87 UK 160.00 70.00 372
AHA3 105 32 59.52 UK 160.00 70.00 368
AHA4 108 38 64.81 UK 160.00 70.00 382
AHA5 87 37 57.47 UK 160.00 70.00 411
AHA6 67 16 76.11 UK 160.00 70.00 496
AHA7 70 45 35.71 UK 160.00 70.00 352
AHA8 95 40 57.89 UK 160.00 70.00 488
AHA9 104 50 51.92 UK 160.00 70.00 441
AHA10 111 48 56.75 UE 160.00 70.00 482
AHA11 88 32 63.63 UK 160.00 70.00 404
AHA12 70 36 48.57 UK 160.00 70.00 326
AHA13 63 34 46.03 UK 160.00 70.00 425
AHA14 82 20 75.60 UK 160.00 70.00 492
AHA15 85 34 60.00 UE 160.00 70.00 502
AHA16 120 50 58.33 UK 160.00 70.00 428
AHA17 71 34 52.11 UK 160.00 70.00 490
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.53. Results of the second optimization method for Patient-9 with 80 % conduction velocity.
Figure 8.62. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 126 60 52.38 UK 160.00 70.00 444
AHA2 166 78 53.01 UK 160.00 70.00 360
AHA3 170 78 54.11 UK 160.00 70.00 367
AHA4 170 84 50.58 UF 160.00 70.00 353
AHA5 141 81 42.55 UK 160.00 70.00 354
AHA6 116 42 63.79 UK 160.00 70.00 417
AHA7 120 90 25.00 UK 160.00 70.00 329
AHA8 156 80 48.71 UK 160.00 70.00 389
AHA9 167 110 34.13 UK 160.00 70.00 379
AHA10 175 100 42.85 UE 160.00 70.00 407
AHA11 142 80 43.66 UK 160.00 70.00 365
AHA12 119 84 29.41 UK 160.00 70.00 293
AHA13 112 82 26.78 UK 160.00 70.00 381
AHA14 140 65 53.57 UF 160.00 70.00 390
AHA15 142 76 46.47 UE 160.00 70.00 405
AHA16 189 110 41.79 UK 160.00 70.00 367
AHA17 122 78 36.06 UK 160.00 70.00 406
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.54. Results of the second optimization method for Patient-9 with 60 % conduction velocity.
Figure 8.63. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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8.1.10 Patient-10
The electrode positioning setup is demonstrated in figure 8.64. The results of both opti-
mization methods are summarized in tables 8.55 - 8.60 for the several conduction velocities.
The minimal errors associated with each electrode setup for each MI position are illustrated
in figures 8.65 - 8.70.
(a) (b)
Figure 8.64. The electrode positions chosen for the Patient-10 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
Both optimization methods mostly found the optimal left electrode position in the lat-
eral wall or posterolateral of the left ventricle (electrode H, K and L). The optimal right
electrode position is mostly in upper or middle septal area (electrode U and M). The
best timing delays range evaluated by the first optimization method is in the range of
105− 160 ms for the A-V delay and 38.18− 70 ms. The best timing delays range achieved
by the second optimization is overall 160 ms for the A-V delay and 70 ms for V-V delay.
DSA optimization delivers a number between 323 to 604 simulations for each pathological
case. A maximum improvement of up to 38 %, the reduction percentage of ERMS and an
improvement of up to 73 %, the reduction percentage of ErrorQRS , can be reached.
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 18.12 15.87 12.43 ML 140.00 57.58 413
AHA2 18.78 16.85 10.30 ML 140.00 57.58 412
AHA3 19.05 17.21 9.67 ML 140.00 57.58 426
AHA4 18.22 16.00 12.20 ML 140.00 57.58 418
AHA5 17.97 15.77 12.21 ML 140.00 57.58 426
AHA6 18.74 16.65 11.17 ML 140.00 57.58 420
AHA7 20.36 18.26 10.34 UL 140.00 57.58 362
AHA8 19.78 17.80 10.00 UL 140.00 57.58 414
AHA9 18.91 16.92 10.51 MK 140.00 57.58 473
AHA10 20.51 18.18 11.33 ML 140.00 57.58 446
AHA11 20.91 19.01 9.06 UK 160.00 70.00 441
AHA12 22.12 20.32 8.14 UK 160.00 70.00 438
AHA13 20.46 18.01 11.97 MK 160.00 70.00 443
AHA14 19.72 17.81 9.71 ML 140.00 57.58 418
AHA15 15.43 12.54 18.74 ML 130.00 52.15 446
AHA16 15.63 13.03 16.66 ML 140.00 57.58 438
AHA17 19.06 17.01 10.76 ML 140.00 57.58 420
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.55. Results of the first optimization method for Patient-10 for 100 % conduction velocity.
Figure 8.65. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 20.51 16.34 20.33 UK 140.00 57.58 378
AHA2 20.94 17.32 17.28 ML 130.00 53.71 377
AHA3 21.14 17.65 16.50 UK 140.00 60.70 362
AHA4 20.58 16.50 19.80 UK 140.00 57.58 412
AHA5 20.33 16.30 19.82 UK 140.00 60.70 388
AHA6 21.02 17.16 18.38 ML 120.00 46.72 387
AHA7 22.64 18.67 17.50 UK 140.00 60.70 421
AHA8 21.95 18.28 16.70 ML 120.00 46.72 437
AHA9 21.02 17.21 18.15 MK 120.00 46.72 369
AHA10 22.80 18.64 18.26 UK 140.00 57.58 398
AHA11 22.98 19.47 15.27 ML 120.00 46.72 389
AHA12 24.15 20.72 14.20 ML 120.00 46.72 357
AHA13 22.85 18.60 18.60 XK 140.00 57.58 416
AHA14 21.86 18.30 16.31 ML 120.00 46.72 345
AHA15 18.14 13.23 27.07 ML 120.00 46.72 412
AHA16 18.31 13.53 26.14 ML 127.50 46.89 389
AHA17 21.30 17.47 17.98 UK 140.00 57.58 371
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.56. Results of the first optimization method for Patient-10 for 80 % conduction velocity.
Figure 8.66. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ERMS ERMS % ERMS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 25.18 17.21 31.64 MK 110.00 42.85 587
AHA2 25.22 18.06 28.38 MK 115.00 44.00 578
AHA3 25.32 18.35 27.53 MK 115.00 44.00 528
AHA4 25.18 17.27 31.43 MK 110.00 42.85 566
AHA5 24.94 17.03 31.74 MK 115.00 44.00 582
AHA6 25.52 17.85 30.05 MK 115.00 44.00 562
AHA7 27.16 19.56 27.99 MK 115.00 44.00 560
AHA8 26.27 18.96 27.83 MK 115.00 44.00 586
AHA9 25.24 18.14 28.12 MK 110.00 41.29 544
AHA10 27.33 19.31 29.36 MK 115.00 44.00 604
AHA11 27.18 20.13 25.93 MK 115.00 44.00 575
AHA12 28.28 21.34 24.55 MK 112.50 42.26 555
AHA13 27.52 19.38 29.58 MK 105.00 38.18 577
AHA14 26.14 18.97 27.44 MK 115.00 44.00 552
AHA15 23.25 14.29 38.53 MK 115.00 44.00 587
AHA16 23.35 14.54 37.75 MK 115.00 44.00 596
AHA17 25.75 18.20 29.29 MK 110.00 42.85 537
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.57. Results of the first optimization method for Patient-10 for 60 % conduction velocity.
Figure 8.67. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 71 19 73.23 UK 160.00 70.00 517
AHA2 92 26 71.73 UK 160.00 70.00 405
AHA3 87 30 65.52 UK 160.00 70.00 542
AHA4 70 29 58.57 MK 160.00 70.00 524
AHA5 69 38 44.92 MK 160.00 70.00 446
AHA6 70 33 52.86 UK 160.00 70.00 496
AHA7 72 22 69.44 UK 160.00 70.00 490
AHA8 88 25 71.59 UK 160.00 70.00 495
AHA9 84 30 64.28 UK 160.00 70.00 519
AHA10 79 29 63.29 UK 160.00 70.00 528
AHA11 69 20 71.01 UK 160.00 70.00 485
AHA12 69 20 71.01 UK 160.00 70.00 461
AHA13 75 20 73.33 MK 160.00 70.00 491
AHA14 70 25 64.28 MK 160.00 70.00 471
AHA15 69 29 57.97 UK 160.00 70.00 480
AHA16 69 20 71.01 UK 160.00 70.00 493
AHA17 70 29 58.57 MK 160.00 70.00 497
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.58. Results of the second optimization method for Patient-10 with 100 % conduction velocity.
Figure 8.68. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 102 45 55.88 UK 160.00 70.00 505
AHA2 128 58 54.68 UK 160.00 70.00 333
AHA3 125 56 55.20 MK 160.00 70.00 480
AHA4 103 55 46.60 UK 160.00 70.00 502
AHA5 102 64 37.26 MK 160.00 70.00 484
AHA6 102 55 46.07 MK 160.00 70.00 504
AHA7 104 52 50.00 MK 160.00 70.00 452
AHA8 125 58 53.60 MK 160.00 70.00 479
AHA9 121 58 52.06 MH 160.00 70.00 489
AHA10 112 55 50.89 UK 160.00 70.00 515
AHA11 102 52 49.01 UK 160.00 70.00 486
AHA12 102 52 49.01 UK 160.00 70.00 475
AHA13 108 52 51.85 MK 160.00 70.00 494
AHA14 102 56 45.09 UK 160.00 70.00 471
AHA15 102 55 46.07 UK 160.00 70.00 446
AHA16 102 52 49.01 MK 160.00 70.00 490
AHA17 102 55 46.07 UK 160.00 70.00 489
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.59. Results of the second optimization method for Patient-10 with 80 % conduction velocity.
Figure 8.69. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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Infarction ErrorQRS ErrorQRS % ErrorQRS Opt. elec Opt. Opt. Nr. of
position (phy-path) (phy-pac) reduction positions A-V V-V sim.
ms ms ms ms
AHA1 154 90 41.55 UK 160.00 70.00 436
AHA2 190 114 40.00 UK 160.00 70.00 323
AHA3 184 100 45.65 MH 160.00 70.00 443
AHA4 156 100 35.90 UK 160.00 70.00 373
AHA5 154 104 32.47 MK 160.00 70.00 445
AHA6 154 90 41.55 UK 160.00 70.00 461
AHA7 158 95 39.87 UH 160.00 70.00 377
AHA8 183 108 40.98 UK 160.00 70.00 397
AHA9 180 102 43.33 UH 160.00 70.00 459
AHA10 168 95 43.45 MK 160.00 70.00 409
AHA11 154 90 41.55 UK 160.00 70.00 464
AHA12 154 90 44.78 UH 160.00 70.00 440
AHA13 163 90 44.78 MH 160.00 70.00 439
AHA14 155 95 38.70 MK 160.00 70.00 422
AHA15 154 95 38.31 MH 160.00 70.00 386
AHA16 154 90 41.55 MK 160.00 70.00 465
AHA17 154 95 38.31 UK 160.00 70.00 448
phy-path: between physiology and pathology, phy-pac: between physiology and pacing, Opt: optimal, elec:
electrodes, Nr. of sim: number of simulations.
Table 8.60. Results of the second optimization method for Patient-10 with 60 % conduction velocity.
Figure 8.70. The minimal ERMS achieved by the first optimization method versus AHA segments 1 to
17 corresponding to the 17 different infarction positions. (Each circular point is related to one pair of
electrodes. The optimal electrode set up is demonstrated with a green line while the blue line shows the
ERMS pathology without pacing.)
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8.2 Discussion on the Results
Several key observations can be made from this investigation: The influence of pacing lo-
cations on reducing electrical dyssynchrony. Placing the LV pacing tip on the lateral or
postero lateral section of LV and pacing leads sequentially with a delay of 40− 70 ms
helps to reduce dyssynchrony.
The optimal pacemaker setups achieved by both optimization methods for all patients
(ERMS and QRS based) are demonstrated in figures 8.71 - 8.76. It can be observed that
the most optimal A-V delay achieved by the ERMS based optimization is in the range of
120− 160 ms and by the QRS based method only 160 ms. The range of V-V delay for the
the first method is 45− 70 ms and in the second method only 70 ms. The most frequent
position of the left electrode is the LV lateral and posterolateral area.
For obtaining a global view upon the ERMS based optimization method, the 10 patients
data including the 17 infarction positions and the 3 different conduction velocities creating
a sample space of 510 sample points are investigated. The distribution of the calculated
values over the population is illustrated in the plotted histograms in figures (8.77 - 8.78).
It is noticeable that the most frequent A-V delay is 160 ms and V-V delay is 70 ms. For
each case, the most dominant value covered almost half of the population. In addition,
it is interesting to note that A-V and V-V are not normally distributed, neither are they
following a specific trend, which underlines the necessity of patient specific data analysis
for establishing the optimal electrodes positions. The patient specific agreement between
the timing delays and the electrode setups were calculated for determining if the analyzed
optimization methods deliver equal results. The results are included in table 8.61 and they
indicate that the agreement range of timing delays are varying between 5.9 % and 98 % .
The agreement range of the electrode positions varies widely, somethimes the results are
not equal while some results are 96 % identical. The association between the physiological,
pathological and reduction errors of the two optimization methods were analyzed with
Pearson correlation method [184]. For all three sets of data, the level of association is
significant:
1. Correlation coefficients of QRS error and ERMS between physiological and pathological
cases: r=0.46, p<0.001.
2. Correlation coefficients of QRS error and ERMS between physiological and pacing
cases: r=0.25, p<0.001.
3. Correlation coefficients of QRS and ERMS for reduction errors: r=-0.24, p<0.001.
The relation between the parameters of the two optimization methods is depicted in figures
8.79 - 8.81. The large variations of agreement ranges and the correlation coefficients prove
that even though the two optimization methods are significantly associated, one cannot
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be used as a confounder of the other. The r value and the frequent number of cases per
analysis deliver the p values.
Figure 8.71. The optimal pacing parameters achieved by the first optimization method for all patients
with different conduction velocities (The electrode setups versus A-V delays).
Figure 8.72. The optimal pacing parameters achieved by the first optimization method for all patients
with different conduction velocities (The electrode setups versus V-V delays).
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Figure 8.73. The optimal pacing parameters achieved by the first optimization method for all patients
with different conduction velocities (The V-V delays versus A-V delays).
Figure 8.74. The optimal pacing parameters achieved by the second optimization method for all patients
with different conduction velocities (The electrode setups versus A-V delays).
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Figure 8.75. The optimal pacing parameters achieved by the second optimization method for all patients
with different conduction velocities (The electrode setups versus V-V delays).
Figure 8.76. The optimal pacing parameters achieved by the second optimization method for all patients
with different conduction velocities (The V-V delays versus A-V delays).
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Figure 8.77. Histogram of the optimal A-V delays achieved by the first optimization method. The sample
space N, mean value and standard deviation are 510, 143.06 and 17.92, respectively.
Figure 8.78. Histogram of the optimal V-V delays achieved by the first optimization method. The sample
space N, mean value and standard deviation are 510, 60.71 and 9.82, respectively.
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Patient ID Equal A-V delay (%) Equal V-V delay (%) Equal electrode setups (%)
1 98 98 96.1
2 25.5 25.5 31.4
3 62.7 62.7 94.1
4 52.9 52.9 64.7
5 51 51 54.9
6 35.3 35.3 2
7 31.4 31.4 52.9
8 62.7 62.7 0
9 52.9 52.9 2
10 5.9 5.9 21.6
all 47.84 47.84 41.96
Table 8.61. Percentage range of agreement of timing delays and electrode setups for both optimization
methods in all patients. All optimal pacing setups achieved from both optimization methods in 32.35 % of
cases are equal.
The values corresponding to the electrodes positions, identified over all 10 patients includ-
ing 17 infarction positions and 3 different conduction velocities were pooled and statisti-
cally tested according to the error. The descriptive statistics of the obtained distributions
for each electrode position are incorporated in table 8.62.
Figure 8.79. Regression line demonstrating the relation between both optimization methods in terms of
physiological-pathological error.
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Figure 8.80. Regression line demonstrating the relation between both optimization methods for in terms
of physiological-pacing error.
Figure 8.81. Regression line demonstrating the relation between both optimization methods for in terms
of reduction error percentage.
8.2. Discussion on the Results 211
Effect Mean Standard error
MC 84.28 36.07
ME 82.35 17.38
MH 167.33 21.19
MK 121.39 15.26
UA 62.58 16.16
UB 107.51 13.70
UE 111.86 11.46
UF 165.58 13.02
UG 126.30 11.44
UH 164.62 12.60
UK 121.37 11.79
UL 79.58 26.95
XG 95.41 32.21
XH 148.38 31.16
Effect is electrode position setups.
Table 8.62. Descriptive statistics of the obtained distributions for each electrode position.
The variables corresponding to the pacing electrodes were tested for normality using
Shapiro-Wilk, Kolmogorov-Smirnov, Cramer-von-Mises and Anderson-Darling tests. The
results of the tests are included in table 8.63.
In these tests, the null hypothesis is that the data is normally distributed and if the p value
is small (<0.05) the hypothesis is being rejected. Therefore, all four tests underline that
the data is normally distributed, which allow further statistical analysis. The chosen level
of significance was 0.05. For the first two tests, the probability is larger than this value,
meaning that the hypothesis of a normal distribution is correct. For the second two test,
the probability is only a little bit smaller than 0.05, meaning that there is no significant
evidence for rejecting the hypothesis. With two tests confirming the normal distribution
and two tests very closely not confirming, it can be assumed that the data is normally
distributed.
Tests for Normality
Test Statistic p Value
Shapiro-Wilk W 0.995020 Pr < W 0.0995
Kolmogorov-Smirnov D 0.032847 Pr > D >0.1500
Cramer-von Mises W-Sq 0.132227 Pr > W-Sq 0.0428
Anderson-Darling A-Sq 0.781781 Pr > A-Sq 0.0436
Table 8.63. Tests of normality.
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Following the difference in mean physiological-pacing values between electrode positions
were globally evaluated with multiple regression analysis. The Null Hypothesis is that the
means physiological-pathological levels are the same between electrode positions. The p-
value <0.0001 indicates there is a significant difference in mean response levels between
electrodes. From the results, illustrated in table 8.64. It can be concluded that there is a
significant difference in mean physiological-pacing levels between electrodes.
Tests of Fixed Effects
Effect Num. DF Den. DF F Value Pr >F
Electrode position setups 13 219 10.05 <.0001
Num: numerator, DF: degree of freedom, Den: denominator
Table 8.64. Tests of fixed effects between electrode position setups.
9Clinical Verification of the Methods
Multichannel ECG measurements (BSPM) and MRI data acquisition are carried out on
three patients at University Hospital Mannheim in order to gain the individual pathology
by solving the inverse problem of electrocardiography. The models resulting from MRI
data sets based on geometries described in section 6.2 are implemented together with
the 64 ECG channels measurements to solve the inverse problem. The inverse solver is
based on optimization approach discussed in section 5.3. An electrophysiological cardiac
model is created in which the parameters are varied until the simulated ECG is as similar
as possible to the measured one. The solution of inverse problem enables the simulation
of excitation propagation in the ventricular myocardium and conduction system. After
optimizing the pacing setups, the BSPM is simulated by solving the forward problem of
electrocardiography. The resulting simulated ECG signals are compared with the measured
ECG signals after implantation in order to verify the results of the optimization procedure.
9.1 Verification of the Optimization Method for Patient-11
The general information of Patient-11 about the pathologies and geometries is shown in
tables 6.1 - 6.2. The demonstration of the heart and torso are in figures 6.12 and 6.16,
respectively.
9.1.1 ECG Measurements of Patient-11
The measured ECGs before and after pacemaker implantation are demonstrated in figure
9.1 - 9.2. The signal processing steps including baseline wander cancellation, denoising,
averaging of multiple ECG cycles in each channel were performed. For the signals after
implantation, an additional signal processing step was performed in order to suppress the
stimulus artifacts.
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Figure 9.1. The measured 64 channels ECG before implantation for Patient-11.
Figure 9.2. The measured 64 channels ECG after implantation for Patient-11.
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9.1.2 Parameter Optimization of Patient-11
The inverse problem of electrocardiography was solved at least 8 times to achieve the
optimal results. The best results including the optimal parameters based on the least
ERMS between measured and simulated ECG were selected. The initial and optimized
values for excitation conduction velocity in different tissues and the location of myocardial
infarction are demonstrated in table 9.1. The initial values are the first estimation of
the pathological parameters and were extracted from the previous studies [94, 216]. The
12 standard ECG channels were extracted from the measured 64 channels ECG. These
signals are compared to the simulated ECG for 12 standard channels based on optimized
parameters of inverse solver before implantation. The simulated and measured 12 channels
ECG pre-implantation are demonstrated in figures 9.3 and 9.4, detailed in figures 9.5 to 9.8.
The correlation coefficients between the simulated and measured ECGs are demonstrated
in figure 9.9. The signals are highly correlated (up to 0.8) in the interval of QRS complex.
Tissue class Initial values Optimized values
Infarction position (x, y, z) 157 132 100 (AHA10) 155 102 108 (AHA15)
Infarction size (voxels) 20 18.90
ECV in LV myocardium 1065 mm/s 1315.70 mm/s
ECV in RV myocardium 1065 mm/s 1675.40 mm/s
ECV in RV Purkinje fibers 4862.02 mm/s 3762.15 mm/s
ERMS 0.136043 0.123527
ECV: the excitation conduction velocity (mm/s). Number of iterations: 272.
Table 9.1. Initial and optimized values for infarction location and excitation conduction velocity in dif-
ferent tissues.
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Figure 9.3. The simulated ECG channels of Patient-11 pre-implantation.
Figure 9.4. The measured ECG channels of Patient-11 pre-implantation.
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Figure 9.5. The simulated ECG channels of Patient-11 pre-implantation (Einthoven and Goldberger).
Figure 9.6. The measured ECG channels of Patient-11 pre-implantation (Einthoven and Goldberger).
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Figure 9.7. The simulated ECG channels of Patient-11 pre-implantation (Wilson).
Figure 9.8. The measured ECG channels of Patient-11 pre-implantation (Wilson).
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(a)
(b)
Figure 9.9. Correlation coefficients between simulated and measured 12 standard ECG channels before
implantation: (a) Heart cycle. (b) QRS complex.
9.1.3 CRT Optimization of Patient-11
The pathological heart is simulated based on the optimized parameters achieved with
the inverse solver. Furthermore, the optimal setup parameters were discovered using the
optimization methods for CRT developed in this work. The electrode positions are demon-
strated in figure 9.10. The optimal results of both optimization methods based on ERMS
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and QRS duration were achieved and a trade off between the results leads to following
consideration:
• Pacing the leads in RV apex (X) and the LV posterolateral area (J).
• Setting the timing delays to 140 ms for A-V delay and 58 ms for V-V delay.
(a) (b)
Figure 9.10. The electrode positions chosen for the Patient-11 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the upper septum, middle septum and apex of the right
ventricle respectively.
9.1.4 Forward Calculation of Simulated ECG for Patient-11 after Pacing
The BSPM of the patient model based on the optimal BVP setup was simulated. The
12 standard ECG leads system were extracted (see figure 9.11) and compared to the
corresponding channels in measured ECG after implantation (see figure 9.12) in terms of
QRS durations.
9.1.5 Discussion on the Results
The QRS duration before and after implantation are calculated in both measured and sim-
ulated ECG based on the automatic QRS detection method described in chapter 7. The
QRS duration before and after implantation are compared together and demonstrated in
figure 9.13. It can be observed that QRS durations are reduced both in measured and
simulated ECG after implantation.
The simulated optimized electrode positions are comparable to the ones used in hospital.
The timing delays used in hospital are 130 ms for A-V and 0 ms for V-V delay, while the
values obtained in this work are slightly larger.
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Figure 9.11. The simulated ECG channels of Patient-11 post-implantation.
Figure 9.12. The measured ECG channels of Patient-11 post-implantation.
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(a)
(b)
Figure 9.13. QRS duration of the 12 channels ECG before and after implantation: (a) Simulated. (b)
Measured.
9.2 Verification of the Optimization Method for Patient-12
The general information of Patient-12 about the pathologies and geometries is shown in
tables 6.1 - 6.2. The demonstration of the heart and torso are in figures 6.13 and 6.17,
respectively.
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9.2.1 ECG Measurements of Patient-12
The measured ECGs before and after pacemaker implantation are demonstrated in figures
9.14 - 9.15. The signal processing steps including baseline wander cancellation, denoising,
averaging of multiple ECG cycles in each channel were performed.
Figure 9.14. The measured 64 channels ECG before implantation for Patient-12.
Figure 9.15. The measured 64 channels ECG after implantation for Patient-12.
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For the signals after implantation an additional signal processing step was performed in
order to suppress the stimulation artifacts.
9.2.2 Parameter Optimization of Patient-12
The inverse problem of electrocardiography was solved at least 8 times to achieve the
optimal results. The best results including the optimal parameters based on the least
ERMS between measured and simulated ECG were selected. The initial and optimized
values for excitation conduction velocity in different tissues are demonstrated in table 9.2.
The initial values are the first estimation of the pathological parameters and were extracted
from the literature. The 12 standard ECG channels were extracted from the measured 64
channels ECG. These signals are compared to the simulated ECG for 12 standard channels
based on optimized parameters of inverse solver before implantation. The simulated and
measured 12 channels ECG pre-implantation are demonstrated in figures 9.16 and 9.17,
detailed in figures 9.18 - 9.21.
Tissue class Initial values Optimized values
ECV in the left bundle branch 800 mm/s 796.55 mm/s
ECV in LV myocardium 852 mm/s 856.80 mm/s
ECV in RV myocardium 958 mm/s 983.70 mm/s
ECV in RV Purkinje fibers 3889.62 mm/s 3824.55 mm/s
ERMS 0.138776 0.12934
ECV: the excitation conduction velocity (mm/s). Number of iterations: 185.
Table 9.2. Initial and optimized values for excitation conduction velocity in different tissues.
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Figure 9.16. The simulated ECG channels of Patient-12 pre-implantation.
Figure 9.17. The measured ECG channels of Patient-12 pre-implantation.
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Figure 9.18. The simulated ECG channels of Patient-12 pre-implantation (Einthoven and Goldberger).
Figure 9.19. The measured ECG channels of Patient-12 pre-implantation (Einthoven and Goldberger).
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Figure 9.20. The simulated ECG channels of Patient-12 pre-implantation (Wilson).
Figure 9.21. The measured ECG channels of Patient-12 pre-implantation (Wilson).
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The correlation coefficients between the simulated and measured ECGs are demonstrated
in figure 9.22. The signals are highly correlated (up to 0.8) in the interval of QRS complex.
(a)
(b)
Figure 9.22. Correlation coefficients between simulated and measured 12 standard ECG channels before
implantation: (a) Heart cycle. (b) QRS complex.
9.2.3 CRT Optimization of Patient-12
The pathological heart is simulated based on the optimized parameters achieved with
the inverse solver. Furthermore, the optimal setup parameters were discovered using the
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optimization methods for CRT developed in this work. The electrode positions are demon-
strated in figure 9.23. The optimal results of both optimization methods based on ERMS
and QRS duration were achieved and a trade off between the results leads to following
consideration:
• Pacing the leads in RV upper septal area (U) and the LV posterolateral area (J).
• Setting the timing delays as 130 ms for A-V delay and 49 ms for V-V delay.
(a) (b)
Figure 9.23. The electrode positions chosen for the Patient-12 heart model. The electrodes A, B, C and
D are referred to the anterior branches of coronary sinus. The electrodes I, J, K and L are referred to the
posterior branches of coronary sinus. The electrodes E, F, G and H are located on the left ventricular free
wall. The electrodes U, M and X are located at the right ventricular upper septum, middle septum and
apex respectively.
9.2.4 Forward Calculation of Simulated ECG for Patient-12 after Pacing
The BSPM of the patient model based on the optimal BVP setup was simulated. The
12 standard ECG leads system were extracted (see figure 9.24) and compared to the
corresponding channels in measured ECG after implantation (see figure 9.25) in terms of
QRS duration.
9.2.5 Discussion on the Results
The QRS durations before and after implantation are calculated in both measured and
simulated ECG based on the automatic QRS detection method described in chapter 7. The
QRS duration before and after implantation are compared together and demonstrated in
figure 9.26. It can be observed that QRS duration are increased both in measured and
simulated ECG after implantation.
The simulated optimized electrode positions are comparable to the ones used in hospital.
The timing delays used in hospital are 130 ms for A-V and 0 ms for V-V delay, while the
V-V delay obtained in this work is slightly larger.
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Figure 9.24. The simulated ECG channels of Patient-12 post-implantation.
Figure 9.25. The measured ECG channels of Patient-12 post-implantation.
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(a)
(b)
Figure 9.26. QRS duration of the 12 channels ECG before and after implantation: (a) Simulated. (b)
Measured.
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9.3 Verification of the Optimization Method for Patient-13
The general information of Patient-13 about the pathologies and geometries is shown in
tables 6.1 - 6.2. The demonstration of the heart and torso are in figures 6.14 and 6.18,
respectively.
9.3.1 ECG Measurements of Patient-13
The measured ECGs before therapy is demonstrated in figure 9.27. The signal processing
steps including baseline wander cancellation, denoising, averaging of multiple ECG cycles
in each channel were performed.
Figure 9.27. The measured 64 channels ECG before therapy for Patient-13 showing 2 heart cycles with
an extrasystole.
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9.3.2 Parameter Optimization of Patient-13
The inverse problem of electrocardiography was solved at least 3 times to achieve the op-
timal results. The best results including the optimal parameters based on the least ERMS
between measured and simulated ECG were selected. The initial and optimized values
for excitation conduction velocity in different tissues and the location of extrasystole are
demonstrated in table 9.3. The initial values are the first estimation of the pathological
parameters and were extracted from the literature. The 12 standard ECG channels were
extracted from the measured 64 channels ECG. These signals are compared to the sim-
ulated ECG for 12 standard channels based on optimized parameters of inverse solver
before implantation. The simulated and measured 12 channels ECG pre-implantation are
demonstrated in figures 9.28 and 9.29, detailed in 9.30 to 9.33 .
Tissue class Initial values Optimized values
Extrasystole location 127 53 80 (AHA17) 104 83 112 (AHA7)
ECV in RV myocardium 479.25 mm/s 653.70 mm/s
ECV in LV myocardium 479.25 mm/s 646.96 mm/s
ECV in RV Purkinje fibers 1983.47 mm/s 2299.87 mm/s
ECV in LV Purkinje fibers 2917.21 mm/s 1229.56 mm/s
ERMS 0.155873 0.0960135
ECV: the excitation conduction velocity (mm/s).
Table 9.3. Initial and optimized values for extrasystole location and excitation conduction velocity in
different tissues.
The correlation coefficients between the simulated and measured ECGs are demonstrated
in figure 9.34. The signals are highly correlated (up to 0.8) in the interval of QRS complex.
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Figure 9.28. The simulated ECG channels of Patient-13 (extrasystolic beat).
Figure 9.29. The measured ECG channels of Patient-13 (extrasystolic beat).
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Figure 9.30. The simulated ECG channels of Patient-13 (Einthoven and Goldberger).
Figure 9.31. The measured ECG channels of Patient-13 (Einthoven and Goldberger).
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Figure 9.32. The simulated ECG channels of Patient-13 (Wilson).
Figure 9.33. The measured ECG channels of Patient-13 (Wilson).
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(a)
(b)
Figure 9.34. Correlation coefficients between simulated and measured 12 standard ECG channels with
extrasystole: (a) Heart cycle. (b) QRS complex.
9.3.3 Discussion on the Results
An extrasystolic beat can be modeled by defining a spontaneous excitation in the my-
ocardium near epicardium. The excitation is conducted through the myocardium until it
reaches the excitation conduction system. Afterwards the excitation is spread over the
endocardium by the conduction system [94]. The estimated position of the extrasystole
and the optimized location after solving the inverse problem is demonstrated in isochrones
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of figure 9.35. The first activated areas are demonstrated by dark blue color. More infor-
mation about this patient after the therapy was not available at this time.
(a) (b)
Figure 9.35. Location of extrasystole (dark blue area) in Patient-13: (a) Estimated. (b) Optimized.
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Discussion
The presented data bring evidence that correlating the heart model results with the clinical
recordings is an effortful procedure. Heart failure is a complex condition and capturing
the variations in conduction block and ischemia for each patient is a hard process [227].
Extracting BSPMs to evaluate the optimal setting for CRT devices is clinically relevant.
The results presented in this work constitute an important step toward the goal of clinical
use of BSPMs and are a good indicator of the potential of the present approach. It would
be premature at this time to speculate how successful this technique would be at improving
patient response. Clearly, there are several factors that need to be considered before this
method can be applied in daily clinical practice. However, with a careful approach in future
research projects, it seems feasible that both the BSPM and the heart model simulations
could be valuable tools to help optimize resynchronization therapy.
10.1 Comparison with Clinical Studies from Literature
The simulation results of both optimization methods presented in this work on the 10 data
sets demonstrated that a minimal root mean square error and QRS duration error between
the physiological and therapeutic excitation could be achieved with respect to a proper
pacing se tup. Using DSA as a fast computational algorithm to find the optimal timing
delays saves the time in comparison with the clinical practice optimization methods. How-
ever, the DSA still needs validation and adjustment in order to avoid suboptimal results.
The optimization algorithms can be applied for individual patients either pre-operatively
to find the optimal lead positions and timing parameters or post-operatively for optimal
adjustment of the timing delays. The major advantage of the presented method is that it
is non-invasive and pre-operative.
Most studies of CRT involve simultaneous pacing of right and left ventricle. However, the
results of this paper agree with the results of the study of Perego et al. [204], supporting
the hypothesis that the best efficiency is not necessarily obtained by simultaneous delivery
of stimulus in both ventricles. In our work, since the left stimulation electrode is placed
240 Chapter 10. Discussion
virtually transvenously through the coronary sinus leading to an epicardial implantation,
a delay in the transmission of the stimulus occured. The effect would decline with stimu-
lating the left ventricular electrode before right pacing electrode.
The review paper of Bax et al. [24] investigated different echocardiographic approaches
to predict the response to CRT and demonstrated that the latest mechanical activity is
frequently located in the lateral wall followed by anterior and posterior regions, whereas
the inferior wall infrequently had latest mechanical activity. It is also shown that Tissue
Doppler Imaging (TDI) may allow precise assessment of inter-ventricular dyssynchrony. In
the presented work, the LV lateral wall and posterolateral positions were used to place the
stimulus electrodes comparing well with the results presented in several research papers
[24, 139, 252, 264, 273]. The optimal timing delays achieved in this work are similar to the
studies of Perego et al. [204] and Whinnett et al. [287].
Moreover, based on the AHA model for the left ventricle in the patient model, TDI can
be used for estimation of excitation conduction velocity for each segment [24]. The inter-
ventricular dyssynchrony in different regions of TDI images corresponding to AHA seg-
ments should be taken into account in order to model the reduction of the excitation
conduction velocity for each individual patient by adaptation of a conduction velocity
factor. In clinical practice, multiple lead positioning for the evaluation of different lead
positions and related optimization of timing is inapplicable due to the time consump-
tion. The presented computer algorithms can be run automatically in order to determine
the optimal pacing parameters including electrode positioning pre-operatively. By running
the algorithm post-operatively, the timing delays for a fixed electrode positioning can be
adjusted.
10.2 Comparison with Clinical Trials in University Hospital Mannheim
The results presented in chapter 8 and 9 mostly show an optimal parameter set up when the
right electrode is placed in the RV apex or septal area and the left electrode is in lateral or
posterolateral positions of left ventricle. The LV electrode position agrees with the clinical
practices in University Hospital Mannheim. For the RV electrode, the surgeons would also
prefer to use the septal position as they believe that a larger distance between electrodes
results in a better coverage of the ventricular area. However, achieving the septal position
is a difficult process and to avoid the risk of injuries, usually the apical positions in right
ventricle is selected. The method we used can be adopted to any individual anatomy and
pathology. Additionally, due to the pre-operative advantage, our method in comparison to
clinical optimization, leads to a less invasive procedure for the patient and is time efficient,
both aspects being essentially beneficial for the patient. The timing delays used in hospital
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were 100− 130 ms for A-V delay and 0 ms for V-V delay, while the values obtained in
this work are slightly larger.
10.3 Study Limitation
The results of optimization show a reliable improvement in cardiac activation. However,
activation time alone does not reflect directly the cardiac contraction, hence the results of
this work need clinical validation. The optimization would be better evaluated in terms
of cardiac output and aortic (beat to beat) blood pressure measurements. Changing the
timing parameters affects the rate of pressure variation in left ventricle, which results in
aortic differential pressure and cardiac output changes [17, 139, 204]. The aortic pressure
and the cardiac output could be calculated with an electromechanical heart model. Since
this model is still under development, the present work depends on the assumption that
the cardiac output is correlated to a physiological excitation propagation. Hence, if the
excitation propagation of a diseased heart is corrected to the physiological excitation prop-
agation by means of pacing, it is assumed that the optimal cardiac output of the diseased
heart also approximates to the output of the physiological heart. Considering that the
mechanical activation will follow the electrical activation with a constant delay, the simu-
lation results are all valid. In order to validate the results, an extended electromechanical
model based on the paper of Sermesant [243] can be developed.
The relationship between electrical dyssynchrony and mechanical performance needs to be
established. Based on the results, CRT pacing induces an electrical pattern of activation,
which can be used to reduce the electrical dyssynchrony between the ventricles, but on the
other hand the BSPM do not provide any information about how these patterns improve
cardiac output, which is the right goal of CRT. Echocardiographic studies will be required
to measure the dyssynchrony to find the link between cardiac performance and optimized
CRT [99, 183, 217].
A recent review of Kerckhoffs et al. [141] investigating an electromechanical model for
different pacing parameters in CRT showed that the best results are achieved when the
electromechanical function was optimized. By measuring the cardiac output as ejection
fraction (EF) and stroke work (SW), it was noticeable that always if the electromechan-
ical parameters were optimized also the QRS duration was minimal; this supports the
approach that optimization of electrophysiological function leads to an optimization of
electromechanical function.
The inverse solution algorithm yields an estimate of the epicardial potential distribution.
The estimation inaccuracy can be influenced by lead position, segmentation error, inaccu-
rate geometry and recorded noise [126]. For a better segmentation of the coronary sinus,
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it is necessary to acquire higher resolution MR images or to use registered MR/CT im-
ages. A better segmentation of the coronary sinus would also increase the accuracy of left
ventricular electrode positioning.
Finally, given the inapplicability of invasive, expensive and time consuming protocols in
clinical practices, further efforts on enhancement of the heart model such as including the
cardiac motion would be devoted to a non-invasive parameter optimization which simplifies
the therapeutic strategy for the individual patient.
11
Conclusions and Future Work
This work offers an optimization strategy to find the best pacing sites and timing delays in
CRT for patients suffering from LBBB and MI. Different reduced conduction velocities to
80 % or 60 % of the physiological value and different allocation of infarction are considered
to implement several pathologies. Two optimization methods based on calculation of the
activation times and QRS duration are implemented to achieve the best parameter setups.
A close cooperation with University Hospital Mannheim provides the opportunity of mea-
suring 64 channels ECG of patients which is used to solve the inverse problem of elec-
trocardiography. This leads to a better parameterization of the pathological model and
therefore to an optimization of the cellular automaton parameters such as conduction ve-
locity in different parts and detecting approximately the infarction position. The aim of
this parameter optimization is to simulate a realistic model of the pathology, in which
the simulated 64 ECG channels will be as similar as possible to the measured one. The
similar QRS duration between measured and simulated ECG channel is a good indica-
tor of the method success. Both optimization methods are implemented and the BSPM
is calculated due to the optimal pacing parameters. The simulated ECG extracted from
BSPM is compared with the measured ECG of the patient after implantation. The results
of the comparison in terms of ERMS and correlation coefficient are determined and the
efficacy of the optimization algorithm is investigated. It is planned to measure the influ-
ence of pacemaker timing changes on the BSPM of the patient after implantation, which
provides valuable information to validate the CRT optimization method. Since a clinical
validation of the results would require a careful consideration of the ethical aspects and
preceding animal studies, the results were verified in this work by pre-implatative and
post-implantative measurements of the BSPM. Both measurements were compared and
the success of the method was established.
In the future, it will be necessary to get an improved parameterization of the computer
model. This could be done with Tissue Doppler Imaging (TDI), which can be used to
determine areas of asynchronous contraction of the heart. As mentioned above, the opti-
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mization method will have to be validated in experimental and clinical studies. For clinical
optimization, the current optimization methods like blood pressure measurements, cardiac
output measurements and ultrasound measurements can be used and compared with the
results from the method presented in this work. Additionally, an implementation of the
cardiac contraction into the computer model would allow the straight-forward determi-
nation of cardiac output. The optimization method would optimize directly the cardiac
output. Therefore, the presented investigation represents a crucial step in the biomedical
engineering research of pacing optimization, being of future aid to patients with LBBB
and MI.
AAppendix
A.1 Abbreviations
2D 2 Dimensional
3D 3 Dimensional
ACA Adaptive cellular automaton
ACE Angiotensin converting enzyme
AF Atrial fibrillation
AHA American Heart Association
AP Action potential
ATP Adenosine triphosphat
AV Atrio-ventricular node
AVB Atrio-ventricular block
A-V Atrio-ventricular
BE Boundary element
BEM Boundary element method
BSA Body surface area
BSPM Body surface potential map
BVP Biventricular pacing
CHF Congestive heart failure
CI Cardiac index
CO Cardiac output
COG Center of gravity
CRT Cardiac resynchronization therapy
CT Computed tomography
CT Crista terminalis
CURE Circumferential uniformity ratio estimate
CV Conduction velocity
DCMP Dilated cardiomyopathy
DLC Delayed longitudinal contraction
DSA Downhill simplex algorithm
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DWT Discrete wavelet transform
ECG Electrocardiogram
EDP End diastolic pressure
EDV End diastolic volume
EF Ejection fraction
EMAT Electromechanical activation time
ePAD Estimate the pulmonary artery diastolic pressure
ERMS Root mean square error
ESV End systolic volume
FDA US food and drug administration
FDM Finite difference method
FEM Finite element method
FVM Finite volume method
GSVD Generalized singular value decomposition
HF Heart failure
HR Heart rate
IBT Institut fu¨r Biomedizinische Technik
ICD Implantable cardioverter defibrillator
IEGM Intracardial Electrogram
IHM Implantable hemodynamic monitor
IVCD Intra-ventricular conduction delay
JSR Junctional sarcoplasmic reticulum
LA Left arm
LA Left atrium
LAD Left anterior descending artery
LBBB Left bundle branch block
LCA Left coronary artery
LCX Left circumflex artery
LL Left leg
LV Left ventricular
LVA Left ventricular apex
LVEDd Left ventricular end diastolic diameter
LVEDV Left ventricular end diastolic volume
LVEF Left ventricular ejection fraction
LVESd Left ventricular end systolic diameter
LVESV Left ventricular end systolic volume
LVOT Left ventricular outflow tract
MAD Median absolute deviation
MI Myocardial infarction
MPI Myocardial performance index
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MR Mitral regurgitation
MRI Magnetic resonance imaging
NYHA New York heart association
Pdf Probability density function
PEA Peak endocardial accleration
RA Right arm
RA Right atrium
RBBB Right bundle branch block
RCA Right coronary artery
RV Right ventricular
RVA Right ventricular apex
RVOT Right ventricular outflow tract
SA Sinoatrial node, sinus node
SD Standard deviation
SP Systolic pressure
SR Sarcoplasmatic reticulum
SV Stroke volume
SVD Singular value decomposition
SVT Supraventricular tachycardia
SW Stroke work
TDI Tissue doppler imaging
TMV Transmembrane voltage
Ts Time to peak myocardial sutained systolic
TSI Tissue synchronization imaging
TT Tissue tracking
VF Ventricular fibrillation
VTI Velocity time integral
V-V Inter-ventricular
WCT Wilson central terminal
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A.2 Graphical User Interface for CRT
In order to make data processing more efficient, a graphical user interface (GUI) was devel-
oped. The GUI provides the user with an interactive tool, which automatically generates
the parameter files and Perl scripts necessary for a simulation. The calculations are per-
formed with C++ programs which are controlled by Perl scripts. The calculations could
be done for ERMS and QRS based optimization methods. Both calculations use mainly
the BeatGTI program. For QRS calculation ASCIILatticeMMD is additionally required
to find the minimal and maximal values of converted lattice file (ASCII). This toolset of
different programs receives the parameters via the command line. A Perl script executes
the programs and provides them with the respective command line parameters. The data
for the calculations are stored in folders with a fixed structure. The IBT CRT application
allows to enter parameters easily, to store them, to reload them and to start the Perl
scripts. By selecting ’Start Job’, the application creates a parameter file and a Perl script
with all information needed for the calculation. When the selected computer is available,
the calculation starts immediately. So, it is not necessary to edit parameter files or Perl
scripts manually.
In figure A.1, the main window with the list of jobs is demonstrated. In figure A.2 the
data entry window is shown. The user can enter data for the following parameters:
1. Simulation and data set description
2. Electrode positions
3. A-V and V-V delay values
4. Infarction position
5. Simulation mode: physiology, pathology and pacing (sequential/simplex)
6. Computer ID where the job should be executed
7. The path to the simulation data
8. The percentage of conduction velocity (*.mp files)
9. Optional start values for the simplex algorithm
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Figure A.1. Screenshot of the GUI data input (data entry window).
Depending on the selected simulation mode, different Perl scripts are generated. Further-
more, the project folder is renamed according to the simulation mode.
Figure A.2. Overview over simulation jobs.
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A.3 Graphical User Interface for Clinical Application
This tool is used for clinical application. The user provides 3 pairs of A-V and V-V values
as starting entries. For these values, the actual QRS duration is measured and entered
in the third column labeled ’result’. Then, the DSA [213] calculates a new pair of timing
values in which the QRS duration should be again measured. This step is repeated until
the change in QRS duration is smaller than a predefined threshold and the criterion is
fulfilled.
(a) (b)
Figure A.3. Simplex GUI for clinical application: (a) Data entry. (b) Calculated data from file.
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yThe efficacy of cardiac resynchronization therapy (CRT) through 
biventricular pacing (BVP) has been demonstrated by numerous 
studies in patients suffering from congestive heart failure. In 
order to achieve a guideline for optimal treatment with BVP 
devices, an automated non-invasive strategy based on an elect-
rophysiological computer model of the heart is presented. The 
presented research investigates an off-line optimization algo-
rithm based on different electrode positioning and timing delays. 
A computer model of the heart was used to simulate the left 
bundle branch block (LBBB), myocardial infarction (MI) and 
reduction of intraventricular conduction velocity. The optimiza-
tion method evaluates the error between the healthy case and 
the pathology with/without pacing case in terms of activation 
times and QRS duration.The clinical measurements of body 
surface potential map (BSPM) are used to parameterize the 
computer model of the heart to represent the individual patho-
logy by solving the inverse problem, which leads to a more rea-
listic heart model for simulations. Afterwards, the simulated 
ECGs for optimal pacing are compared to the measured ECGs 
after implantation. The similarity in the QRS duration between 
measured and simulated ECG signals indicates the success of 
the method.
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